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ABSTRACT 
 
 
 
Robert C. Fellner 
 
Prouroguanylin’s Role in the Homeostatic Response to Dietary Sodium: 
Hormone Precursor or Active Signaling Agent? 
(Under the direction of Dr. Michael F. Goy) 
 
High blood pressure affects more than 70 million Americans, putting them at a 
much greater risk for heart disease or a stroke. Sodium (Na+) is a major determinant 
of blood osmolarity and volume, and therefore plays a critical role in blood pressure 
regulation. Prouroguanylin (proUgn) has been implicated as a signal being sent from 
the small intestine to the kidney, in response to oral Na+ intake, that intestinal Na+ 
adsorption is eminent and renal Na+ excretion is necessary to maintain homeostasis. 
This concept, known as post-prandial natriuresis, is based on past observations of a 
faster natriuretic response from an oral salt load than from an equimolar intravenous 
infusion of NaCl. This role for proUgn is contentious however, as it has not been 
clearly shown if the role played by proUgn is that of a primary messenger from the 
intestine to the kidney in response to salt, if it is a intrarenal paracrine mechanism 
secondary to some other extrarenal signal in response to oral Na+ or even if it is 
proUgn itself or one of its’ metabolites that are acting in the kidney. My studies 
address identification and quantification of proUgn and Ugn in relevant tissue 
compartments and additionally, I look at the effects of dietary Na+ on changes in the 
expression of proUgn and Ugn in these tissues. A novel adaptation of a binding 
 iii 
assay technique allowed for urinary Ugn measurements that were found to directly 
correlate with dietary Na+ intake on a time scale that the prior techniques were 
insufficiently sensitive to achieve. Enteric and plasma proUgn do not change in 
response to dietary Na+, however renal proUgn expression and Ugn in the urine do. 
Changes in plasma proUgn elicit a greater natriuretic response with a lower urinary 
Ugn concentration than urinary Ugn concentrations from infusions of Ugn into the 
blood. My conclusion is that proUgn is a secondary agent involved in volume and 
Na+ homeostasis, acting though some as yet unidentified renal metabolite/receptor 
mechanism. Further studies should focus on if there is another active cleavage 
product of proUgn and what receptor it (proUgn or Ugn) acts through. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 iv 
 
 
 
 
 
DEDICATION 
 
 
This dissertation is dedicated to all my family and friends who have believed in me 
and inspired me throughout the process and especially in memory of my friend 
Andrew Rachlin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 v 
 
 
 
 
 
ACKNOWLEDGEMENTS 
 
 
I would like to thank first and foremost my dissertation advisor Dr. Michael 
Goy for all his support, patience and friendship throughout the process. He was 
there for me 100% from the very start in any way I could imagine both personally 
and professionally. Additionally, I owe a huge thanks to Dr. Nicholas Moss who has 
been a great guide, teacher and colleague, an excellent co-mentor for me 
throughout the process. I can be headstrong and determined to do things my way 
and both have shown great skill at steering me as much as possible to the right path 
and then patience in helping me recover from my mistakes and finding the best way 
to accomplish my goals. You both have helped greatly not only with professional but 
also personal growth. 
I also owe a huge debt to all my committee members for not only their 
guidance in my dissertation quest but for overall assistance with my career; Dr. 
James Faber immediately took me under his wing both as an advisor and a friend, 
escorting me to both conferences and on climbing trips to learn about the world of 
academic science as well as my new home state of North Carolina. Dr. William 
Arendshorst showed me the world of renal microvasculature and introduced me to 
the important people in the field, opening the door for the next step in my academic 
career. Dr. Nobuyo Maeda had faith enough in me to grant me a fellowship in the 
IVB training program and to mentor me through such even before coming onto my 
 vi 
committee. Dr. Kathleen Caron was instrumental in helping me recognize how to set 
and accomplish realistic goals in my graduate career.  
I have mentored a series of undergraduates in the lab and they have proved 
valuable both in helping achieve goals in my research and in teaching me to be a 
better teacher. Thanks Amanda Fitzgerald, Ariana Horvat-Fisher, Mark AbuMoussa, 
Sam AbuMoussa and Sharon Yu.  
The bedrock of my graduate career comes from my friends, especially Julie 
Rasmussen, Dr. Dan Chalothorn, Ari Bowers, Dr. Nicole Ramocki, Mike Kerber and 
Dr. Kate Hamilton. Without these friendships this process might have broken my 
sanity. Many other great friends have assisted and accompanied me along the way; 
Alexis Mastromichalis, Dr. Aparna Bohil, Cathleen O’connell, Dr. Cauveh Erami, 
Caroline and Dr. Alex Couture, Dr. Damon Jacobs, Dana Williams, Erica Hauck, 
Jason Sayers, Jeremy Sadler, Dr. Marc Spingola, Dr. Matt Medlin, Dr. Melanie 
Schikore, Dr. Melinda Devito, Dr. Nikki Worthington, Rachel Liesman, Dr. Rebecca 
Sayers, Dr. Rob Tarran, Dr. Rob Onyenwoke, Dr. Suman Sen, and Dr. Vicki Newton 
have all been very close and their support is greatly appreciated. 
Finally and especially I would like to thank my family for all the years of 
support and inspiration that I could and should try to achieve up to my greatest 
potential. Thanks to my brother Bill and wife Lora for allowing me to sleep in their 
basement. I thank my parents, Cindy and William Coty, and Thomas and Lanelle 
Fellner for all the efforts to make my continued education possible and the 
encouragement that the chosen path was the best thing for me. It would never have 
happened without all your support and inspiration…   THANKS!! 
 vii 
 
 
 
 
 
TABLE OF CONTENTS 
 
 
 
 
ABSTRACT……………………………………………….………………………………….ii 
  
DEDICATION…………..........…………………………..…………………………………iv  
 
ACKNOWLEDGEMENTS.....…………………………..…………………….……….……v  
 
TABLE OF CONTENTS.........…………………………..…………………….…………..vii 
 
LIST OF TABLES………….…….……………………….…………………..…..…………x 
 
LIST OF FIGURES……….…….…………………………………………….…..………...xi 
 
ABBREVIATIONS………………………………………………………….………….…..xiv 
 
 
CHAPTER  
 
 
I. BACKGROUND AND SIGNFICANCE……………………..…….……….1 
 
A. The Discovery of Uroguanylin (Ugn) and  
Prouroguanylin (proUgn), and Their Hypothesized  
Participation in Sodium Homeostasis……………….….…….......2 
 
B. Sodium and Volume Homeostasis…………….……………………….4 
 
C. The Guanylin family of Peptides,  
Regulators of Volume Homeostasis...........................................7 
 
D. Guanylyl Cyclase C………….………………………..……………….11 
 
E. Prouroguanylin………………..……………………….….…………….14 
 
F. Hypothesis and Aims…………………………………………………..23 
 
 
 viii 
II. UROGUANYLIN, AN INTESTINAL NATRIURETIC……….….….……31 
  PEPTIDE, IS DELIVERED TO THE KIDNEY  
   AS AN UNPROCESSED PROPEPTIDE  
 
AND 
 
CIRCULATING PROUROGUANYLIN IS PROCESSED  
 TO ITS ACTIVE NATRIURETIC FORM EXCLUSIVELY  
 WITHIN THE RENAL TUBULES 
       
A. Introduction……………………………………….……………….....….32 
 
B. Material and Methods……………………………………..……...……35 
 
C. Results………………………………………….………………….……48 
 
D. Discussion……………..…………………………………………..……64 
 
 
III. DEVELOPMENT AND VALIDATION OF QUANTITATIVE……………84 
  ASSAY FOR THE ASSESSMENT OF UGN IN BIOLOGICAL  
  SAMPLES  
 
A. Introduction…………………………....…………………………...……85 
 
B. Material and Methods…………………..………...……………………89 
 
C. Results………………………………………………………..…………93 
 
D. Discussion……………..……………………….………...……………103 
 
 
 
IV. INTESTINAL PROUROGUANYLIN PLAYS A………………...………113  
 ROLE IN VOLUME HOMEOSTASIS, POSSIBLY  
 A DIRECT RESPONES TO ORAL SODIUM 
 
A. Introduction…………………………………………….………………114 
 
B. Material and Methods……………………………...…………………121 
 
C. Results………………………………………………...….……………129 
 
D. Discussion……………..………………………...…….………………139 
 
 
 ix 
 
V. SCIENTIFIC DISCUSSION………..……………………………………160 
 
A. A Role for Prouroguanylin……………………………………………161 
 
B. Prouroguanylin, an Unconventional Endocrine Agent…………….162 
 
C. Prouroguanylin as a Control Mechanism of Basal……...…………168  
Sodium Excretion 
 
D. Prouroguanylin as a Control Mechanism of Renal Sodium………171 
Excretion in Response to High Na+ Intake 
 
E. Final Thoughts………………………………………...………………173 
 
 
 
 
VI. APPENDIX: LIST OF PUBLICATIONS………………………………..176 
 
 
 
 
REFERENCES…………………………………………….………………………..178 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 x 
LIST OF TABLES 
 
 
TABLE 
 
1.1. Details From Experiments Analyzing Effects of Altered………….………..……..26 
Oral Sodium Intake on Ugn and/or proUgn Levels  
in Tissues, Urine, or Plasma.  
 
2.1. proUgn constructs used in this study…………………………………...…………..72 
 
2.2. proUgn and Ugn Levels of Tissues and Plasma…………..….……….……....….72 
 
2.3. Time Constants (t) for the Clearance of proUgn and………...………………......73 
Inulin in Control and Anephric Animals.  
 
4.1. Primers and Probes for rtPCR………..…………………….………………..……146 
 
4.2. Sodium Diet Study Data……………..………………………….………….………146 
 
4.3. Analysis of Diet and Circadian Effects on Plasma proUgn…………................147 
 
4.4. Analysis of Diet and Circadian Effects on Urinary Ugn………….……..……….147 
 
4.5. Estimation of proUgn to Ugn Conversion with……………….………..…………148 
  Effects of Diet and Circadian Variation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xi 
LIST OF FIGURES 
 
FIGURE 
 
1.1. Model of Post Prandial Natriuresis………………………………………………….27 
 
1.2. Structure of Guanylin-family of Peptides…………..………………………………28 
and the E. Coli Enterotoxin Sta  
 
1.3. T-84 Cell Assay for Detection of Ugn…………………………………...……….…29 
 
1.4. Western blot analysis of proUgn ………………………………...…………..…..…29 
Expression in a Variety of Tissues.  
 
1.5. Ugn -/- Animal Chronic Response to Oral Salt…………………..…...…...….…. 30 
 
1.6. Ugn -/- Animal Acute Response to Oral Salt…………………..………...…….….30 
 
2.1. Biochemical confirmation that gut ……………………………......………….….…74 
extracts contain authentic proUgn.  
 
2.2. C-18 Reverse Phase HPLC Analysis of the Native proUgn-like……………......75 
Immunoreactivity Present in Rat Jejunum.  
 
2.3. ProUgn and Ugn Levels in Extracts of Rat Small Intestine……………………...76 
 
2.4. HPLC and Bioassay Analysis of Ugn-like Bioactivity…….….……………….…..77 
From Proximal Small Intestine.   
 
2.5. Authentic, Full-length proUgn Circulates in Plasma………..…………….………78 
 
2.6. Distribution of Radiolabel in Tissues and Fluid……………….…………………..79 
Compartments at the End of a 60 Min Steady  
Intravascular Infusion of 35S-proUGn.   
 
2.7. A Bolus Dose of 35S-proUgn was Cleared Rapidly……………………………….80 
From the Plasma of a Normal Animal, and Much 
More Slowly After Renal Ablation.  
 
2.8. Metabolites Accumulating in Kidney and Urine……………………..……..….…..81 
During Prolonged Infusion of Radiolabeled proUgn.  
 
2.9. During Prolonged Infusion of Radiolabeled………..………………………………82 
proUgn, the Kidney Extracted the Propeptide  
From the Plasma, While Secreting Radiolabeled  
Amino Acids Back into the Circulation.  
 xii 
 
2.10. Infused hu-proUgn is Natriuretic and Diuretic in…………………..…………….83  
Rat Renal Clearance Studies.  
 
3.1. Graphic of T-84 Cell Assay vs Membrane Binding Assay………………..…….106 
 
3.2. Specific Binding Curve……………………………………….………..……..…….107 
 
3.3. Association Rate Binding Curve…………………..……………………………....107 
 
3.4. Disassociation Rate Binding…………………….……………………..….………108 
 
3.5. Association Curve at Various pHs………………….……………………..………108 
 
3.6. Radioligand Displacement by Recombinant Rat Ugn…………….….….……...109 
 
3.7. Radioligand Displacement by Recombinant Rat proUgn……………………….109 
 
3.8. Radioligand Displacement by Recombinant……………………………………..110 
Human Ugn-A and Ugn-B. 
 
3.9. Radioligand Displacement by Recombinant Rat Gn……….……….…..………110 
 
3.10. Radioligand Displacement by E. Coli Sta……………………..……..…………111 
 
3.11. Radioligand Displacement by Rat Urine……………………..…………………111 
 
3.12. Radioligand Displacement by Rat Urine………………………..………………112 
 
3.13. Radioligand Displacement by Ugn-/- Mouse Urine………..…………………..112 
 
4.1. Sodium Diet Study Feeding Protocol………………..………………………...….149 
 
4.2. Na+ Handling and Food Consumption During Sodium Diet Study………….....150 
 
4.3. Water Handling During Sodium Diet Study……………………..………………..151 
 
4.4. Circadian changes in Circulating proUgn and Urinary Ugn Excretion……...…152 
 
4.5. Plasma proUgn Levels Change Following………………..……………..……….153 
Entero-Hepatic Circulation Ligation.  
 
4.6. Urinary Ugn Excretion During Sodium Diet Study………..……………………..154 
 
4.7. Urinary Ugn Excretion Correlated to Na+ Excretion…….…...………………….155 
 in Diet Study Animals and Compared to  
 xiii 
Knockout Mouse Phenotype Data. 
 
4.8. Circulating Plasma proUgn During Sodium……………..….……….…….……..156 
Diet Study and processing into Urinary Ugn 
 
4.9. Ugn mRNA Expression Changes in Response to Diet………………………....157 
 
4.10. Urine Ugn Excretion in Response to Intravenous……………....…………..…158 
Infusions of Rat proUgn and Ugn.  
 
4.11. Sodium Excretion (UNaV, nEq/min/gKW) in Response………….………..….159 
to Intravenous Peptide Infusions. 
 
 
5.1. Model of Hypothetical Sources for Urinary Ugn…………….……….…….…….175 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xiv 
ABBREVIATIONS 
 
 
 
AALAC  Association for Assessment and Accreditation of 
 Laboratory Animal Care 
 
A/D    analog to digital 
 
ADH   anti-diuretic hormone, also referred to as Vasopressin  
 
ANOVA  analysis of variance 
 
ANP    atrial natriuretic peptide  
 
BDT   below detection threshold 
 
BNP                         brain or B-type natriuretic peptide  
 
CΔ    recombinant rat proUgn missing the C-terminal 15 amino acids   
 
cDNA    complementary deoxyribonucleic acid 
 
CFTR   cystic fibrosis transmembrane conductance regulator  
 
cGMP   cyclic guanosine monophosphate  
 
CHF    congestive heart failure  
 
CNP    C-type natriuretic peptide  
 
Ct    cycle times to threshold detection for rt-PCR amplification 
 
CTEP   carboxy-terminal extension peptide   
 
Δ-Ct   differences in Ct between gene of interest (proUgn) to  
housekeeping gene (ß-Actin) in q-rt-PCR results 
 
Δ-Δ-Ct   computational method for mRNA quantification analysis 
 
DLAM   Division of Laboratory Animal Medicine 
 
EC   enterochromaffin cell  
 
ECF   extracellular fluid  
 
 xv 
GC-A   receptor guanylyl cyclase type A 
 
GC-B   receptor guanylyl cyclase type B 
 
GC-C    receptor guanylyl cyclase type C  
 
GFR   glomerular filtration rate  
 
Gn   guanylin  
 
H2O    water 
 
HPLC   high-pressure liquid chromatography 
 
hUgn-A, hUgn-B human uroguanylin topoisomers A, and B 
 
HS   diet study phase when rats are fed 3.1% Na+ chow ad libitum 
 
K+   potassium  
 
KD    disassociation constant 
 
KI   binding inhibition constant (indicative of disassociation constant) 
 
Lgn    lymphoguanylin   
 
LI-COR   imaging system for western blot quantitation 
 
LS   diet study phase when rats are fed 0.02% Na+ chow ad libitum 
 
MAP   mean arterial pressure  
 
Meq   milliequivalents of an ion 
 
mRNA  messenger ribonucleic acid 
 
N    native proUgn molecule 
 
Na+    sodium 
 
NHE3   Na+/H+ exchanger  
 
NS   diet study phase when rats are fed 0.26% Na+ chow ad libitum 
 
OK-GC  receptor guanylyl cyclase type opossum kidney 
 
 xvi 
Rgn   renoguanylin  
 
rGC   receptor guanylyl cyclases  
 
PKG II  cGMP-dependent protein kinase  
 
PPN       post prandial natriuresis 
 
proUgn   prouroguanylin  
 
qRT-PCR   quantitative real time polymerase chain reaction 
 
R    recombinant rat proUgn standard 
 
RAAS   renin-angiotensin-aldosterone system  
 
RP-HPLC   reverse phase high-pressure liquid chromatography 
 
RIA    radioimmunoassay 
 
SEM    standard error of the mean 
 
SNS   sympathetic nervous system  
  
STa   E. coli. Heat-stable bacterial toxin  
 
UK+v   urinary potassium excretion in milliequivalents per time 
 
UNa+v   urinary sodium excretion in milliequivalents per time 
 
rtPCR   real time polymerase chain reaction  
 
Ugn   uroguanylin 
 
Ugn+/+   wild-type 129/SvJ mouse  
 
Ugn-/-   129/SvJ mouse that has uroguanylin gene expression disabled 
 
Y-Ugn  synthetic uroguanylin with a non-native tyrosine residue added 
 to the amino terminus  
 
 
 
 
 
CHAPTER I  
 
 
 
BACKGROUND AND SIGNIFICANCE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2 
A. The Discovery of Uroguanylin (Ugn) and Prouroguanylin 
(proUgn), and Their Hypothesized Participation in 
Sodium Homeostasis 
 
Guanylin, Uroguanylin and their Enteric Receptor, Guanylyl Cyclase-C. 
 
Guanylin (Gn) and uroguanylin (Ugn) are structurally related peptides that are 
produced in the gastrointestinal tract (40, 82, 113, 179). The discovery of these 
intestinal peptides was preceded by the cloning of their putative receptor, receptor 
guanylyl cyclase type C (GC-C), from an intestinal cDNA library (92). Ligand 
activation of GC-C leads to the synthesis of the second messenger cGMP, which 
affects transport of water and electrolytes across epithelial monolayers (61). GC-C 
was originally described as an orphan receptor, identified by cloning on the basis of 
its sequence homology with other members of the family of receptor guanylyl 
cyclases, including GC-A, the receptor for atrial natriuretic peptide (ANP), and GC-B, 
the receptor for C-type natriuretic peptide (CNP) (60, 104, 166). The initial cloning 
study showed that GC-C is highly expressed in the intestine (166) and that it serves 
as the receptor for a bacterial toxin (STa) that causes diarrheal disease (54, 188, 
166). Although at the time there was no known endogenous ligand for GC-C, it was 
presumed that there would be one; otherwise, evolutionary pressure would have 
eliminated the receptor along with the lethal mechanism that it initiates.     
 Based on this presumption, intestinal extracts were screened for agents that 
induce cGMP production by GC-C (99). Active molecules were identified on the 
basis of their ability to elevate cyclic GMP levels in T-84 cells, a human colon 
carcinoma-derived cell line that expresses very high levels of GC-C (182). Using this 
assay, guanylin (Gn) was purified from extracts of the jejunum of rats, and identified 
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as a ligand for GC-C (40, 61). Subsequently, Ugn was found in the urine of possums 
(Didelphis virginiana)(83), rats (84), rabbits (55) and humans (99) using the same T-
84 cell assay screening technique, and was subsequently shown to be produced in 
the intestine (82, 113, 116). Though 15 amino acid Ugn was the first form of the 
protein identified in the urine of opossum, the form shown to be produced and stored 
in the intestine is predominantly an 86 amino acid propeptide, prouroguanylin 
(proUgn)(82, 113). 
 
The Concept of an Entero-Renal Endocrine Link 
 
An entero-renal endocrine link was proposed by Robert Carey in the 70’s 
based on experiments showing faster urinary excretion of sodium (Na+) in response 
to an oral versus an intravenous salt load (19). In humans, dogs and rabbits, he 
subsequently showed that an oral NaCl load induced greater Na+ excretion at 
comparable time points than did an equimolar salt load injected into the blood (19, 
21, 111, 112).  
The implication of these experiments is that the GI tract sends a signal to the 
kidney to indicate that intestinal Na+ absorption is imminent and renal Na+ excretion 
is necessary to maintain homeostasis (see figure 1.1). The slower time course of 
Na+ excretion in response to intravenous NaCl implies that there is a luminal 
sensing mechanism in the gut. This signal could be conveyed by either a humoral 
factor or by a neural signal. The component of Na+ excretion that is dependent on 
oral intake is sometimes referred to as post-prandial natriuresis (64, 185). proUgn is 
a plausible candidate for mediating the post-prandial response, because it is 
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produced in an organ where such a signal could originate (the small intestine), has 
the ability to regulate epithelial electrolyte transport, and is present in the urine 
(indicating that it has access to the lumen of the nephron, a relevant target tissue for 
homeostatic regulation of Na+ excretion).  
 
B. Sodium and Volume Homeostasis 
Volume and Sodium Homeostasis is a Crucial Biological Function with a 
Complex Regulatory System. 
 
Sodium is a major determinant of extracellular fluid (ECF) osmolality and 
volume. Therefore, controlling Na + balance is essential for maintaining ECF volume 
homeostasis (70). ECF volume in the vascular system is a determinant of pressure 
in both the arterial and venous circulations (12, 175). Fluid and Na+ levels in 
mammals must be tightly regulated to ensure proper biological functions as diverse 
as neural signaling and membrane transport (12). Dysregulation of water and Na+ 
can result in pathologies such as hypertension, cardiac arrhythmia, and stroke (12, 
124). Alternatively, underlying pathological conditions like heart and kidney failure 
can be the cause of such dysregulation (4, 115). Understanding the complex 
interrelationship between volume-regulatory mechanisms and disease is critical for 
improving clinical care for many pathological states.   
Control mechanisms for fluid and Na+ homeostasis typically detect 
fluctuations in plasma osmolality, blood pressure and atrial stretch, which serve as 
feedback signals for systems that adjust renal Na+ excretion to match dietary Na+ 
intake (121, 147). Some of the better-described mechanisms include anti-diuretic 
hormone (ADH), atrial natriuretic peptides (ANP and BNP), the sympathetic nervous 
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system (SNS), and the renin-angiotensin-aldosterone system (RAAS)(6, 10, 11, 12, 
15, 37, 79, 98, 133, 158). Additionally, an autoregulatory system controls renal blood 
flow, and this has critically important effects on Na+ retention and ECF volume (121, 
175). 
 
The Natriuretic Peptides 
 
The natriuretic peptides ANP and BNP signal through guanylyl cyclases to 
affect Na+ excretion by the kidney (15, 28, 122, 123). ANP is a 28-amino acid 
peptide produced and secreted by atrial myocytes in response to atrial distension 
(15). BNP, named because it was first discovered in the brain, is a 32-amino acid 
peptide also synthesized and secreted from the heart in response to stretch, mainly 
from the ventricles (12). Along with ANP, BNP is thought to induce natriuresis 
through Guanylyl Cyclase type-A (GC-A) in the kidney (28, 47).  
 Urodilatin is an alternate cleavage product of proANP produced selectively by 
the kidney (72, 183). Urodilatin was once thought to be involved in post-prandial 
natriuresis but is now generally believed to play a role as a feedback mediator that 
responds to expanded blood volume (90).  
 
The Renin Angiotensin Aldosterone System (RAAS) 
 
The RAAS provides critical control over Na+ and fluid retention (37, 80, 88, 
90). This hormone cascade is initiated by the release of renin into the blood stream 
from the cells of the juxtaglomerular apparatus of the kidney (11, 88, 90). This can 
be in response to baroreceptor stretch, SNS nerve activity or NaCl concentration 
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within the lumen of the nephron (88, 133). This initiates a sequence of catalytic 
events culminating in increased plasma angiotensin II (Ang II) and aldosterone (26, 
31). Ang II is a potent regulator of general vascular tone, renal blood flow, 
glomerular filtration rate (GFR) and Na+ reabsorption in the tubules (133, 158).   
Aldosterone is mineralocorticoid that is produced in the adrenal gland (12).  
Production and release of aldosterone is stimulated by increases in plasma Ang II or 
plasma potassium (K+) (6). Aldosterone acts in the distal tubule and collecting ducts 
to up-regulate and activate ion channels and pumps that promote Na+ retention and 
K+ excretion. 
 
Other Sodium Homeostatic Feedback Mechanisms 
 
 The Sympathetic nervous system (SNS) modulates renal Na+ handling in 
multiple ways. Neurons terminate at various sites within the nephron to regulate 
renal blood flow, tubular Na+ reabsorption and renin secretion (11). Under conditions 
of low SNS activation, Na+ reabsorption increases and, as a result, the blood volume 
expands (6). At more intense activation of the SNS, through the effects of the SNS 
on Ang II and norepinephrine, there is a further modulation of vasoconstriction and 
renal blood flow (6, 98).   
Anti-diuretic hormone (ADH, also referred to as Vasopressin) is a 9 amino 
acid peptide that is synthesized in the hypothalamus and stored and released from 
the pituitary gland in response to decreases in plasma osmolality (10). ADH acts in 
the distal tubule and collecting ducts to increase membrane permeability to H2O via 
aquaporin-2 and thus promote renal retention of fluid and electrolytes (184). 
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Nitric oxide, prostaglandins, reactive oxygen species and other paracrine 
agents work in the kidney to alter GFR, ion transport, and water transport (70, 175). 
These agents act in various parts of the nephron to adjust renal Na+ handling 
through mechanisms that affect renal vascular tone, ion transporters and channels, 
and renin secretion (175).   
In general, these systems require a change of some physiological parameter 
that is affected by Na+ in order to trigger a feedback loop. Such feedback systems 
can take many hours or days to accurately match Na+ intake with excretion (80, 
175). For this reason, the concept that the kidney (the body’s salt excreting organ) 
and the intestine (the body’s salt absorbing organ) could be linked by a rapid 
endocrine axis that helps to balance uptake and excretion over short time frames is 
attractive. The guanylin family of peptides, acting through a member of the receptor-
guanylate cyclase family that mediates responses to other natriuretic peptides, are 
thought to play key roles in rapid fluid and Na+ homeostasis, but their mechanisms 
are not clearly defined (60, 62, 73, 103). 
 
C. The Guanylin family of Peptides, Regulators of Volume 
Homeostasis? 
 
A Conserved Structure Among Family Members Based on Disulfide Bonds 
 
Three mammalian peptides share the ability to stimulate GC-C-mediated 
catalysis of cGMP: Guanylin, Uroguanylin and Lymphoguanylin (Lgn)(64, 103, 113). 
In most mammals all three peptides have a high level of sequence homology with 
Ugn, being 55% homologous with Gn, and 80% homologous with Lgn. However, Lgn 
is only found in opossums (62, 64, 99).  Additionally, GC-C can be stimulated by a 
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similar peptide, renoguanylin (Rgn), found in teleosts (190) and also the family of 
heat-stable bacterial toxin (STa) peptides (3, 35). All of these peptides share a 
common feature: they are cysteine rich and contain specific disulfide bonds  (Figure 
1.2). Gn, Ugn and Rgn contain 4 cysteines that form two specific disulfide bonds (1-
3 and 2-4) but Lgn only has 3 cysteines and one disulfide bond (60, 64). The STa 
family has two additional cysteines forming a third disulfide bond, which stabilizes 
the molecule, but the cysteines homologous to those in Ugn and Gn still adopt the 
same 1-3 2-4 configuration (73). These specific disulfide configurations (1-3, 2-4) are 
required for potent activation of GC-C leading to the synthesis of the second 
messenger cGMP.  
Lgn is unique not only for containing only 3 cysteines but also in that it has 
only ever been found as a transcript. No one to date reports finding this as an 
endogenous peptide, and the transcript has only been found in opossum, with no 
identified mammalian ortholog (64, 113). It is named for the fact that the expression 
has been noted most highly in opossum lymphoid tissue, with lesser amounts in 
testis, spleen and heart (64). Synthetic Lgn is able to fully activate GC-C; however, 
its potency is much lower than that of Ugn or Gn at any pH (64). 
 
STa Activation of GC-C Induces Diarrhea 
 
 As described above, the first identified ligand for GC-C was the heat stable 
peptide produced by entero-toxigenic E. coli. This peptide can have 18 or more 
amino acids, depending on the strain but the 5 most common strains (2 human, 2 
porcine and 1 bovine) all have 18 residues (3, 36, 46). The toxins have high 
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structural homology between strains, especially 6 key cysteine residues that are 
perfectly conserved between strains, including the 3 specific disulfide bonds they 
form (36). Two of these disulfide bonds (1-4 and 3-5) are required for GC-C 
activation (figure 1.2) (3). This enterotoxin is the secretagogue that is responsible for 
traveler’s diarrhea, a condition that is still a prominent cause of mortality in 
underdeveloped countries, particularly in children under the age of 5 (3). It is through 
GC-C activation that STa induces the bulk movement electrolytes and water into the 
lumen of the colon to cause the rapid expulsion of enteric contents and allow the 
bacteria to colonize a new host. High mortality in children would constitute a special 
evolutionary burden. Thus, the high conservation of sequence in GC-C and the 
guanylin family of peptides, and the preservation of the genes that encode these 
polypeptides across a large number of mammalian species, implies an important 
function. 
 
Guanylin 
 
Guanylin is synthesized and stored as a 115 amino acid propeptide (proGn), 
predominantly in the intestine (33, 40, 41, 51, 82). It is expressed in a rostral to 
caudal gradient, with peptide and mRNA levels being lowest (barely detectable) in 
the duodenum and highest in the colon (33, 51). ProGn is produced by goblet cells, 
which are also responsible for the production of mucin. It is therefore hypothesized 
that Gn plays a role in hydrating the mucosal layer (required for conversion of mucin 
to mucus) and additionally in maintaining fluidity of the luminal contents of the colon 
(3, 113, 150). 
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A major structural difference between Gn and Ugn is that Gn has an internal 
aromatic residue (phenylalanine or tyrosine, depending on the species) instead of 
the asparagine that is characteristic of Ugn. This aromatic residue affects the 
potency of Gn and makes it more susceptible to proteolytic cleavage (82, 101). 
Proteolytic susceptibility is probably the reason why Gn is not found in the urine, 
even though proGn is present in plasma and kidney extracts (33, 51, 82, 101). The 
aromatic residue generates a consensus cleavage site for a chymotrypsin-like 
endopeptidase located on the brush border of proximal tubules in the kidney. This 
leads to degradation of any filtered peptide, prevents it from accumulating in the 
urine, and reduces the chance of it having any renal effects (12, 82). 
The binding of Gn to GC-C is pH dependent. The peptide has less ability to 
stimulate cGMP production at lower pHs (73, 159). At a pH of 8.0, Gn, and Ugn have 
almost the same ability to stimulate cGMP synthesis, but Gn is 100-fold less potent 
than Ugn at a pH of 5.0 (73). This lends additional credence to the theory that Gn 
plays a physiological role in the colon but not the kidney, as the pH in the lumen of 
the colon is basic while the pH in the lumen of the nephron is acidic (156, 190). 
 
Renoguanylin and Uroguanylin Play a Role in Adaptation to Water Salinity in 
Teleost Fish 
 
Rgn is a Ugn-like peptide discovered in the kidney of teleosts (35, 120, 190). 
Euryhaline teleost fish migrate between marine and freshwater environments, 
making them an interesting model for adaptation to oral Na+ handling (180). These 
fish also express homologues of Gn and Ugn, with sequence similarity to the rat and 
human forms at the critical cysteine residues and the aromatic position in Gn, which 
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determines proteolytic susceptibility (190). A third peptide (Rgn) has 55% sequence 
similarity to Ugn and, notably, contains the same four cysteines, disulfide bridges 
and the internal asparagine residue that distinguishes it from Gn (190). The tissue 
expression of Ugn in the species is similar to that seen in mammals, but Rgn 
expression seems to be restricted to the intestine and the kidney, with highest levels 
in the latter—hence its name (190). 
Interestingly, in experiments where fish are moved from a fresh-water to a 
salt-water milieu, renal Rgn expression doesn’t change significantly but intestinal 
and renal Ugn expression both increase significantly (120, 180, 190), and the 
intestinal Rgn expression increases significantly in response to the alteration in 
water salinity. Both peptides increase in the tissues where their expressions are low 
(Rgn increases in the intestine, while Ugn increases in the kidney) which implies that 
the two peptide family members could be playing complementary roles in Na+ 
handling. It has been hypothesized that as a consequence of these expression 
changes there is delayed enteric salt absorption (mediated by Rgn) and accelerated 
renal salt excretion (mediated by Ugn) (191). 
 
D. Guanylyl Cyclase C 
GC-C is A Member of the Family of Natriuretic Peptide Receptors   
 
As detailed above, the natriuretic peptides play a role in the maintenance of 
Na+ and volume homeostasis and their main mode of action is through the activation 
of receptors that belong to a family of receptor guanylyl cyclases (rGC). GC-A and 
GC-B are the best-described members of this family (27, 28, 79, 122). GC-C was 
discovered in 1990 through homology cloning, based on sequence similarities to 
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GC-A and GC-B, and was named C because it was the third family member 
discovered (164). 
GC-C, like the other family members, has a ligand-binding extracellular 
domain (ECD), a single trans-membrane domain, an intracellular kinase-like 
regulatory domain and an intracellular catalytic guanylyl cyclase domain. Binding of 
ligands to the ECD leads to a conformational change that relieves an intramolecular 
inhibitory effect of the kinase-like domain and allows the catalytic domain to produce 
cGMP, which acts as a second messenger. The only known ligands for GC-C are 
the Guanylin family of peptides and the family of heat-stable bacterial toxin (STa) 
peptides (73, 165). STa is the most potent ligand when administered to T-84 cells, 
with a KD for stimulation of cGMP production that is ~10 fold lower than that of Ugn-
15 at pH 5.0 (71). The propeptides (proGn and proUgn) are unable to elicit cGMP 
production by GC-C (71, 82). Activity from these propeptides is only observed after 
processing to Gn or Ugn (47, 69, 82). 
A feature that differentiates GC-C from the other members of the rGC family 
is a carboxy-terminal extension peptide (CTEP)(42, 167). This CTEP is believed to 
play a role in trafficking GC-C to the apical membrane of epithelial cells. When this 
domain is deleted, the receptor is no longer preferentially targeted to the apical 
membrane of polarized cells, and also no longer responds to Sta or the guanylin 
family peptides to produce cGMP (42). 
In the intestine, GC-C activation and the subsequent increase in intracellular 
cGMP have three main effects: a) the cystic fibrosis transmembrane conductance 
regulator (CFTR) is phosphorylated through activation of a specific isoform of cGMP-
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dependent protein kinase (PKG II), and this increases its chloride and bicarbonate 
conductance, b) cGMP inhibits a Na+/H+ exchanger (NHE3), perhaps through 
phosphorylation (though this is unclear, at present) (128); and c) bicarbonate/Cl- co-
transporters are activated by an unknown mechanism (168). The combined effect of 
these three physiological alterations is to block Na+ uptake from the lumen, promote 
chloride, bicarbonate, and Na+ secretion into the lumen, and enhance the osmotic 
accumulation of water in the lumen. Further data suggest that GC-C activation also 
affects cell proliferation and apoptosis, from experiments both in cultured cells and in 
polyps from a mouse model of colon cancer (34, 110). 
 
T-84 Cells are an Immortalized Cell Line that Produces cGMP   
 
T-84 cells are intestinal epithelial cell line that is derived from a human 
colorectal adenocarcinoma. These cells are immortalized and express high levels of 
GC-C (45). T-84 cells in culture can be stimulated to produce cGMP in a 
concentration dependent manner by any of the known GC-C ligands (figure 1.3)(73). 
This is thought to occur exclusively through GC-C, as the cells neither express any 
of the other rGCs nor do they produce cGMP in response to other natriuretic 
peptides outside of the Guanylin Family of peptides (92, 163, and unpublished data 
of mine). 
T-84 cells are useful as a reporter cell line, as they can be used to determine 
the amount of a Ugn-like peptide in a sample, based on the amount of cGMP they 
produce when the cells are exposed to the sample. Note, however, that multiple Gn-
family peptides are active on these cells, so all samples must be analyzed 
biochemically (for example by reverse phase HPLC) to determine which peptide is 
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inducing the response. I used this assay extensively in my early studies as a way to 
measure Ugn-like peptides in tissue extracts and in plasma (Chapter 2). However, 
analysis of urine proved problematic for a number of reasons (described in detail in 
Chapter 3), necessitating the development and validation of a new assay that would 
work well for urine samples.  
 
E. Prouroguanylin  
Uroguanylin versus proUroguanylin 
 
As with Gn, Ugn is first synthesized as a propeptide (86 amino acids) that is 
subject to proteolytic cleavage (82). 15 amino acid Ugn was the first form identified 
in the urine of the opossum, and other slightly longer, N-terminally extended forms of 
the peptide have subsequently been noted (81, 85). However, as I will show in 
Chapter 2, the predominant form stored in the intestine is actually the propeptide 
(99, 113). The propeptide is expressed in a rostro-caudal gradient, with highest 
levels in the duodenum and almost undetectable levels in the colon (113, 162).  
 One long standing difficulty in the Ugn field has been measuring (and 
discriminating) Ugn and proUgn in biochemical studies. This has stemmed from the 
techniques used to assay them. (a) The original method of detection was the T-84 
cell bioassay (see figure 1.3), which relies on binding of the peptide to GC-C. 
ProUgn is unable to stimulate cGMP production by T-84 cells. Therefore, this 
method is specific to Ugn, and is unable to detect proUgn (82, 114). However, 
trypsin digestion converts proUgn to Ugn, which can then be measured in the T-84 
cell assay. This proteolytic procedure has been used for an indirect assessment of 
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proUgn by several labs. However, the digestion introduces error to the results if it is 
not carefully controlled with respect to the stoichiometry of the proUgn-to-Ugn 
conversion, and the extent to which Ugn itself is degraded during the reaction (82, 
1114). (b) A radioimmunoassay (RIA) was subsequently developed, utilizing an 
antibody directed against a peptide sequence that is common to both Ugn and 
proUgn. Because both molecules contain the epitope detected by the antibody, the 
assay cannot differentiate them (24, 139). The assay becomes specific for proUgn 
and/or Ugn only if it is coupled with an HPLC fractionation that separates the two 
molecules. However, this labor-intensive method is seldom employed, and many 
published papers therefore report “Ugn-like immunoreactivity”, without being able to 
discriminate Ugn from proUgn. (c) When I began my project, one of the first things I 
did was to help generate a proUgn-specific assay, based on an antibody that is 
selective for proUgn over Ugn. This assay (described in detail in Chapter 2) uses an 
electrophoretic Western blot method to separate proUgn from Ugn. (d) I also 
developed a quantitative binding assay that can be used to measure Ugn without 
responding to proUgn (Chapter 3). This binding assay has several major advantages 
over the T-84 cell bioassay: it is much faster to perform, it is more sensitive by a 
factor of ~100-fold, and it is less sensitive to interference from other constituents of 
urine or tissue extracts.  
Western and Northern blot studies have shown that proUgn expression is 
limited almost exclusively to the alimentary tract and the kidney (figure 1.4) (134). 
Using the assay methods described above, I quantitatively analyzed the levels of 
proUgn and Ugn in these tissues, and in plasma. As will be shown in Chapter 2, I 
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determined that very little processing of proUgn takes place within tissues. I also 
demonstrated that intact proUgn circulates at relatively high levels in plasma, 
whereas levels of circulating Ugn are below the detection limit of my most sensitive 
assay. Using radiolabeled recombinant proUgn, I also showed that the propeptide 
circulates intact, and is only converted to Ugn within the renal tubules after filtration 
at the glomerulus. This is distinct from other typical endocrine axes where the 
prohormone is processed to the mature peptide at the site of synthesis, and is 
delivered to the target in active form. This has led me to propose that proUgn is the 
circulating “endocrine” agent that carries information from the intestine to the kidney. 
 
proUgn Expression in Humans and Rats 
 
Ugn was identified as a 15 amino acid sequence in opossums, but was next 
found as a 16 amino acid peptide in the urine of humans, with an additional leucine 
attached at the carboxyl terminus (99). It was subsequently found in the urine of rats 
in both 15 and 18 amino acid N-terminally extended forms (99). An additional 
species found by RP-HPLC of human plasma contained 24 amino acids, 
corresponding to the originally described 16 residue species with an 8 extension at 
the N-terminus (85). 
In 1996, a few years after Ugn’s discovery, a group in Japan observed the 
existence of two different topological isomers while attempting to synthesize the 
human 16 amino acid sequence (29). When carefully constructing the peptide with 
its disulfide bridges in the correct linkage, they found that the order of establishing 
these linkages would create two distinct species, differentiated by RP-HPLC 
fractionation (29, 87). The two peptide isomers, named hUgn-A and hUgn-B, also 
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differed in their ability to stimulate T-84 cells to produce cGMP, with the A conformer 
being a potent activator and the B conformer being ~100-fold less potent (29, 135). 
Further analysis revealed that the additional leucine present at the carboxyl terminus 
of the human form is responsible for steric hindrance to interconversion between 
these two isomers, allowing them to be isolated as independent species (87). It was 
later shown that the two human Ugn isomers do transition back and forth, with a 
half-life of ~2 days. The rat, mouse and opossum forms of Ugn, as well as Gn 
species (all of which lack the C-terminal leucine), make this transition at a rate of 1 
to 2 cycles per second at 37 ° and pH 7.0, making them a racemic mix (87). 
Dr. Nicholas Moss in our lab showed that both peptides have effects on the 
rat kidney, despite h-Ugn-Bs lack of ability to stimulate T-84 cells. However, there is 
a difference in the natriuresis seen, both in its intensity and its temporal 
characteristics (135). The B isomer causes greater Na+ excretion, more rapidly and 
at a lower dose than does the A isomer (135). 
 
Physiological and Genetic Evidence that Ugn and proUgn Participate in Na+ 
Homeostasis  
 
The effects of Ugn and proUgn on the kidney have been studied both in vivo 
in rats and mice and in isolated perfused rat kidneys. Using an a technique known 
as the sealed-mouse renal function assay, dose dependent increases in UK+v, 
UNa+v and urine volume were seen when Ugn was infused intravenously (23). Ugn 
infused into an isolated perfused kidney elicited diuresis, natriuresis and an increase 
in GFR (57, 76, 139, 186). In whole animals, a limited number of experiments have 
 18 
shown that when proUgn is infused, there is an increase in Na+ excretion and urine 
volume but no change in GFR or UK+v (76, 136).  
The generation of a Ugn knockout mouse by Dr. Mitchell Cohen’s group at 
University of Cincinnati was a major step forward in the investigation of proUgn as 
the agent responsible for post-prandial natriuresis  (118).  These mice were 
developed by substitution of a neomycin resistance gene cassette in for the first 
exon of the Ugn gene in embryonic stem cells, creating a whole animal knockout. 
Analysis by both Northern and Western blot showed that neither proUgn protein nor 
mRNA was present in any of the tissues that are normally positive for Ugn 
expression in wild type animals. 
The baseline phenotype of these animals was relatively normal: animals were 
viable through adulthood, of a similar body weight to wildtype animals, and capable 
of reproducing normally. However they did have hypertension, as their mean arterial 
pressure (MAP) was significantly elevated relative to Ugn+/+ animals. The MAP was 
not sensitive to the level of salt in the diet: both mutant and wild type animals 
showed only small changes in MAP in response to large changes in the NaCl 
content of the food (0.01% vs. 1% vs. 5%), and the small responses of the mutants 
were indistinguishable from those of the wild type strain (118). 
Another prominent defect in these animals is their impaired ability to excrete 
an acute oral Na+ load. When challenged with a bolus of NaCl (300mmol) 
administered by gastric gavage, the Ugn-/- mice showed significantly less 
cumulative Na+ excretion than wild-type animals at every time point after 20 min 
(Figure 1.5, (118)). In contrast, when the same bolus of NaCl was administered 
 19 
intravenously, mutant and wild type animals excreted it at the same rate (data not 
shown). In an extension of these studies, the same group analyzed the longer-term 
effects of changes in oral NaCl in conscious animals (50). Animals were housed in 
metabolic cages and dietary Na+ in the chow was switched from 1% NaCl to 
5%NaCl. In these circumstances, daily cumulative urinary Na+ excretion over the 
first 48 hours was significantly higher in the Ugn+/+ mice compared to Ugn-/- 
animals (Figure 1.5 and reference (50)). By the third 24-hour collection, however, the 
mutant animals had caught up to the wild type animals. There was no longer a 
significant difference in Na+ excretion, and both strains were once again balanced 
with respect to intake and excretion.  
The data from these knockout studies support the hypothesis that Ugn and/or 
proUgn play a role in the handling of oral Na+ (as suggested by the transient defect 
in Na+ balance displayed by the Ugn knockout animals during a diet shift), as well as 
a potentially distinct role in overall Na+ homeostasis (as suggested by the chronic 
hypertension exhibited by these animals that is independent of their level of oral Na+ 
intake). That the animals’ hypertension is not salt sensitive is perhaps not surprising, 
given that numerous long term Na+ homeostasis mechanisms remain intact and 
could come into play during prolonged shifts in Na+ intake. What is significant is that 
animals lacking the Ugn-dependent mechanism have impaired Na+ excretion over 
the first two days after a switch to high salt, the critical period where other 
homeostatic control mechanisms have not yet come into balance. 
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GC-C Knock Out Animals are Still Renally Responsive to Ugn   
 
As described above, GC-C is a member of the group of natriuretic peptide 
receptors, several of whose other members are highly expressed in the kidney of 
mammals and play roles in Na+ regulation. Two different groups have developed 
GC-C knockout mice, and, as expected, they have lost the intestinal response to 
STa (127, 166). However, these mice have no overt Na+-handling phenotype (50), 
are viable and can reproduce normally.  
When Gn and Ugn were infused into GC-C -/- mice, the animals showed a 
time and dose dependent increase in renal Na+ excretion that was similar to 
responses observed in wild type mice (22, 23). Additionally, these renal effects of 
Ugn appeared to be independent of cGMP as its levels in urine were unchanged 
during the infusions (50). Related studies in principal cells isolated from human 
kidneys showed a depolarization in response to Ugn that was independent of GC-C, 
as no GC-C transcript was detected in these cells by rtPCR (22, 168). These types 
of studies have provided strong evidence that GC-C is not the only renal receptor for 
Ugn, and—potentially—may not play any role at all in mediating renal responses to 
the peptide. 
 
An Alternative Receptor to GC-C May Play These Extra-Intestinal Roles  
   
 In light of an absence of a requirement for GC-C in the kidneys  
for renal effects of Ugn on volume homeostasis, there must be an alternate, cGMP-
independent receptor. Several groups have suggested that this renal receptor for 
Ugn is a pertussis toxin-sensitive G protein (74).  
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Opossums are again unique from other mammals in that they express an 
alternate rGC that is stimulated by the guanylin-family of peptides (46). This rGC 
(termed OK-GC ) has ~75% sequence homology to GC-C (117) and is expressed in 
the digestive, renal, central nervous, reproductive, and immune/lymphoid systems of 
the opossum (117). No homolog to OK-GC has been found in humans, rats or mice. 
As opossums are marsupials (in contrast to all other species studied), and are the 
only known species to express Lgn, these unique features could be related to their 
unusual reproductive scheme (139).  
 
Pathological States that Result in Changes in Ugn and proUgn 
 
Congestive heart failure (CHF) is a disease state in which compromised 
cardiac function results in pathological fluid retention (50). In patients with severe 
CHF, urinary Ugn (24 hour total excretion) is elevated as much as 70 fold over 
healthy control individuals (24, 141). Based on these results, Ugn could participate in 
a protective mechanism contributing to reduce blood volume and pressure (24).  
Studies on a rat model of nephrotic syndrome revealed elevated levels of 
urinary Ugn-like activity, which might be expected as the filtration barrier in the 
kidney is compromised (93). These animals also have a four-fold increase in plasma 
Ugn immunoreactivity, but the assay used was unable to discriminate between the 
Ugn and proUgn peptides. Multiple studies have seen similar elevated urinary Ugn-
like peptides and plasma proUgn in humans with various forms of renal disease (68, 
140). 
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Differences in proUgn related peptides in tissue compartments involved in 
Na+ handling during these different disease conditions suggest that the peptides 
might play a role in Na+ homeostasis during pathological states, in addition to their 
proposed roles under normal physiological conditions. This might allow for proUgn or 
its metabolites to serve as indicators of disease severity, and (perhaps) as the 
starting point for the design of therapeutic agents to ameliorate the pathological 
symptoms in these diseases. 
 
Changes in Ugn and proUgn Expression and/or Secretion Evoked by 
Orogastric Sodium Loading 
 
Studies in rats, humans and mice have evaluated the effects of dietary Na+ on 
Ugn expression (24, 25, 50, 95, 100, 152). These data are summarized in table 1, 
showing the species, the tissue analyzed and the changes seen. In summary, the 
studies report no significant change in enteric Ugn expression in response to a high 
salt stimulus, but some change in renal Ugn expression and a much more significant 
change in urinary Ugn excretion. 
All of these studies lack adequate temporal analysis of changes in Ugn or 
proUgn levels (either at the mRNA or polypeptide level) following the dietary 
intervention. In particular, all published studies all focus on late time points following 
a diet shift (after animals have reestablished an equilibrium between Na+ intake and 
Na+ excretion), whereas the documented defects in Na+ excretion in the Ugn (-/-) 
animals occur at early time points presumably before equilibrium has been attained 
(see figure 1.6 and reference 118).  Additionally, some of the studies utilize the RIA 
assay described above that is not specific for Ugn over proUgn, thus limiting our 
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ability to discern the essential signaling mechanisms (24, 95, 110, 152). Further 
studies with better time resolution of sample analysis at critical points in the diet 
intervention are required to more definitively resolve the role played by Ugn or 
proUgn in Na+ homeostasis. This is the major objective of my studies reported in 
Chapter 4.  
 
F. Hypothesis and Aims 
Uroguanylin or Prouroguanylin as an Endocrine Agent?   
 
My dissertation work has addressed four central issues in the Ugn field. (1) It 
was known that the majority of the proUgn in the body is produced by the intestine, 
but the conversion of this enteric pool of proUgn to Ugn had never been 
investigated. Does it occur within the gut itself, within the circulatory system, or 
within the renal tubules? (2) Some proUgn is also found within the kidney. Is any 
portion of this intrarenal pool of proUgn processed and stored as Ugn? (3) Does the 
intestine signal to the kidney through a Ugn-based endocrine axis? In other words, is 
Ugn (or proUgn) released into the plasma from the gut? Does this circulating peptide 
account for some or all of the Ugn found in urine? (4) Is the Ugn signaling pathway 
turned on or off by changes in oral salt intake? In other words, do plasma and/or 
urinary levels of Ugn or proUgn change in an appropriate way and over an 
appropriate time frame in response to changes in oral salt intake? The proposed 
studies to answer these questions serve as critical tests of the hypothesis that Ugn 
and proUgn participate in an endocrine signaling axis that is mobilized by orogastric 
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salt intake. I have used biochemical analysis and physiological interventions to 
address these questions. My studies are divided into three specific aims, as follows.  
 
Aim 1  
The objective of Aim 1 was to define the amounts of proUgn and Ugn in the 
tissue compartments relevant to post-prandial natriuresis. My studies addressed (a) 
intestinal presence and processing of proUgn; (b) plasma presence and processing 
of proUgn; and (c) renal presence and processing of proUgn. Direct measurements 
of peptide levels were coupled with infusion studies that introduced radiolabeled 
proUgn into the circulation to determine where processing takes place and into what 
metabolites. These studies are described in Chapter 2. 
 
Aim 2 
The objective of Aim 2 was to develop assays that reliably measure proUgn 
and Ugn independently and with adequate sensitivity in biological samples. A new 
Western blot-based assay for proUgn is described in Chapter 2. A new assay was 
developed for Ugn by adapting and validating a commonly used method of 
competitive receptor binding with a radioligand, as described in Chapter 3. 
 
Aim 3 
The objective of Aim 3a was to investigate the relationship between the 
amount of Na+ in the diet and the levels of proUgn transcript, proUgn polypeptide 
and Ugn polypeptide in relevant tissue compartments. This was accomplished by 
placing animals in metabolic cages and adjusting the amount of Na+ in their chow, 
then determining the effects of these manipulations on protein and mRNA levels. 
The objective of Aim 3b was to investigate whether there is a product-precursor 
relationship between plasma proUgn and urinary Ugn. These studies are described 
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in Chapter 2 (vascular infusion of radiolabeled proUgn followed by HPLC analysis of 
radiolabeled urinary metabolites) and Chapter 4 (vascular infusion of unlabeled 
proUgn followed by direct measurement of urinary Ugn levels). 
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Tables 
Paper Animal Tissue 
Protein/mRNA 
(detection 
method) 
Diet condition Increase/decrease 
Urine 
 
Protein 
(Non-Specific 
RIA) 
425(HS) vs 
128(LS) 
pmol/day 
 
Plasma 
 
Protein 
(Non-Specific 
RIA) 
No Diff. 
Kidney 
 RNA (rtPCR) 
0.77 (HS) vs 0.32 
(LS) 
UGn/ß-Actin 
Fukae, 
et.al. 2002 
(24) 
Rat 
SI RNA  (Northern Blot) 
7 day Low 
(.08% NaCl) 
 
 
7 day High 
(4% NaCl) 
 
7.04 (HS) vs 5.15 
(LS) UGn/GAPDH 
4 day Normal 
(.6% NaCl) 
compared to 
4 day Low 
(.06% NaCl) 
Duo   -52% 
Jej   -27% 
Ile    -20% 
Col       -8% 
Kid No Diff. Carrithers, et.al.  2002 
(25) 
Rat 
Duodenu
m 
Jejunum 
Ileum 
Colon 
Kidney 
RNA 
(rtPCR) 4 day Normal 
(.6% NaCl) 
compared to 
4 day High 
(7% NaCl) 
Duo No Diff. 
Jej +5% 
Ile No Diff. 
Col No Diff. 
Kid No Diff. 
Kita, et.al.  
1999 
(100) 
Rat SI (perfused) 
Luminal Protein 
(Non-Specific 
RIA) 
Anesthetized 
animals 
intestine was 
perfused with 
different molar 
Na+ solutions 
Minor increase 
(insignificant) at 
the highest NaCl 
infusion 
3 day Normal 
(.6% NaCl) No Diff. 
3 day Low 
(.06% NaCl) No Diff. 
3 day High 
(7% NaCl) No Diff. 
Potthast, 
et.al.  2001 
(152) 
Mouse 
 Kidney 
RNA 
 (rtPCR) 
3 day High 
(1% NaCl H2O) 
75% increase 
Day 2 No Diff. 
 
Day 4 low (-40%) 
 
Elitsur, 
et.al.  2006 
(50) 
Mouse 
 Plasma 
proUgn 
(WB Ab6910) 
1% NaCl 1st 3 
days then 
switch to 5% 
next 3 days Day 6 No Diff. 
 
 
Low 7 g/day 
 
95 pmol/day Kinoshita, et.al.  1997 
(95) 
Human 
 
Urine 
 
Protein 
(Non-Specific 
RIA) 
 High 10g/day 143 pmol/day 
Table 1.1 Details from experiments analyzing effects of altered oral Na+ intake on 
Ugn and/or proUgn levels in tissues, urine, or plasma. Entries highlighted in light 
gray were performed with an assay that cannot discriminate Ugn from proUgn.   
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Figures 
 
 
 
Figure 1.1 Model of Post Prandial Natriuresis Orogastic Na+ enters the intestine 
where a undefined sensing mechanism in turn releases a natriuretic endocrine factor 
into the circulation. It travels via the circulation to the kidney where it is filtered at the 
glomerulus and has effects on Na+ excretion in order to maintain balance with the 
enteric lumenal Na+ load that is being adsorbed. 
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Figure 1.2 Structure of guanylin-family of peptides and the E. Coli enterotoxin 
Sta Conserved cysteine residues are highlighted in Yellow and shared disulfide 
bonds are marked with black lines. Additional cysteines and disulfide bond unique to 
STa is denoted with red lines. 
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Figure 1.3. T-84 Cell Assay for detection of Ugn. Standard curve showing the 
concentration response relationship between Ugn administered to T-84 cells and 
cGMP production in response, to a dilution series of recombinant rat Ugn standard 
(black circles and line). Blue dot indicates the response from ANP, which potently 
activates GC-A. Red dot indicates the response from proUgn, which requires 
processing to activate GC-C.  
 
 
Figure 1.4. Western blot analysis of proUgn expression in a variety of tissues. 
Brain was divided into three regions: cerebellum, cortex, and subcortex (all of the 
structures within the forebrain that lie beneath the cortex). Stomach was cut into five 
approximately equal portions to provide rostral, intermediate, and caudal samples 
(labeled I–V). Other tissues were removed intact, and extracts were made from the 
whole organ. Comparable aliquots (60µg protein) from each tissue were tested with 
two different antibodies (6910 and 6912). The position of the proUgn band is marked 
by the black arrowheads. Polypeptides in the pancreas and spleen that are detected 
by only one of the two antibodies cannot represent authentic proUgn, and most likely 
represent molecules that contain cross-reacting epitopes. 
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Figure 1.5 Ugn -/- Animal Chronic Response to Oral Salt Data taken from studies 
performed by Elitsur et.al. 2006 (50). White symbols indicate Na+ excretion from 
proUgn knockout mice. Black symbols indicate Na+ excretion from wild-type mice. 
The shaded pink area between the curves highlights the time when Na+ excretion 
differs between strains in the study. 
 
 
Figure 1.6 Ugn -/- Animal Acute Response to Oral Salt Cumulative Na+ excretion 
(UNa+V) before and after NaCl administration. Number of animals in each group is 
shown in parentheses. †P < 0.05 compared with the corresponding time point in the 
Ugn+/+ group. (Taken from Lorenz JN et.al.  The Journal of Clinical Investigation 
2003:112;8)(118) 
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A INTRODUCTION 
 
An orally-delivered salt load is excreted faster than an equivalent intravenous 
salt load (19, 21, 112, 174). Although the mechanisms underlying this “postprandial 
natriuresis” are not fully understood, an intestinal peptide known as uroguanylin 
(Ugn) has been identified as a likely participant (63, 65). Perhaps the strongest 
evidence for this comes from genetic ablation of the uroguanylin gene in mice, which 
produces chronic hypertension and significantly retards urinary Na+ excretion after 
an oral Na+ load (50, 118). In addition, both Ugn and its propeptide precursor, 
prouroguanylin (proUgn), circulate in the plasma (53, 85, 95), and—when plasma 
levels are raised by intravenous infusion of exogenous Ugn—the rate of urinary salt 
excretion increases (23, 56, 65). Furthermore, the principal site of Ugn expression in 
the rat intestine is the enterochromaffin (EC) cell (39, 139, 150), an intestinal 
endocrine cell long known to secrete amines and peptides into the interstitium, and 
thence into the general circulation (59, 144). Ugn gene expression is regulated in 
these cells by orally administered salt in the intestine of the intact rat (25), and is 
also regulated by extracellular hypertonicity in an intestinally derived epithelial cell 
line (177). Taken together, these observations are consistent with the hypothesis 
that Ugn functions as the endocrine mediator of an entero-renal hormonal axis that 
regulates urinary Na+ excretion in response to dietary Na+ intake.  
 
To meet the requirements of this hypothesis, however, the renal natriuretic 
response must be initiated by Ugn that originates from within the intestine. 
Somewhat surprisingly, this fundamental principle has not yet been established. 
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Although Northern blot studies have shown that the small intestine is by far the 
major site for preprouroguanylin mRNA expression (53, 113, 132), detectable 
amounts of preprouroguanylin mRNA and/or immunoreactive Ugn-like polypeptides 
have been reported in a variety of other tissues, including the kidney itself, as well as 
the colon, heart, stomach, lung, pancreas, brain, testis, ovary, oviduct, epididymis, 
prostate, parotid gland, submandibular gland, nasal mucosa, and gall bladder (52, 
53, 81, 89, 106, 107, 108, 110, 113, 124, 126, 132). One caveat to these studies is 
that the methods employed have either been indirect (RNA-based) or non-
quantitative (immunocytochemical), and, where antibodies have been used, they 
have, for the most part, been unable to discriminate between Ugn and proUgn. 
Thus, the relative potential of each of these tissues to contribute to plasma pools of 
Ugn and proUgn remains undefined.  
 
As a further complication, a proUgn-like polypeptide is readily detected in 
extracts of rat small intestine using standard Western blotting techniques (150, 153), 
but Ugn itself appears to be present in these extracts only at very low levels (132). 
Thus, if the intestine is the source of Ugn that is destined for the kidney, it is not 
clear when and where propeptide processing takes place. Moreover, the Ugn 
concentrations reported in plasma are also very low, relative to the levels that are 
required to induce physiological responses in the kidney. Thus, published plasma 
Ugn levels are in the femtomolar to picomolar range, depending on the species (67, 
93, 140), whereas physiological thresholds for renal responses have been 
established in the nanomolar range by prolonged agonist infusions (56), or have 
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been based on a bolus injection procedure that produces very high doses of agonist 
over a very short (non-physiological) time course (22, 77). The “pharmacological” 
nature of the concentrations employed in these studies has been a source of 
concern, with respect to the putative endocrine role of Ugn. 
 
To address these issues, we developed a new immunoassay that is specific 
for proUgn and does not cross-react with free Ugn. We used this assay to quantify 
proUgn levels in tissues and in plasma, and to determine the effects of gut ablation 
on the size of the plasma pool. We also measured Ugn levels in parallel, using a 
quantitative bioassay. Our results demonstrate that the dominant form of the peptide 
stored in the intestine and secreted into the plasma is proUgn rather than Ugn. To 
investigate the biological significance of this circulating pool of proUgn, we infused 
exogenous propeptide intravenously at a “physiological” concentration, and 
measured the subsequent effects on renal function. The prominent natriuresis 
evoked by this infusion suggests that some form of post-secretory processing of 
proUgn must occur, in order to convert the biologically inactive propeptide to its 
mature, bioactive form.  
 
To investigate potential post-secretory processing mechanisms that could 
convert circulating proUgn to active metabolite(s), as well as the means by which the 
propeptide and/or its metabolites are cleared from the plasma, we infused animals 
intravenously with radiolabeled recombinant proUgn. HPLC analysis of tissue 
extracts, urine, and plasma from these animals has provided a clear picture of the 
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relevant mechanisms. Surprisingly, the data show that the propeptide remains in an 
intact state throughout its time in the circulation. This suggests that processing of 
circulating proUgn most likely occurs after the propeptide has been delivered to its 
target organ(s). Our data also reveal that one well-established target organ (the 
kidney) is able to effectively metabolize proUgn. The resulting peptides, which 
include Ugn and several other unidentified fragments, are retained within the 
nephrons and are eliminated in the urine. This is reminiscent of the proposed 
handling of proUgn in the intestine, where intraluminal digestive enzymes, such as 
chymotrypsin, are thought to rapidly convert luminally-secreted propeptide into 
active Ugn (106). 
 
 
B. MATERIALS AND METHODS 
 
Experimental Animals 
 
Male Wistar or Sprague-Dawley rats (250 - 300 g) were purchased from 
Charles River Laboratories (Wilmington, MA) and maintained for several days on a 
12 hour light/dark cycle in an AALAC-approved facility with continuously available 
veterinary care and uninterrupted access to water and standard rat chow. All 
experimental procedures were approved by the Institutional Animal Care and Use 
Committee at the University of North Carolina at Chapel Hill, and were carried out in 
accordance with the NIH Guide for the Care and Use of Laboratory Animals. 
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Bacterially-expressed proUgn Standard 
 
We subcloned the cDNA sequence encoding proUgn into an expression 
plasmid (pMal-CM, New England Biolabs), downstream from the E. coli maltose 
binding protein with an intervening thrombin cleavage site. The insert was PCR-
amplified from a previously-cloned preproUGn cDNA (23), with an Nde I restriction 
site added to the forward primer, (5’-CATATGGTCTACATCAAGTACCATGG-3’), 
and a Hind III restriction site added to the reverse primer (5’-
AAGCTTTCAGCAGCCCGTAC-3’). The peptide encoded by the insert (Table 2.1, 
plasmid pMal-R) lacks the predicted 21 residue N-terminal signal peptide (7, 131), 
but contains 4 non-native residues that were added to the N terminus to generate 
the thrombin cleavage site. A similar construct was created using the same forward 
primer and a different reverse primer (5’-AAGCTTTCAGGTCCTCAAGGCCTTGA-
3’), in which both the signal peptide and the last 17 amino acids at the proUgn C-
terminus were deleted (Table 2.1, plasmid pMal-CD). The PCR products were 
ligated into linearized pMal-CM and introduced into E. coli strain DH5a. After single 
colony isolation and amplification in bacteria, the sequence and orientation of the 
inserts were confirmed. 
Bacterially-expressed fusion proteins were affinity-purified on amylose beads 
(New England Biolabs, Ipswitch MA) as described by the manufacturer, and cleaved 
by incubation with thrombin-coated agarose beads (Sigma Chemical Company, St. 
Louis MO). After cleavage the polypeptide was purified by a two-step 
chromatographic procedure. Active fractions were again confirmed by Western 
blotting. 
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We used four methods to quantify the final yield of recombinant rat proUgn 
standard (R) after HPLC purification, obtaining comparable results in each case. The 
first method was by direct protein assay, using a commercially-supplied kit (BioRad, 
Hercules CA). In addition, we also used the silver stain method (SilverSNAP Stain 
Kit II, Pierce, Rockford, IL) to compare samples of R side-by-side with standard 
curves prepared from known amounts of three different commercially-purchased 
peptides, including (a) 99% pure recombinant human proUgn (BioVendor Laboratory 
Medicine, Inc., Czech Republic), (b) 99% pure cytochrome C (Sigma Chemical 
Company, St. Louis, MO), and (c) 99% pure aprotinin (Sigma Chemical Company, 
St. Louis, MO). 
 
Collection of Plasma and Tissues 
 
Animals were anesthetized (1.6 g urethane/kg body weight, ip). The carotid 
artery was cannulated with PE 50 tubing for blood withdrawal. After tissue and blood 
removal, animals were euthanized by anesthetic overdose.  
Blood samples were typically obtained from a freshly-anesthetized animal, 
but, in some cases, were taken both before and 30 min after surgical removal of the 
small intestine. In this case, extracellular volume was maintained by infusion of 
isotonic saline through the jugular vein at 30 µl/min/100g body weight. Blood was 
collected into heparinized tubes (Sigma Chemical Company, St. Louis, MO), 
centrifuged (16,000 x g for 5 min), and stored frozen at -80° C until used for further 
analysis.  
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Individual organs were removed intact, subdivided into smaller pieces as 
necessary, and rapidly frozen. Prior to freezing, the intestine was cut longitudinally, 
and rinsed thoroughly with saline to eliminate any contents, and each kidney was 
flushed intravascularly with 15 ml of saline to ensure that it was free of plasma and 
ultrafiltrate. All frozen tissues were homogenized in buffer (25 mM HEPES, pH 7.4, 
containing protease inhibitor cocktail (Sigma Chemical Company, St. Louis, MO) at a 
ratio of 4 ml buffer/g tissue. Homogenates were centrifuged at 60,000 x g for 30 min 
at 4° C, and the supernatant fraction was stored at -80° C. 
 
Quantitative T84 Cell Assay for GC-C-stimulating Activity 
 
Plasma and intestinal extracts were bioassayed for Ugn-like activity, based on 
the method of Currie et al. (40). This assay measures the cyclic GMP responses that 
are evoked by ligands that activate GC-C (in rats, the known ligands are Ugn and its 
structurally-related analog guanylin (Gn) (40, 113, 132). Neither proUgn nor proUgn 
has significant activity in this assay (82, 113, 165). 
Typically, a standard curve was also constructed, using known amounts of 
synthetic rat Ugn (Peptides International, Louisville KY). The responses evoked by 
the standards were fit using the Michaelis-Menten equation: (pmol cGMP/well) = 
(Vmax x concentrationUGn)/(EC50 + concentrationUGn). An estimate for the EC50 
for rat Ugn was obtained from a previously published study (51), and the value of 
Vmax was varied to achieve an optimal fit by eye. Standards and unknowns were 
assayed in duplicate or triplicate. Results for each unknown are reported as pmol 
Ugn-like activity per well (mean ± sem), as determined by interpolation from the 
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standard curve, followed by a correction for sample loss during processing, based 
on the activity recovered from the spiked samples (34 ± 8% recovery, n = 10). No 
difference in recovery was apparent between spiked gut and spiked plasma 
samples. 
 
Western Blotting and Quantitative Immunoassay for proUgn 
 
We developed a Western blot-based immunoassay to measure tissue and 
plasma levels of rat proUgn. This assay employs a standard curve constructed with 
known amounts of our bacterially-produced recombinant rat proUgn (see above), 
using either antibody 6910 or 6912 (113, 150) as the primary detection antibody. To 
perform the assay, the five left-hand lanes of a gradient gel (4 - 12% polyacrylamide, 
Invitrogen Corporation, Carlsbad CA) were loaded with a dilution series of the 
recombinant standard (typically spanning the range from 10 - 500 fmol). The 
remaining lanes were loaded with test samples. After electrophoresis, protein was 
electroblotted onto 0.2 micron nitrocellulose membrane. The membrane was then 
incubated for 2 hr with primary antibody (diluted 1:500 in TBS-T), washed and 
incubated for 1 hr in the dark with infrared-emitting secondary antibody (IRDye 800 
Rockland Inc, Gilbertsville PA; diluted 1:2000), and washed in the dark for 1 hr with 
TBS-T, followed by 20 min with TBS. Immunoreactive proteins were then detected 
and quantified with an Odyssey infrared gel imaging system (LI-COR Biosciences, 
Lincoln, NE). 
This assay is linear (R2 = 0.98 ± 0.003, n = 19) up to at least 5 pmol, with a 
lower detection limit of ~0.01 pmol. The average coefficient of variation for identical 
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test samples run in the same assay is 11 ± 2% (mean for 11 independent assays, ± 
SEM). The sensitivity of the assay is adequate for extracts of intestinal tissue, which 
provide a strong proUgn signal when 50 µg of total protein are run on a gel. The 
amount of proUgn present in 75 µl of plasma is also well within the range that we 
can detect with our assay, but analysis of plasma samples required a pre-extraction 
procedure, using a Superdex 75 10/300 GL size exclusion column (GE Healthcare, 
Life Sciences, Piscataway, NJ) to separate proUgn from high-abundance plasma 
proteins that would otherwise have interfered with electrophoresis. The Superdex 
column was eluted and proUgn-containing fractions were pooled and dialyzed 
against distilled water, using the 1 kDa cutoff dialysis membrane described above. 
Dialyzed samples were dried under vacuum, resuspended in boiling SDS sample 
buffer, and electrophoresed as described above. Recovery of proUgn from the 
chromatography and dialysis steps was 30 ± 2% (n = 5). Correction for these sample 
losses has been included in all our plasma calculations. 
 
Production of Isotopically-Labeled Recombinant proUgn 
 
The rat proUgn sequence was subcloned into an expression vector optimized 
for high yield in vitro translation (pCITE-4a(+), Novagen/EMB Biosciences, Madison, 
WI). This vector encodes an S-tag peptide and a thrombin cleavage site upstream 
from the multiple cloning site. The proUgn insert was PCR amplified from a 
previously-cloned cDNA using a forward primer with an added Nco1 restriction site 
(5’-TCATGCCATGGTCCAAGTCCAGCTAGAA-3’) and a reverse primer with an 
added Xho I restriction site (5’-TGTACGGGCTGCTGACACTCGAGCACGAGC-3’). 
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These primers were chosen to eliminate both the 21 residue signal peptide and an 
internal Nco 1 site near the 5’ end of the proUgn coding sequence. Additionally, by 
inserting a methionine residue adjacent to the thrombin cleavage site, this construct 
enhanced radiolabeling of any peptide fragments that might be cleaved from the 
amino terminal region of the propeptide. The PCR product was ligated into linearized 
pCITE-4a(+), and, after single colony isolation and amplification in bacteria, the 
sequence and orientation of the insert were confirmed. The insert encodes the 
amino acid sequence 
GSMVQVQLESVKKLNELEEKQMSDPQQQKSGLLPDVCYNPALPLDLQPVCASQE
AASTFKALRTIATDECELCINVACTGC.  
Plasmid DNA was then used as the template for a coupled in vitro 
transcription/translation reaction (TnT rabbit reticulocyte lysate system, Promega 
Corp., Madison, WI) in the presence of 35S-cysteine and 35S-methionine (ProMix, 
Amersham-Pharmacia Biotech/GE Healthcare, Life Sciences, Waukesha, WI). 
Labeled proUgn was subsequently affinity purified on S-protein-coupled agarose 
beads (Novagen), and released from the beads by digestion with biotinylated 
thrombin (Novagen). The thrombin was then bound to streptavidin-agarose beads 
(Novagen). After removing the beads, the recombinant propeptide in the supernate 
was applied to a VYDAC 218TP1010 C-18 reverse phase column (The Separations 
Group Inc. (Grace Vydac), Hesperia, CA). The column was eluted at a flow rate of 1 
ml/min, with an immediate step increase to 36% acetonitrile, followed by a linear 
gradient of acetonitrile from 36% to 45% over 40 min. Two closely eluting peaks of 
labeled material were identified by liquid scintillation spectroscopy. Two lines of 
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evidence demonstrate that the later peak corresponds to 35S-proUGn: (a) its 
retention time (35 - 40 min) was identical to that of native proUgn on this gradient, 
and (b) the material eluted in this second peak tested positive for full-length proUgn 
in a Western blot. After HPLC purification, solvents were removed under vacuum, 
and the recombinant 35S-labeled propeptide was resuspended in phosphate-
buffered saline for infusion into anesthetized animals.  
 
Intravenous infusion of labeled, recombinant proUgn 
 
Animals were deprived of food (but not water) overnight, then anesthetized 
with urethane (1.6 g/kg body weight, ip). To prepare animals for these experiments, 
surgeries were performed as described prior. Radiolabeled proUgn was then 
administered as either (a) a bolus injection (5 x 106 cpm) through the jugular vein, or 
(b) a priming dose (6 x 105 cpm) given by bolus injection followed by a maintenance 
dose (5 x 106 cpm) added to the infusion solution over a long (60 - 360 min) period. 
Plasma and urine were collected at intervals, as described in the Results. Plasma 
samples (heparinized) and urine were stored on ice for the duration of the 
experiment, then frozen and stored at -80° C prior to analysis by HPLC (see below). 
At the end of the infusion period, tissues were removed and flash-frozen on dry ice. 
Note that most tissues were frozen immediately, but kidneys were flushed with 
15mls of saline before freezing, to clear radioactive materials from both the 
intravascular and intratubular compartments. All frozen tissues were homogenized in 
ice-cold homogenization buffer (4 ml/g tissue), using a motor-driven Potter-Elvehjem 
homogenizer fitted with a glass pestle. After homogenization, the extracts were 
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centrifuged at 27,000 x g for 30 min at 4°C in a Ti-50 rotor (Beckman Instruments), 
and the pellets discarded. Supernatant fractions were stored at -80° C prior to 
analysis by HPLC (see below). At the end of the experiment, after all tissues and 
fluids had been collected, animals were euthanized by anesthetic overdose. 
 
HPLC analysis of radiolabeled proUgn metabolites in liver, kidney, plasma, 
and urine 
  
Tissue, plasma, and urine samples were passed through a 0.2 µm Acrodisc 
syringe filter (Pall Corporation, Ann Arbor MI), then applied to the C-18 reverse 
phase column described above, after pre-equilibration with HPLC grade water 
containing 0.1% trifluoroacetic acid. The column was eluted at a flow rate of 1 
ml/min, with a linear gradient of acetonitrile from 2% to 50% over 30 min, followed by 
a step increase to 100% acetonitrile for 10 min (see figures 2.6 – 2.8). 1 ml samples 
were collected, dried in a centrifugal vacuum concentrator (Savant SpeedVac, 
Thermo Electron Corporation, Waltham MA), and dissolved in scintillation fluid 
(Scintisafe, Fisher Scientific) to determine the retention times and establish the 
relative amounts of radioactivity incorporated into metabolites. 
 
Inulin and proUgn clearance measurements 
 
FITC-conjugated inulin (Sigma St Louis MO) was dissolved in isotonic saline 
at a concentration of 40 mg/ml in a boiling water bath and dialyzed against isotonic 
saline (SpectraPor 6 dialysis membrane, 1000 Da cutoff-limit, Spectrum 
Laboratories, Rancho Domingo, CA). The dialyzed solution was filtered through a 
0.2 micron membrane and then administered to anesthetized Wistar rats as a bolus 
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injection of 0.5 ml into the jugular vein. Blood samples were collected through the 
carotid artery cannula into heparanized hematocrit tubes at 0.25, 2, 5, 10, 20, 40, 60, 
100, and 120 min following the bolus injection. The procedure was repeated in a 
separate group of “anephric” rats 5-10 minutes after bilateral ligation of the renal 
pedicles. The fluorescence intensity obtained from the first plasma sample (30 sec 
after bolus injection) was set at 100% and subsequent plasma inulin values are 
expressed as a percentage of this value. 
35S-proUGn disappearance curves were generated by a similar procedure in 
normal and acutely nephrectomized rats, except that the bolus injection contained 5 
x106 counts of 35S-proUGn produced by the in vitro reticulocyte expression system 
described above. Plasma samples were taken at 0.25, 5, 10, 30, 60 , 90, and 120 
minutes. Fewer samples were collected than in the inulin experiments, as a greater 
volume of plasma was needed at each time point for HPLC analysis. A 100 µl aliquot 
of plasma from each sample was fractionated on a C-18 reverse phase HPLC 
column to separate 35S-proUGn from other labeled metabolites that might have 
accumulated in blood over the duration of the experiment. Fractions from the C-18 
column were transferred to scintillation vials, dried under vacuum, and reconstituted 
in Scintiverse (Fisher Scientific, Pittsburgh PA) for liquid scintillation counting. 
proUgn was estimated as the total counts (blank subtracted) summed across the 
fractions that coincided with the known retention time for rat proUgn. This always 
corresponded to a distinct peak of radioactivity (see figure 2.6). 
  A separate group of 5 rats were cannulated for an infusion of FITC-labeled 
inulin (Sigma chemical Co, St Louis MO) at a rate of 100µg/min in isotonic saline at 
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30 µl/min. After 1 hour of equilibration 0.5 ml blood samples were taken from the 
carotid artery and left renal vein, for analysis of plasma inulin and endogenous (non-
radioactive) proUgn concentrations. The renal extraction ratios for each substance 
were calculated from the arteriovenous concentration differences. Given the well-
established renal handling of inulin, the inulin extraction ratio represents the filtration 
fraction, or the proportion of renal plasma flow that is filtered into the nephrons at 
that moment. Thus, a comparison of the extraction ratios for proUgn and inulin 
reveals the extent to which peptide removal by the kidneys corresponds to the 
amount of peptide filtered into the nephrons. 
 
Renal function studies 
 
An experimental group (8 rats, mean body weight 297±6 g) received an 
intravenous infusion of recombinant human prouroguanylin (hu-proUgn, BioVendor 
Laboratory Medicine, Inc., Czech Republic) and a control group (9 rats, mean body 
weight 309±9 g) received isotonic saline in place of peptide. Animals were 
anesthetized with sodium pentobarbital (Sigma Chemical Co, St. Louis MO 60 mg/kg 
body weight ip, dissolved in water at 50 mg/ml). Supplemental doses of anesthetic 
were provided as needed. Animals breathed spontaneously through a tracheotomy 
tube (PE240) installed at the start of each experiment. The femoral artery was 
cannulated with PE 50 tubing for arterial pressure measurement and blood 
withdrawal. The ureters were exposed through a midline abdominal incision and 
cannulated with PE10 tubing about 1 cm from each kidney. Urine was collected over 
20 minute intervals and the volume was determined gravimetrically. Blood samples 
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(50 µl) were collected at the mid points of each urine collection. A continuous 
intravenous infusion of 0.9% NaCl was provided into the left jugular vein at a rate of 
10 µl/min/100 g body weight. A portion of this infusion (10 µl/min) was provided 
through a PE10 cannula connected to a 1 ml syringe. The remainder, provided 
through a separate cannula, contained 3 mg/ml FITC-conjugated inulin (Sigma 
Chemical Co. St Louis MO). The inulin infusion solution was pre-dialyzed overnight 
across a 1 kDa cutoff membrane against isotonic saline (to remove unconjugated 
FITC and small inulin polymers), then filtered through a 0.2 micron membrane 
(Steriflip, Millipore Inc. Billerica, MA). 
GFR was determined from the clearance of FITC-labeled inulin using the 
quantitative fluorescence technique described by Lorenz (119).  FITC-inulin 
concentrations in plasma and urine samples were analyzed in 10 ml capillary tubes 
(Microcap, Clay Adams, Inc.) with an epifluorescence microscope (Zeiss Axioscope) 
fitted with a CCD camera (Hamamatsu Orca). Metamorph imaging software was 
used to measure the mean pixel intensity from a central region of each sample over 
a precisely timed exposure period. Absolute inulin concentrations in plasma and 
urine were obtained from a standard curve prepared from the infusion solution used 
in that experiment. Sodium concentrations in plasma and urine were determined by 
flame photometry (IL Model 943, Instrumentation Laboratory Co., Lexington MA). 
Blood pressure and heart rate were displayed on an analog monitor (Stoelting 
Instruments, Wood Dale, IL Model 50110 with pressure transducer Model 56360) 
and directed to a USB-A/D module (Keithley instruments, Cleveland, OH Model 
KUSB 3100). A/D output was displayed on a PC using acquisition software 
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constructed around the DTx_EZ open source system. Data were analyzed with the 
Prism 5 graphing and analysis program (Graphpad Software, San Diego CA). 
Each experiment consisted of seven 20 min clearance periods. After two 
control periods, rats in the experimental group received recombinant hu-proUgn via 
the 10 µl/min intravenous infusion line (described above) during the third, fourth, and 
fifth clearance periods at a rate of 1.66 µg/min/kg body weight (equivalent to 172 
pmol/min/kg body weight, or about 50 pmol/min for a 300 g animal). The experiment 
then continued for two post-infusion clearance periods. Control rats were treated in 
exactly the same way as the experimental group except no proUgn was infused. At 
the end of the last collection period, animals were euthanized by anesthetic 
overdose. 
 
Curve fitting 
 
We used curve fitting procedures in Igor Pro (WaveMetrics, Lake Oswego, 
OR) and Prism 5 (Graphpad Software, San Diego CA). These procedures use the 
Levenberg-Marquardt algorithm to iteratively adjust the parameter values of a given 
function until the weighted sum of the squared residuals (χ2) is minimized. We used 
this algorithm to define single, double, and triple exponential functions that would 
approximate the plasma proUgn and inulin disappearance curves. After each fit was 
optimized, the resulting χ2 values were used to calculate Akaike’s Information 
Criterion (AIC) for each function. In each case, the lowest AIC value was observed 
for the triple exponential function, indicating that it is the preferred model, with the 
better fit to the data. 
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C. RESULTS 
Extracts of rat intestine contain intact proUgn 
 
A previous study identified an immunoreactive molecule in rat gut extracts 
whose intestinal expression pattern closely paralleled that of proUgn mRNA, and 
whose size on an immunoblot approximated the size predicted for the proUgn 
polypeptide (153). Positive staining with two different anti-proUgn antibodies 
confirmed that this native polypeptide was structurally related to proUgn, but it 
remained unclear whether it was proUgn itself, or a large processing fragment 
derived from proUgn during the production of Ugn. In the present study, therefore, 
we have used a bacterial expression system to generate a recombinant rat proUgn 
standard (R) and a truncated version of rat proUgn from which the C-terminal Ugn 
sequence had been deleted (CΔ); these two standards were then compared to the 
native proUgn-like molecule on immunoblots, using three different anti-peptide 
antibodies (6912, 6910, and 1-11). The specificities of the antibodies and the 
structures of the recombinant standards are presented schematically in Figure 2.1a.  
Figure 2.1b shows an immunoblot of an extract of small intestine stained with 
antibody 6912. As in previous studies, we observed a prominent immunoreactive 
polypeptide (marked by the black arrowhead) whose apparent molecular weight was 
consistent with the size predicted for proUgn (~9.4 kDa). This native molecule (N) 
was just slightly smaller than R, and much larger than CΔ (Figure 2.1c). The slight 
size discrepancy between N and R (observed on many, but not all, gels) is 
consistent with the addition of 4 extra N-terminal amino acids to the recombinant 
protein, as required to generate a thrombin cleavage site in the fusion protein 
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precursor (see figure 2.1a and Methods). In addition, like R (and unlike CΔ), N was 
recognized by all three antibodies (figure 2.1d), confirming that it contains the intact 
C-terminus of proUgn. Thus, based on its size, and its pattern of immunological 
reactivity, N must correspond to full-length proUgn. Furthermore, as shown in Figure 
2.1c, we could not detect proUgn processing fragments (molecules whose size was 
comparable to CΔ, or smaller), even when we deliberately overloaded the gel with a 
large excess of gut extract (up to 120 µg of total protein, the limit that can be 
electrophoresed without serious distortion of the gel). 
To look more rigorously for proUgn processing fragments, we used HPLC to 
enrich our samples before applying them to gels. We first passed a crude gut extract 
over a sephacryl column and pooled the fractions containing molecules in the 1 - 17 
kDa range. This pooled material was concentrated and applied to a C18 reverse 
phase column to fractionate the peptides of interest. Immunoblots of individual C-18 
column fractions are shown in Figures 2.2a and 2.2b. At a moderate sample load, a 
prominent peak of immunoreactivity was observed in fraction 48 (Figure 2.2a, 1X 
sample load). This molecule must be full length proUgn, as it co-eluted from the C-
18 column with our recombinant proUgn standard (the retention time of R is 
indicated by the black arrow), had the same molecular weight as R on the gel, and 
was recognized by all three anti-proUgn antibodies (Figure 2.2b, fraction 48). When 
we overloaded a gel with material from the same column fractions (Figure 2.2a, 20X 
sample load), we could still observe the proUgn peak centered in fraction 48 (though 
it was greatly broadened due to overloading), but, in addition, we could now detect a 
minor immunoreactive species in fraction 44. We believe that this latter molecule 
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represents a C-terminally truncated processing fragment of proUgn, as it co-eluted 
from the C-18 column with our CΔ standard (the retention time of CΔ is indicated by 
the white arrow), had the same molecular weight as CΔ on the gel, and was 
recognized by antibodies 6910 and 6912, but not 1-11 (Figure 2.2b, fraction 44). 
However, the lack of reactivity with antibody 1-11 could also reflect the very small 
amounts of the candidate molecule in the sample, since antibody 1-11 binds less 
well to full length rat proUgn than do antibodies 6910 and 6912 (Figure 2.2b, fraction 
48). If the CΔ -like molecule is, indeed, a proUgn processing fragment, then its 
abundance is extremely low, relative to the abundance of full-length proUgn (Figure 
2.2a). Furthermore, no other candidate processing fragment was observed in any 
other HPLC fraction (including the early and late fractions, which were tested but are 
not shown in the figure). 
 
Quantitation of proUgn expression in the rat gut 
 
Having established that the small intestine contains authentic, full-length 
proUgn, we then developed an assay to measure the levels of the propeptide in 
tissue extracts. To ensure that the assay results would reflect the total tissue pool of 
proUgn, we removed the entire length of the small intestine, transected it at the 
midpoint, and prepared separate extracts from the proximal and distal halves without 
discarding any tissue. Using the assay procedure described in the Methods (and 
shown in Figures 2.3a and 2.3b), we established a specific activity of 12.6 ± 1.0 fmol 
proUgn/µg protein (n = 21) in proximal extracts, and 10.0 ± 1.0 fmol proUgn/µg 
protein (n = 17) in distal extracts. This corresponds to a tissue content of 1.32 ± 0.16 
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nmol proUgn in the proximal half, and 0.98 ± 0.12 nmol proUgn in the distal half, or a 
total of ~2.3 nmol for the small intestine as a whole (Table 2.2). 
 
Extracts of rat intestine contain relatively little Ugn 
 
To compare the proUgn values reported in Table 2.2 to levels of Ugn in the 
same regions of intestine, we measured the amount of biologically active peptide in 
gut extracts, using a well-established T84-cell-based bioassay. This assay is highly 
selective for Ugn and a related intestinal peptide, guanylin (Gn), but does not 
recognize proUgn (see Methods). 
Initial pilot studies revealed that the amount of Ugn-like bioactivity in gut 
extracts was near the detection limit of the bioassay. Therefore, to concentrate our 
samples prior to assay, we passed 1 ml aliquots of each of them over a C18 
SepPak, washed the SepPak with water, and used 10% acetonitrile to elute all of the 
bound activity (Figure 2.3c). The 10% SepPak fraction from each gut extract was 
then dried, resuspended in a small amount of bioassay medium, and applied to the 
T84 cells. After SepPak enrichment, all gut-derived samples evoked small, 
reproducible responses in the cells (Figure 2.3d). By interpolating the responses on 
a standard curve constructed with known amounts of synthetic Ugn (Figure 2.3d, 
black bars and inset), we could calculate that each sample contained, on average, 
0.52 ± 0.27 pmol of Ugn-like bioactivity. To correct for any losses that might have 
occurred due to irreversible binding to the SepPak, or to proteolysis at any step 
during sample processing, we added 30 pmol of Ugn to small frozen pieces of gut 
tissue, then homogenized these spiked samples and subjected them to the same 
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processing steps outlined above. On average, 34 ± 8% (n = 10) of the spiked 
material was recovered. Taking into account this recovery factor, we could then 
calculate that extracts of proximal small intestine contained, on average, 0.54 ± 0.16 
fmol of Ugn-like bioactivity/µg protein (mean ± sem, n = 5; see Table 2.2). 
 However, not all of the bioactive material in these extracts was necessarily 
equivalent to Ugn, since T84 cells respond to both Ugn and Gn, and rat jejunum 
contains both of these peptides (40, 113, 153). To investigate the identity of the 
molecule(s) responsible for the bioactivity, we SepPak-purified a larger amount of 
jejunal extract (6 ml), and fractionated this scaled-up preparation by reverse phase 
HPLC. Column fractions were dried, reconstituted, and bioassayed to establish the 
elution profile of the biologically active species (Figure 2.4a). One major and one 
minor peak of activity were evident. The retention time of the major peak (labeled 2 
in Figure 2.4a) was identical to that of a synthetic rat Ugn standard (marked by the 
black arrow), while the retention time of the minor peak (labeled 1 in Figure 2.4a) 
was very similar to that of a synthetic rat Gn standard (marked by the white arrow). 
As a further test of the identities of the endogenous bioactive molecules, we 
examined the pH dependencies of the responses that they evoked in T84 cells, 
since it has previously been well documented that responses to Ugn are greater at 
low pH, while responses to Gn are greater at high pH  (84). As shown in Figure 2.4b, 
the responses to peak 2 and authentic rat Ugn were affected identically by pH, 
whereas the response to peak 1 resembled neither Ugn nor Gn in its pH 
dependency. Thus, by two criteria (retention time and pH-dependency), the majority 
of the biological activity present in crude extracts of proximal small intestine is 
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attributable to authentic Ugn. The identity of the minor peak remains unconfirmed, 
though it most likely represents a Gn-related peptide. The data presented in Figure 
2.4 are thus generally consistent with previous studies showing that rats and mice 
express higher levels of proUgn than proUgn in the small intestine (both at the 
mRNA and propeptide levels), and higher levels of proUgn than proUgn in colon 
(113, 132, 153, 188). It should be noted, however, that this differential pattern of 
peptide distribution is not observed in other species, such as opossum (53, 116) or 
human (126).  
 Furthermore, although Figure 2.4 demonstrates that most of the Ugn-like 
bioactivity reported in Table 2.2 is indistinguishable from authentic Ugn, this 
nevertheless represents only a tiny fraction (~4%) of the total uroguanylin-related 
peptide stored in the tissue. The bulk of the peptide is present in the form of intact 
proUgn (Table 2.2). 
 
Intact proUgn circulates at much higher levels in rat plasma than does Ugn 
 
The ~23:1 ratio of proUgn to Ugn in the intestine suggests that the intact 
propeptide might the preferred secretory product. To verify that proUgn is a 
constituent of rat plasma, we performed Western blots after fractionating plasma on 
a size exclusion column. This size fractionation step was required to separate 
proUgn-sized peptides from very abundant higher molecular weight plasma proteins 
that interfere with electrophoresis. The blots revealed the presence of an ~9.4 kDa 
proUgn-like immunoreactive polypeptide that eluted between 125 – 150 min (Figure 
2.5a). To confirm the identity of this peptide, we compared its properties to those of 
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intestinal proUgn. The two molecules migrated identically on a high-resolution 
gradient gel, and both were recognized by all three of the anti-proUgn antibodies 
(Figure 2.5b). Thus, the plasma molecule was immunologically and 
electrophoretically identical to the full-length proUgn molecule found in intestinal 
extracts. Based on its column behavior, proUgn in plasma had a size comparable to 
that of an ~10 kDa globular protein (Figure 2.5c). Thus, it was not complexed with 
any high molecular weight protein, such as a plasma binding protein. 
To quantify the levels of proUgn in plasma, we analyzed 100 µl samples on a 
smaller, higher resolution Superdex size exclusion column, which can process 
multiple samples more efficiently. Arterial plasma was obtained from 21 independent 
animals. Each sample was individually applied to the column, and the proUgn-
containing fractions from each sample were pooled and subjected to the proUgn-
specific immunoassay (Figure 2.5d). On the basis of these measurements (including 
a correction for recovery from the column), we determined that proUgn circulates in 
plasma at 10.3 ± 1.7 pmol/ml (mean ± sem, n = 21). Assuming a plasma volume of 9 
ml for a 300 g rat (149), the estimated circulating pool of proUgn therefore amounts 
to ~93 pmol, corresponding to ~4% of the total intestinal pool (Table 2.2). 
For comparison, we then used the T84 cell bioassay procedure described 
above to measure Ugn-like bioactivity in plasma. Again, we pre-fractionated each 
plasma sample on a SepPak before applying it to the reporter cells. However, even 
when we loaded up to 3 ml of plasma onto the SepPak, we did not recover any 
signal that could correspond to endogenous Ugn (Figure 2.5e, white bar). By 
contrast, plasma samples spiked with 30 pmol of Ugn provoked robust responses, 
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with the same 34% recovery that was observed with gut samples (data not shown). 
By taking the response to 10-9 M Ugn as the limit of detection for the bioassay 
(Figure 2.5e, black bars), and factoring in the appropriate volumes and the recovery 
factor, we calculate that the upper limit for the plasma concentration of Ugn is 0.25 
pmol/ml. Thus, the plasma concentration of Ugn is less than 2.5% of the plasma 
concentration of proUgn (Table 2.2). In fact, the percentage is probably much lower, 
since sensitive radioimmunoassay measurements have established a circulating 
level of 0.003 pmol/ml for Ugn in human plasma (97). (Note that the published 
assays of Ugn levels in rat plasma report only “total Ugn-like” immunoreactivity, 
without separating Ugn from proUgn (67, 93)—see the Discussion for further 
elaboration of this point). 
 
The intestine is the likely source of circulating proUgn 
 
We then used our gel-based proUgn assay to quantify propeptide levels in 
colon and kidney, for comparison to the levels in small intestine. The results are 
shown in Table 2.2. The total proUgn content of the small intestine is approximately 
10 times greater than that of the kidney, and approximately 85 times greater than 
that of the colon. Thus, although our results do not rule out the possibility that some 
of the other tissues that we tested may contain levels of proUgn that fall below the 
detection limit of our gel-based assay, it is, nevertheless, reasonable to consider 
only the intestine and the kidney as plausible tissue sources of the high levels of 
proUgn observed in plasma, with small intestine being the best candidate. 
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Direct evidence for intestinal secretion of proUgn 
 
To more directly investigate the hypothesis that circulating proUgn is derived 
from the intestine, we used our proUgn assay to measure the level of propeptide in 
the venous outflow of the intestine (portal vein plasma) relative to that in the 
systemic circulation (carotid artery plasma). In paired measurements, portal plasma 
contained almost twice as much proUgn as did systemic plasma obtained at the 
same time from the same animal (portal levels were 177 ± 16% of arterial levels; n = 
20, p = 0.002, paired t-test), providing strong evidence that the intestine is a source 
of circulating proUgn. In contrast, the kidney does not appear to play a significant 
role in maintaining the plasma pool. Paired measurements of proUgn levels in the 
renal vein and the renal artery revealed that there was significantly less proUgn in 
the venous outflow from the kidney than was present in the arterial input to the 
kidney (renal vein levels were 63 ± 5% of renal artery levels; n = 8, p = 0.02, paired 
t-test). Thus, the net contribution of the kidney is to remove proUgn from the plasma, 
rather than to supply the propeptide to the plasma. 
As a final test of the origin of circulating proUgn, we measured levels in 
systemic plasma before and after complete resection of the small intestine. At 30 
min after resection, proUgn levels were reduced to 27 ± 6% of the pre-resection 
level (n = 3, p = 0.01, paired t-test), whereas in control animals maintained for 30 
min under identical conditions, but with no intestinal resection, plasma proUgn levels 
remained constant (levels at 30 min were 104 ± 2% of the “zero time” control; n = 3). 
These effects of resection, coupled with the regional plasma measurements 
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described above, indicate that most (and very likely all) of the proUgn in the 
circulation is derived from the gut. 
 
During infusion of radiolabeled proUgn, radioactivity accumulates in liver, 
kidney and urine 
 
After 60 min of continuous infusion with labeled propeptide, only two tissues 
(kidney and liver) accumulated significant amounts of radioactivity (Figure 2.6a, 
white bars). The specific activity of labeled material in the kidney was ~10 times 
higher than that in liver (Figure 2.6a, black bars), and the concentration of 
radioactivity in urine was ~10 times higher than that in plasma (Figure 2.6b), 
consistent with the idea that the kidney plays a dominant role in clearing the 
propeptide from the circulation, as would be expected for a peptide of this size.  
 
Circulating proUgn is rapidly removed from the plasma by renal clearance 
 
To further explore the role of the kidney in proUgn clearance, we measured 
the rate of disappearance of labeled propeptide from plasma after bolus infusion into 
control and anephric animals (the latter produced by ligating the renal pedicles 5 min 
prior to infusion). This type of infusion is equivalent to a classical pulse-chase 
procedure because, as demonstrated in our companion publication, significant 
amounts of endogenous, nonradioactive proUgn are continuously released from the 
intestine into the circulation in both intact and anephric animals. Plasma samples 
obtained at specific times after the bolus infusion were fractionated by reverse phase 
HPLC (Figure 2.7a, control animals; Figure 2.7b, anephric animals). At every time 
point, the radioactivity eluted from the reverse phase column as a single, well-
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defined peak, whose chromatographic behavior was indistinguishable from that of 
authentic proUgn (retention times of HPLC standards are given in figure 2.7c, and 
marked by the arrows in Figures 2.7a and b). The amplitude of this peak decreased 
progressively over time in both types of animal. To evaluate this quantitatively, we 
integrated the area of the peak for each sample, and plotted this value as a function 
of time after infusion (Figure 2.7d). In control animals, proUgn was cleared quickly 
from the circulation, with an overall plasma half-life of 49 sec (Figure 2.7d, white 
symbols). This disappearance curve was best fit by a triple exponential function 
(Table 2.3), suggesting that infused propeptide exits the circulation by a minimum of 
three independent routes. At least one of these routes must involve the kidney, since 
complete nephrectomy increased proUgn’s plasma dwell time by a factor of 7, giving 
a new overall plasma half-life of 351 sec (Figure 2.7d, black symbols). Furthermore, 
although the time-course of propeptide disappearance was again best fit by a triple 
exponential function, the fit in the nephrectomized animals appeared to lack the 
slowest clearance component that was normally observed in control animals, and 
instead included an ultra-slow process (t  > 300 min – see Table 2.3) that was 
difficult to observe under control conditions, due to the exceedingly low levels of 
proUgn present in the plasma at all time points after 30 min when the kidneys were 
functional.  
We also performed experiments to measure the rate of disappearance of 
FITC-labeled inulin after bolus infusions into control and anephric animals (Figure 
2.7e). Inulin has long been used as a filtration marker in renal clearance studies, 
because it is biologically inert, not metabolized by any tissue, freely filtered by the 
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kidney, and neither absorbed nor secreted by the renal tubules. The similar effect of 
nephrectomy on the time constants for proUgn and inulin disappearance (Table 2.3) 
suggests that the two molecules are handled in a similar way; i.e., that the kidney 
provides a prominent route for clearance of both molecules under normal 
circumstances. This is supported by measurements of the renal extraction of inulin 
and native proUgn. Based on the concentration difference between arterial and renal 
venous blood the renal extraction of inulin from arterial blood was 26.6+3.5% 
compared to 29.9+5.0% for proUgn (mean ± sem, n = 5). These values are not 
different, and suggest that that the renal clearance of proUgn is a filtration-
dependent phenomenon that parallels inulin clearance. 
  Note, however, that proUgn was eliminated from the circulation slightly more 
effectively than inulin—both in the presence and the absence of the kidneys 
(compare the inulin curves in Figure 2.7d to the superimposed proUgn curves, 
shown in grey and reproduced from Figure 2.7c). Thus, at least one clearance 
mechanism acts on proUgn that does not act on inulin. 
 
Circulating proUgn is not metabolized within the vascular compartment 
 
The HPLC traces in Figure 2.7a reveal that essentially all of the radioactivity 
in plasma was accounted for by intact proUgn at each time point after bolus 
injection; this remained true even when plasma clearance was greatly retarded by 
removing the kidneys (Figure 2.7b). If there had been significant conversion of 
proUgn to Ugn in the plasma, a radioactive peak should have appeared in the 
chromatogram at 42 – 43 min (the retention time of authentic Ugn). Any such 
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metabolite would have been heavily 35S-labeled, as it would contain the 4 cysteine 
residues that are found at the C-terminus of the propeptide (Figure 2.7c). 
Furthermore, because we added an extra (non-native) methionine residue to the N-
terminus of our recombinant construct, we would also have detected any processing 
fragments derived from this portion of the molecule. Given the precursor/product 
relationship between proUgn and any such metabolites, the levels of the latter 
should have risen as levels of the former fell. However, no fragments of any sort 
were observed in any of the chromatograms at any time point, arguing strongly that 
plasma and endothelial proteases did not process proUgn while it was circulating 
within the vasculature. Furthermore, within the time frame of these bolus infusion 
experiments, any proUgn metabolites that were generated in tissues were not 
returned to the plasma in detectable amounts.  
For comparison to the results obtained with the radiolabeled recombinant 
propeptide, we also investigated the plasma stability of native proUgn. For these 
experiments, we generated 2 µl aliquots from a freshly-drawn sample of plasma, and 
added 500 fmol of native rat proUgn to each. We then incubated the aliquots at 37° 
C for varying amounts of time, terminating any potential ongoing proteolytic activity 
at each specified time point by adding SDS sample buffer and immediately boiling 
the sample. SDS-denatured samples were then applied to polyacrylamide gels, and 
the relative proUgn content was determined by Western blotting followed by 
quantitative densitometry. We observed no significant degradation of proUgn, even 
after 60 min of incubation (more than 70 times longer than the plasma half-life that is 
normally observed in the intact animal): the propeptide content at 60 min was 92 ± 
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7% of the control level measured in samples that had been immediately boiled in 
SDS without any incubation at 37° C (mean ± sem, n = 4).  
 
Circulating proUgn is metabolized by the kidney, and specific metabolites are 
excreted in the urine 
 
As shown above (Figure 2.6a), a significant amount of labeled material 
accumulated in the kidney during prolonged intravenous infusion with radioactive 
proUgn. When analyzed by HPLC, however, kidney extracts actually contained very 
little intact proUgn (Figure 2.8a). Instead, label was principally associated with two 
large HPLC peaks eluting at positions corresponding to free cysteine (peak 1) and 
free methionine (peak 2).  
To evaluate the possibility that the absence of significant amounts of intact 
proUgn in kidney extracts was due to post-homogenization proteolysis of the 
propeptide, we spiked a homogenized sample with a known amount of native 
proUgn and measured the recovery of intact propeptide after prolonged incubation. 
This was similar to the plasma stability studies described above, except that we also 
included our standard protease inhibitor cocktail and performed the incubation at 4° 
C, to parallel the way in which the radioactive samples had been processed. After 60 
min, we recovered essentially all (92.6 ± 2.6%, mean ± range, n = 2) of the spiked 
native material in intact form, indicating that proteolysis was not a significant factor in 
the radiolabeling studies.  
In striking contrast to the limited spectrum of labeled metabolites observed in 
kidney homogenates, radioactivity recovered in the urine was distributed among a 
wide variety of molecular species (Figure 2.8b), including cysteine (peak 1), 
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methionine (peak 2), a small amount of material whose retention time matches that 
of intact proUgn (peak 6), and three additional metabolites (peaks 3, 4, and 5—note 
that peak 3 partially overlaps the methionine peak). One of these metabolites (peak 
5) had a retention time identical to that of an authentic rat UGn15 standard. The 
other metabolites (peaks 3 and 4) are as-yet unidentified. However we believe it is 
likely that they correspond to UGn13 and UGn14, since these alternative proUgn 
cleavage products were both previously identified (along with UGn15) as prominent 
bioactive components of opossum urine (83). It is difficult, however, to rigorously 
compare the previously published and current results on a peak-by-peak basis, 
since substantial differences in pH, ion pairing reagent, and gradient elution profile 
will have affected the relative retention times of the individual molecules. 
  The fact that urinary peptide metabolites of proUgn do not gain access to the 
circulation was further confirmed in samples of blood taken contemporaneously from 
carotid artery and renal vein after 1-2 hours of continuous intravenous 35S-proUGn 
infusion (Figure 2.9a). Consistent with the prolonged nature of this infusion protocol, 
both plasma samples showed a predominant proUgn peak (peak 6). In addition, and 
unlike the bolus infusion studies previously presented in Figure 2.7, modest 
cysteine- and methionine-like peaks were also detectible (peaks 1 and 2). 
Presumably, these were generated within the kidney during the processing of 
proUgn, and then returned to the plasma. As would be predicted by this hypothesis, 
the renal vein contained a significantly higher proportion of the labeled amino acids, 
relative to intact proUgn, than did the systemic circulation (Figure 2.9b). It is 
particularly noteworthy, however, that neither the venous nor the arterial blood 
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sample contained any metabolite of proUgn other than free cysteine and free 
methionine. Thus, even over prolonged time periods, circulating proUgn does not 
serve as a source of circulating Ugn. 
 
Infused proUgn stimulates renal sodium excretion 
 
The data presented to this point demonstrate that, relative to Ugn, proUgn is 
by far the dominant molecular species stored in the intestine and circulating in the 
plasma. This indicates that secretion of proUgn, rather than Ugn, is the likely 
endocrine response of the intestine to salt intake. Might the presumably inactive 
propeptide somehow be capable of triggering physiological responses in the kidney? 
To investigate this question, we infused a commercially available recombinant 
human form of the propeptide (hu-proUgn) into anesthetized rats, and evaluated its 
effects on renal function (note that our recombinant rat propeptide was not available 
in sufficient quantities for these studies).  
In control animals, Na+ excretion, urine flow, glomerular filtration rate (GFR), 
blood pressure, heart rate, and potassium excretion did not change significantly over 
the course of the experiment (Figures 2.10a – 2.10h, white symbols). In contrast, 
intravenous infusion of 100 µg/kg body weight of hu-proUgn over 60 min increased 
total urinary Na+ excretion by ~70% (Figure 2.10a, black symbols), fractional Na+ 
excretion by ~50% (Figure 7b, black symbols), and urine flow by ~20% (Figure 
2.10c, black symbols). These natriuretic and diuretic responses had a relatively slow 
onset and long duration, outlasting the application of the peptide by more than 40 
min, and were not accompanied by changes in GFR, mean arterial pressure, or 
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heart rate (Figure 2.10d, e, and f, black symbols). Potassium excretion was also 
stimulated slightly by propeptide infusion, but the kaliuresis developed very slowly, 
and the statistical significance of the response was marginal (Figure 2.10g and h, 
black symbols). 
Preliminary quantitative studies revealed that our infusion protocol produced a 
3.2 ± 0.36-fold increase in plasma proUgn levels (mean ± range, n = 2). Thus, the 
renal responses observed in Figure 2.10 were evoked by peptide infusions that fell 
within a “physiological” range. The absence of hemodynamic effects of proUgn 
suggests a direct tubular effect of the peptide on Na+ excretion, and this is confirmed 
by the significant increase in fractional Na+ excretion during and after peptide 
infusion. The prolonged time course of the natriuretic response to hu-proUgn in our 
studies is comparable to the prolonged responses evoked by Ugn in the isolated 
perfused kidney (56, 65, 161) or the intact mouse (22, 23). However, the kaliuretic 
responses to propeptide infusion are much less pronounced than those observed in 
previous studies with Ugn. 
 
D.  DISCUSSION 
A number of observations (summarized in the Introduction) have led to the 
hypothesis that Ugn serves as the endocrine mediator of an entero-renal signaling 
pathway that enhances renal salt excretion following oral salt intake (56, 65). Most 
studies investigating this hypothesis have focused on Ugn itself. We provide 
evidence that the Ugn precursor, proUgn, plays a previously under-appreciated role 
in the entero-renal natriuretic axis. The underpinnings of this idea are provided by 
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two key observations, both presented above. First, nearly all of the Ugn that is 
stored within the small intestine is in the form of intact proUgn (Figures 2.1, 2.2, and 
2.3, and Table 2.2). This observation is consistent with the fact that none of the 
potential mono- and dibasic cleavage sites in rat proUgn matches the consensus 
sequence for cleavage by conventional prohormone convertases (48). Second, 
plasma levels of proUgn are also very high (Figure 2.5d and Table 2.2), while 
circulating Ugn levels are so low that they fall below the limit of detection of our 
assay (Figure 2.5e and Table 2.2). 
 
The Ugn and proUgn measurements given in Table 2.2 can be compared to 
previously-published radioimmunoassay (RIA) values for both tissue and plasma 
pools of “Like-like immunoreactivity” (67, 68, 93, 95, 97, 139, 140). In particular, the 
proUgn levels determined with our newly developed assay are substantially higher 
than those published previously. However, the RIA procedures used in all prior 
studies have employed antibodies directed exclusively against the C-terminal amino 
acid sequence that defines Ugn. This introduces several complications. First, any 
such antibody will recognize both Ugn and proUgn (Figure 2.1a), and thus, unless 
the two target molecules are separated before performing the measurement, the 
assay will reflect the contributions of both. Second, even after separation of proUgn 
from Ugn, the concentration of proUgn cannot be measured accurately, since the 
standard curve is established with Ugn and, in general, anti-Ugn antibodies 
crossreact poorly with intact proUgn. Recognizing this problem, some studies have 
proteolytically converted proUgn to free Ugn before performing the assay (139)—
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but, even so, the results provide only a lower limit for proUgn levels because it is not 
possible to assess the stoichiometry of the conversion. 
Our new gel-based proUgn assay eliminates these problems, because it 
detects proUgn directly, does not crossreact with Ugn, requires no proteolysis, and 
is based on an authentic rat proUgn standard. We have used this assay to quantify 
proUgn levels in the plasma, small intestine, colon, and kidney of the rat (Table 2.2).  
The tissue proUgn values obtained in our current studies are consistent with 
tissue levels that have been established for other mammalian GI peptides, such as 
secretin and cholecystokinin, which range from 50 - 500 pmol/g wet weight 
(calculated as the sum of all the known forms of these peptides, both processed and 
unprocessed, that reside in the small intestine) (157). 
As a general rule, peptide hormones are synthesized as inactive propeptide 
precursors, and converted to smaller, biologically-active peptides by specific 
proteolytic cleavages (44, 180). For typical peptide hormones, the most abundant 
intracellular storage form is the mature, processed peptide. For example, only 5% of 
gastrin and 20% of cholecystokinin are found in the small intestine in propeptide 
form (184). However, a few peptide hormones, such as ANP and angiotensin, are 
stored almost exclusively as inactive propeptides (26, 122, 157). In such cases, 
processing occurs as a post-secretory event, mediated by ectoproteases located at 
the site of secretion or within the vasculature. 
Radiolabel infusion studies reveal that Ugn falls into yet a third category. Like 
ANP and angiotensin, Ugn is stored within tissues primarily in propeptide form, and 
significant quantities of the intact propeptide are released into the plasma. 
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However—in contrast to proANP and angiotensinogen—circulating proUgn is not 
processed intravascularly (Figures 2.7a, 2.7b, and 2.9a). Rather, it is cleared from 
plasma by the kidney (Figure 2.7d), and processed intrarenally (Figure 2.8b). With 
the exception of free cysteine and free methionine, the renal metabolites are not 
returned to the general circulation (Figure 2.9a), but rather are excreted in the urine 
(Figure 2.8b).  
In addition, a sampling of published values for the circulating levels of a 
variety of peptide hormones (13, 31, 32, 114, 184) reveals that, while our estimate of 
the plasma proUgn concentration is significantly higher than the levels observed for 
peptides that are processed either prior to or coincident with secretion (e.g. gastrin, 
cholecystokinin, atrial natriuretic peptide, and B-type natriuretic peptide), it is 
nevertheless well below the levels established for two circulating propeptides that 
are only converted to mature peptides subsequent to secretion (angiotensinogen, 
the precursor for angiotensin II, and T-kininogen, a rat-specific propeptide that is the 
precursor for ile-ser-bradykinin). Thus, there is biological precedent for the idea that 
plasma levels of unprocessed propeptides can be very high. Our data also suggest 
that the intestine must maintain a very high rate of proUgn synthesis and secretion in 
order to generate such a large, steady-state plasma pool of propeptide in the face of 
the rapid plasma clearance processes that are observed in figure 2.7. 
In addition to high levels of proUgn, our measurements also demonstrate 
comparatively low levels of Ugn, both in gut extracts and in plasma. The bioassay 
technique that we used to measure Ugn is not as sensitive as an RIA or a Western 
blot. Nevertheless, it was adequate to detect a small pool of biologically active Ugn 
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in extracts of proximal small intestine (Figure 2.3c and d), which, upon quantification 
(Table 2.2), revealed a proUgn-to-Ugn ratio on the order of 23:1. The assay was not, 
however, sufficiently sensitive to detect bioactive Ugn in plasma, even when the 
plasma sample was scaled up to 3 ml (representing nearly one-third of the plasma in 
an individual animal). Thus, we can only set an upper limit on the level of Ugn in 
plasma (Table 2.2), and establish a minimal proUgn-to-Ugn ratio of 40:1. 
One strikingly consistent feature of these measurements is that proUgn levels 
are very much higher than Ugn levels, both in gut extracts and in plasma (indeed, 
the slightly different proUgn-to-Ugn ratios in the two compartments may only reflect 
the potential sources of error in our measurements) and in the ratios of radiolabeled 
proUgn infused to the radioactivity associated with the Ugn-like peak from the urine. 
In terms of an endocrine (tissue-to-tissue) signaling role, this therefore suggests that 
circulating proUgn might be functionally more important than circulating Ugn. This 
concept can only be valid, however, if circulating proUgn is capable of eliciting 
appropriate responses from the target tissue. To investigate this latter possibility, we 
infused recombinant hu-proUgn into anesthetized rats and measured their renal 
function. As shown in figure 2.10, both Na+ and fluid excretion were significantly 
elevated in response to the propeptide.  
Direct plasma measurements demonstrated that our cold–peptide infusion 
protocol produced an approximately 3-fold increase in plasma proUgn levels. This 
can be contrasted with previously-published studies of Ugn, in which the peptide had 
to be infused at supra-physiological levels, in order to evoke renal responses (22, 
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56). Thus, in contrast to Ugn, proUgn appears to act at levels that are appropriate for 
an entero-renal signaling molecule. 
Our experiments do not identify the intrarenal site where proUgn processing 
occurs. Two distinct possibilities can be considered. First, the propeptide could pass 
intact across the glomerular filtration barrier, for processing within the tubular lumen 
by proteases residing in the epithelial brush border of the proximal tubules. 
Alternatively, the propeptide could be absorbed from the plasma into tubular 
epithelial cells by basolateral endocytosis, then processed within vacuoles for apical 
secretion (in processed form) into the tubular lumen. Although our data do not 
unequivocally discriminate between these models, several lines of evidence provide 
strong support for the former over the latter. First, as shown in Figure 2.5, proUgn 
circulates in plasma as a free 9.4 kDa peptide, uncomplexed with a carrier protein, 
and is thus small enough to be readily filterable. This predicts that, at a minimum, 
approximately 30% of the propeptide entering the kidney at any time will be 
delivered to the tubular lumen in intact form by filtration. This was confirmed by the 
equivalence between renal extraction ratios close to 30% for both proUgn and inulin, 
a classical marker of renal function that is cleared exclusively by glomerular filtration. 
Second, the time course of clearance of plasma proUgn (Figure 2.7d) was very 
similar to that of inulin, which reinforces the idea that the renal clearance of proUgn 
is due to filtration rather than secretion. Third, we observed intense radioactive 
labeling of proximal tubule profiles after intravenous infusion of labeled proUgn (not 
shown), but the tissue content of radioactivity associated with those profiles was 
comprised almost exclusively of free amino acids (Figure 2.8a) rather than the larger 
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peptide metabolites that are found in urine (Figure 2.8b). All of these results are 
more consistent with intratubular processing than with transcytotic intracellular 
processing. 
This “target organ-mediated” model for propeptide processing is unusual, and 
it is worth considering why it might be of particular utility in the case of Ugn and 
proUgn. (a) Ugn, like all GC-C agonists, is highly dependent on disulfide-mediated 
folding for activity, and, if unfolded, will preferentially refold in an inactive 
conformation (86). There is, however, an “intramolecular chaperone” domain at the 
N-terminus of the prosequence that specifies the correct disulfide pairing during 
synthesis, and permits correct refolding of the C-terminus after oxidation (87). Thus, 
the increased stability and oxidation-resistance of full-length proUgn over Ugn 
provides one rationale for favoring the propeptide as the circulating form. (b) When 
Ugn is retained within the prosequence it has little or no biological activity on GC-C-
expressing cells. Consequently, minimizing the level of free Ugn in the plasma will 
limit potential extra-renal systemic actions (for example, activation of GC-C 
receptors in the pancreas (106, 108), the reproductive organs (89), and the liver 
(109)). (c) Embedding Ugn within the prosequence may protect it from plasma, 
endothelial, and tissue ectoproteases. (d) The EC cells that synthesize proUgn have 
long been known to release their previously-identified secretory products (serotonin 
and substance P) both apically, into the intestinal lumen, and basolaterally into the 
circulation (1, 17, 18). This raises the interesting possibility that the cleavage 
products of proUgn that are produced in the lumen of the gut may be distinct from 
those produced in the lumen of the proximal tubule. 
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It is appropriate to acknowledge that the biochemical experiments do not rule 
out the possibility that proUgn may be converted to Ugn in tissues that were not 
studied—although, if this occurs, any Ugn-mediated effects must be strictly local, 
since no measurable amount of Ugn was returned to the plasma even during our 
longest infusion studies. In addition, it is well-documented that small amounts of Ugn 
do, indeed, circulate in plasma (53, 85, 95), and this might become quantitatively 
more important at certain times of day or in response to specific environmental 
stimuli. Thus, we must leave open the possibility that a more conventional Based-
based endocrine pathway may operate in parallel with the propeptide-based 
mechanism that we have described here. 
 
Final Thoughts 
 
In summary, the biochemical and physiological studies presented above, in 
combination with the pulse-chase studies of infused proUgn suggest a unique model 
for proUgn processing. Not only does processing appear to be primarily a post-
secretory event, but, to our knowledge, it is unique among endocrine mechanisms 
identified to date, as it also occurs only after the circulating propeptide has reached 
(and been sequestered within) one of its principal target organs, the renal tubules. 
We propose, therefore, that the N-terminal prosequence may serve as a specialized 
delivery vehicle that shields Ugn—either preventing its destruction or minimizing its 
physiological actions—during its passage from the gut to the kidney. 
 
 
 
 72 
Tables 
 
plasmid encoded propeptide sequence 
pMal-R GSHMVYIKYHGFQVQLESVKKLNELEEKQMSDPQQQKSGLLP 
DVCYNPALPLDLQPVCASQEAASTFKALRTIATDECELCINVAC 
TGC 
pMal-CD GSHMVYIKYHGFQVQLESVKKLNELEEKQMSDPQQQKSGLLP 
DVCYNPALPLDLQPVCASQEAASTFKALRT 
 
Table 2.1 proUgn Constructs Used in This Study 
 proUgn Ugn-like bioactivity 
 
fmol/µg protein 
(n) 
pmol/animal (n) 
fmol/µg 
protein (n) 
pmol/animal 
(n) 
small intestine, 
proximal half 
12.6 ± 1.0 (21) 1322 ± 160 (21) 
≤ 0.54 ± 0.16 
(5)B 
56.8 ± 17 (5) 
small intestine, 
distal half 
10.0 ± 1.0 (17) 978 ± 122 (21)   
small intestine, 
total 
11.3 ± 1.0 (21) 2300 ± 262 (21)   
kidney 2.1 ± 0.3 (12) 247 ± 27 (6)   
colon 1.1 ± 0.3 (5) 27 ± 7 (5)   
     
 pmol/ml estimated 
pmol/animalA 
pmol/ml  
arterial plasma 10.3 ± 1.7 (21) ~93 (21) 
Below 
Detection 
Threshold (5) 
(<0.25)C 
 
 
Table 2.2 proUgn and Ugn Levels of Tissues and Plasma 
A Based on an estimated plasma volume of 9 ml for a typical 300 g animal 
B This represents an upper limit, since a portion (~20%) of the bioactivity is 
chromatographically distinct from authentic Ugn  
C This represents an upper limit, calculated on the basis of the detection limit of the 
assay 
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 proUgn inulin 
 control anephric control anephric 
tfast (sec) 27  77  49  66  
tintermediate (sec) 260  389  210  355 
tslow (sec) 4474  BDTA  1604 BDTA 
tultraslow (sec) BDTA 21296 BDTA 13259 
 
Table 2.3 Time Constants (t) for the Clearance of proUgn and Inulin in Control 
and Anephric Animals. These values were determined by fitting the plasma 
disappearance curves for each solute to a triple exponential decay function (see the 
Methods for details). For control animals, we used the equation: 
 
. 
 
For anephric animals, we assumed that removal of the kidneys eliminated the slow 
clearance mechanism, which revealed an ultraslow process that could only be 
observed in the absence of renal activity. In this case, we used the equation: 
 
.  
A BDT = Below Detection Threshold 
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Figures 
 
 
 
 
 
 
 
Figure 2.1. Biochemical Confirmation that Gut Extracts Contain Authentic 
proUgn. A) Depiction of native rat proUgn (N), showing domains targeted by three 
independent anti-peptide antibodies. Recombinant constructs are aligned beneath 
the proUgn schematic. R is identical to authentic rat proUgn, except that 4 extra, 
non-native residues were added to its N-terminus to generate a thrombin cleavage 
site. CΔ is identical to R, except that 17 residues were deleted from its C-terminus. 
B) An extract of small intestine immunoblotted with antibody 6912. The arrowhead 
marks the putative proUgn band. The scale gives molecular weights of standards, in 
kDa. C) Side-by-side comparison of CΔ, R, and N. A dilution series of gut extract 
containing N was loaded in adjacent lanes of the gel, from left to right, to investigate 
the possible presence of low molecular weight proUgn processing fragments. D) A 
single gel was loaded with samples of CΔ, R, and N, and then cut into three pieces, 
each of which was probed with a different antibody, as indicated. 
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Figure 2.2. C-18 Reverse Phase HPLC Analysis of the Native proUgn-like 
Immunoreactivity Present in Rat Jejunum. A) Half of the material from a single 
jejunum was pre-enriched on a sephacryl column, then loaded onto a C-18 column. 
The elution gradient is shown by the upper dashed line, and the UV profile by the 
solid trace. A Western blot was performed with antibody 6912 on 25% of each 
fraction. Only the fractions eluting between 42 and 56 minutes contained 
immunoreactive polypeptides of appropriate sizes (less than 12 kDa). For simplicity, 
only these fractions are shown in the figure. The retention times of two recombinant 
standards (R and CΔ), as determined in separate column runs, are indicated by the 
black and white arrows, respectively. The structures of these standards are given in 
figure 1a. B) Fractions eluting at 44 and 48 min from the C-18 reverse phase column 
(in panel (a)) were analyzed by Western blotting, in parallel with R and CΔ. Blots 
were probed with three different antibodies (6912, 6910, 1-11), as indicated. Each 
lane was loaded with 25% of the indicated fraction. Only the 3 – 12 kDa regions of 
the blots are shown. 
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Figure 2.3. ProUgn and Ugn Levels in Extracts of Rat Small Intestine. A) 
Western blot assay for proUgn, including a standard curve constructed with known 
quantities of recombinant rat proUgn and samples of gut extract (A – D). A number 
of similar assays were performed to obtain the values presented in Table 2. B) 
Numerical values derived from the blots in panel (a). C) SepPak elution profile of an 
authentic Ugn sample. After applying the peptide to the SepPak, the flow through 
(FT) was collected, followed by sequential elution with increasingly-hydrophobic 
solvent. Peptide recovery in each fraction was measured with the T84 cell bioassay 
(see Methods). Bioactivity eluted from the SepPak in the 10% acetonitrile fraction. 
The native bioactivity in gut extracts elutes with an identical profile (data not shown). 
D) Averaged responses of T-84 cells to Ugn extracted from 1 ml jejunal extract (gray 
bar, mean ± sem, n = 5), after SepPak pre-purification as in panel (c). Responses to 
gut samples are compared to responses obtained with known amounts of synthetic 
Ugn (black bars). The inset shows the responses to a full range of synthetic Ugn 
standards, as performed in a typical assay. Ugn concentrations in the biological 
samples are determined by interpolation on this standard curve (see Methods). 
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Figure 2.4. HPLC and Bioassay Analysis of Ugn-like Bioactivity From Proximal 
Small Intestine. A) Extracts were prepared independently from four separate 
animals, and a 1.5 ml aliquot was withdrawn from each. These aliquots were 
individually purified on C-18 SepPaks, as in figure 3c, then each was applied to a C-
18 reverse phase column and eluted with a gradient of acetonitrile, as indicated by 
the dashed line. UV absorbance is given by the solid trace. One ml fractions were 
collected, and either assayed individually or combined in pairs (as indicated) using 
the T84 cell bioassay. The symbols plot the average of the duplicates, and the error 
bars give the range (in most cases, the error bars are hidden beneath the symbol). 
The black and white arrows indicate the retention times of synthetic Ugn and Gn 
standards. This experiment was repeated a second time with very similar results 
(data not shown). B) Aliquots of material in peak 1 (eluting at 39 min) and peak 2 
(eluting at 43 min) were assayed at pH 5 (white bars) and pH 8 (black bars), side-by-
side with authentic Gn and Ugn standards.   
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Figure 2.5. Authentic, Full-length proUgn Circulates in Plasma. A) 
Chromatography of rat plasma on a sephacryl S-100 HR column. Retention times 
and molecular weights of standards used to calibrate the column are indicated at the 
top of the panel. The solid trace shows the UV absorption profile. An immunoblot 
was performed with antibody 6912 on each fraction eluting between 45 and 380 min. 
B) Samples of partially-purified plasma proUgn are compared to samples of partially-
purified intestinal proUgn the same gel, probed with multiple antibodies. C) Log-log 
plot of molecular weight vs retention time for proUgn compared to standards run on 
the same column (taken from panel (a)). D) Quantitative assay for plasma proUgn, 
performed as in figure 3. Plasma was partially purified on a size exclusion column 
prior to the assay. E) Quantitative assay for plasma Ugn, performed on 3 ml samples 
of plasma (white bar, mean ± sem, n = 5), as in figure 3. 
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Figure 2.6. Distribution of Radiolabel in Tissues and Fluid Compartments at 
the End of a 60 Min Steady Intravascular Infusion of 35S-proUGn. A) The bulk of 
the recovered radioactivity (cpm/organ) was found in kidney and liver (white bars). 
However, specific activity of labeling (cpm/µg protein) in the kidney is far greater 
than in any other tissue (black bars). Data report the mean ± sem for 3 independent 
determinations. B) Radioactivity was substantially more concentrated in urine than in 
plasma (mean ± sem, n = 3). 
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Figure 2.7 A Bolus Dose of 35S-proUgn Was Cleared Rapidly From the Plasma 
of a Normal Animal, and Much More Slowly After Renal Ablation. A) 
Representative HPLC analysis of plasma samples obtained from a control animal. 
Radioactive material eluted in each fraction was measured in a scintillation counter, 
and is expressed as cpm recovered per µl of plasma applied to the column (mean ± 
sem for replicate column runs, n = 3). The dotted line shows the gradient of 
acetonitrile that was used to elute the column. B) Representative HPLC analyses of 
plasma samples obtained from an anephric animal, as in panel (C) Schematic 
depiction (not to scale) of cysteine, methionine, Ugn15, proUGnD17, and proUgn 
standards, along with their observed retention times on the C-18 column. The 
retention times are also marked by arrows in panels (a) and (b). The asterisks 
indicate the approximate positions of cysteine and methionine residues that would 
be radioactively labeled in the parent molecule and its metabolites. D) The plasma 
level of radioactive proUgn is plotted as a function of time after a bolus infusion into 
control animals (white symbols) and anephric animals (black symbols). At each time 
point, the amount of proUgn in the plasma was determined by integrating the 
radioactivity in the proUgn peak. To correct for animal-to-animal differences in total 
blood volume and proUgn specific activities, the proUgn levels for each animal were 
normalized to the amount present at that animal’s earliest (15 sec) time point. The 
solid lines represent the best fit of a triple exponential function to the data (see 
Methods). E) Inulin disappearance curves, obtained under the same conditions as 
the proUgn disappearance curves shown in panel (c). The grey curves (for proUgn) 
are reproduced from panel (c) for reference. 
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Figure 2.8 Metabolites Accumulating in Kidney and Urine During Prolonged 
Infusion of Radiolabeled proUgn. A) HPLC analysis of the 27,000 x g supernatant 
fraction (cytosol) obtained from kidney homogenates. Material was applied to a C-18 
reverse phase column and eluted with a gradient of acetonitrile (dashed line). 
Radioactivity eluting in each fraction was measured in a scintillation counter, and is 
expressed as a percentage of the total radioactivity recovered (mean ± sem, n = 4). 
Retention times of cysteine, methionine, Ugn, and proUgn standards are marked by 
the arrows. B) HPLC analysis of urine (mean ± sem, n = 7), performed as described 
for panel (a). Retention times of cysteine, methionine, Ugn, and proUgn standards 
are marked by the arrows. Peaks numbered 3 and 4 represent unidentified 
metabolites. See text for details. 
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Figure 2.9 During Prolonged Infusion of Radiolabeled proUgn, the Kidney 
Extracted the Propeptide from the Plasma, While Secreting Radiolabeled 
Amino Acids Back Into the Circulation. A) HPLC profile of radioactive metabolites 
in systemic plasma, collected from the carotid artery (open symbols), compared to 
plasma collected from the renal vein (filled symbols), as in figure 2. B) Relative 
recoveries of cysteine, methionine, and proUgn. Compared to the systemic 
circulation (open bars), the renal vein (filled bars) contains a significantly higher 
proportion of metabolites, and lower proportion of intact proUgn (mean ± sem, n = 6, 
** = p < 0.01, * = p < 0.05). This is consistent with the loss of some proUgn due to 
renal extraction, coupled with the return of some cysteine and methionine to the 
circulation after digestion of the extracted proUgn. 
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Figure 2.10 Infused hu-proUgn is Natriuretic and Diuretic in Rat Renal 
Clearance Studies. Horizontal bars indicate the duration of hu-proUgn infusion (100 
µg/kg body weight over 60 min) in the experimental group (filled circles, n=8). 
Control rats (open circles, n=9) received isotonic saline in place of proUgn. Asterisks 
indicate a significant difference between the associated data point and the first 
clearance period, as determined by 1 way ANOVA with repeated measures, followed 
by the Bonferonni method for post hoc testing ( * = p < 0.05, ** = p < 0.01). 
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DEVELOPMENT AND VALIDATION OF QUANTITATIVE ASSAY FOR THE 
ASSESSMENT OF UGN IN BIOLOGICAL SAMPLES 
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A. Introduction 
 
To test the role of Ugn in the context of post-prandial natriuresis, a sound 
assay technique is required for the quantification of Ugn in various types of tissue 
samples. Two methods have been used extensively in the past, but both have 
shortcomings that render them inappropriate for my proposed Aim 3 studies.  
The first method is an RIA technique that was developed by the Nakazato 
laboratory in Japan. This sensitive method has been used to quantify urinary peptide 
levels in rats in response to changes in dietary Na+ (24, 111) and both plasma and 
urinary peptide levels in humans with renal disease (141). The drawbacks of this 
method are that 1) the reagents have not been made publicly available (and the lab 
that developed them is, in fact, no longer working in the field of Ugn research), and 
2) neither a Ugn RIA kit, nor a high affinity Ugn antibody, is available commercially 
that would allow me to develop a comparable in-house assay. 
The second method is the previously described bioassay technique that 
measures Ugn-evoked cGMP synthesis in the T-84 reporter cell line. There are also 
problems with using this method for the proposed studies; 1) Even simple biological 
samples (urine) must undergo a purification/enrichment step, due to the presence of 
interfering substances (for example, endogenous cGMP that is already present in 
the sample). 2) Large sample sizes are necessary, due to the relatively low 
sensitivity of the assay. 3) The assay has many steps that allow for the possibility of 
systemic errors, increasing the variability in the results.  
I did employ the T84 cell assay in my initial efforts to quantify Ugn in tissue 
samples, such as plasma, intestinal extracts and kidney extracts (134, 154). 
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However, I quickly found that the protein content or some other aspect of the 
samples disrupted the production of cGMP by T-84 cells, putatively through oncotic 
pressure that negatively affected the cells tonicity and/or inhibited ligand binding to 
or the enzymatic activity of GC-C. Urine, though it has relatively low protein content, 
was particularly problematic for another reason, due to its high and variable level of 
endogenous cGMP. In my initial studies, this contaminating cGMP gave “false 
positive” values that I erroneously attributed to the presence of Ugn in my samples.  
The common remedy for interfering compounds in biological samples is to 
enrich and purify Ugn away from the other constituents in these samples. HPLC 
methods utilizing properties such as size and affinity are commonly used for this, but 
there is inevitable loss of sample during processing that decreases the sensitivity of 
the assay and can be variable. More importantly, this loss during purification 
increases the volume required for analysis. For the greatest accuracy using the T-84 
whole-cell/cGMP based assay, samples were assayed in triplicate and each data 
point required at least 600µl of urine even before purification. Even then, this volume 
usually just produces a barely-detectable signal. For reference, the urine samples 
that I was collecting for my diet studies were on the order of 1-2mls and the samples 
from acute studies where peptides were infused produced samples of ~200µl. Thus, 
the limited sensitivity of the assay and the relatively small volume of urine in each 
sample posed a significant problem. 
In addition to this enrichment step, there are other steps in the T-84 whole-
cell/cGMP assay that lead to intra-sample variability. The first step is to grow the T-
84 cells to confluency in a 24-well culture plate, which is subject to plating and 
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growth conditions that can affect consistency of cell density between wells and/or 
platings.  Next is the extraction and de-acidification of the cell supernate containing 
the cGMP that can also lead to intra- and inter-sample variability. Finally the cGMP 
RIA itself has an intrinsic variability of ±5% for the same sample in replicate (165). 
In an effort to remedy these shortcomings, I explored the possibility of a 
competitive binding displacement assay. This assay is a modification of a previously 
described radio-receptor binding assay (78). My adaptation is based on competitive 
binding between Ugn and 125I -labeled Y-Ugn at GC-C receptors in isolated T84 cell 
membrane preparations.  Concentrations of Ugn in urine samples are calculated 
from a standard curve generated with pure synthetic rat Ugn. Figure 3.1 illustrates 
this difference where panel A shows how T-84 cells grown to confluence are 
incubated with ~200µl of a test solution to elicit cGMP production. Panel B from 
Figure 3.1 shows how the competitive binding reaction is allowed to take place in 
sample solutions as small as 20µl.  
As described in detail in Chapter 1, GC-C is a member of a family of 
membrane bound guanylyl cyclases that are glycoprotein receptors consisting of 
multiple domains. GC-C has a ligand-binding ECD (extracellular domain), a single 
trans-membrane domain, a kinase-like domain and a catalytic guanylyl cyclase 
domain (74). Binding of ligands to the ECD leads to a conformational change that 
activates the intracellular catalytic domain to produce cGMP, which acts as a second 
messenger. The only known ligands for GC-C are the Guanylin family of peptides 
that are endogenous to mammals and then the family of heat-stable bacterial toxin 
(ST) peptides with Ugn being the only family member in the urine of most mammals 
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(73, 165). STa is more potent when administered to T-84 cells with a KD ~10 fold 
lower for stimulation of cGMP production when compared to similar concentrations 
of Ugn-15 at pH 5.0 (73).  
Previous studies using 125I-Y-STa as a ligand have reported that there are two 
distinct binding affinities for GC-C to this radioligand: a high affinity binding and a low 
affinity binding of the receptor with disassociation constants (KD) of 3.1 x10-12 and 
2.2 x 10-9 respectively (36, 43).  The studies also show that >95% of the binding at a 
radioligand concentration of 2.9nM is due to the low affinity receptor. Shifts towards 
a ratio favoring binding to the high affinity receptor do not happen until the 
radioligand is in the picomolar range (36, 42). Additionally, the studies demonstrate 
a binding-dependent shift of affinity of STa for receptors, and a correlation of the 
occupancy of the lowest affinity state of these sites with cyclase activation, 
suggesting that catalytic activity may be required for this shift (42).    
Receptor-ligand binding experiments can be complicated by such factors as 
the presence of a single or multiple classes of receptors, or cooperativity for binding. 
Assumptions that must be made and factors that must be determined include: Is the 
binding reversible? Is there a homogeneous or heterogeneous receptor population? 
Does ligand binding increase the affinity of the receptor for more ligand 
(cooperativity)?  Statistical analysis of results using variations of the Cheng–Prusoff 
equation that account for these factors can help define the nature of the binding 
relationship, based on the adequateness of fit to the data (143). Additionally, 
determining the correct formula to describe the binding relationship will allow for 
accurate interpolation of Ugn levels present in unknown samples.  
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B. Methods and Materials 
 
Peptides Used 
 
The radioligand for these binding studies was prepared from N-tyrosyl rat Ugn 
(Y-Ugn) obtained from Bachem Inc (Torrance CA). huUgnA and huUgnB were 
obtained from a commercial supplier (Bachem, Torrance CA). Synthetic rat Ugn and 
rat Guanylin (Gn) were purchased from Peptides International (Boston, Ma.). STa 
was obtained from Sigma (St. Louis, Mo.). Recombinant rat proUgn was provided by 
Ironwoods Pharmaceutical Inc. 
   
Radiolabeled Tyrosinated Ugn Production and Purification 
 
Radiolabeled Ugn trace was produced by iodinating the tyrosine residue at 
the end of a synthetic rat Uroguanylin-15 with an additional non-native tyrosine 
added at the N terminus (Y-T-D-E-C-E-L-C-I-N-V-A-C-T-G-C-OH (Disulfide bonds 
between Cys4 and Cys12/Cys7 and Cys15))(Bachem, USA) with 125I. Iodination was 
performed by first activating the 125I in pre-coated iodination tubes (Pierce), then 
transferring the activated 125I to the Y-Ugn peptide solution for incubation, quenching 
the reaction with an abundance of free tyrosine and finally separating the peptide 
from the free tyrosine with a PD-Midi Trap Sephadex G-10 (GE Healthcare, 
Piscataway N.J.,USA) size exclusion cartridge. This semi purified 125I-Y-Ugn product 
was then applied to a VYDAC 218TP1010 C-18 reverse phase column (Grace 
Vydac, Hesperia, CA), and eluted with a 0–60% linear gradient of acetonitrile over 
35 min at 1 ml/min flow rate. One minute (1ml) fractions were collected and the peak 
of radioactivity was detected in the fraction eluting from the column at 28 minutes, 
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corresponding to 47% acetonitrile. This is two minutes later and 5% acetonitrile more 
that synthetic Ugn-15 without the tyrosine (26 minutes at 42% Acn). This purified 
125I-Y-Ugn was stored at 4º C. The 59-day half-life of 125I limits use of the 125I-Y-Ugn 
to approximately 8 weeks from synthesis. 
 
Binding Assay Membrane Bound Receptor Preparation 
 
T-84 cells were cultured on tissue culture plastic flasks in DMEM/F12 
supplemented with antibiotics and 10% fetal bovine serum.  Upon attaining 
confluency, cells were harvested by scraping in ice-cold homogenization buffer 
(50mMTris, 10mM NaCl, 5mM MgCl, 2.5mM CaCl2).  The cells were then 
homogenized in a glass tissue grinder (Radnoti, Monrovia, CA. USA) and 
centrifuged at 100,000 × g for 50 min at 4 °C.   The supernatant was discarded and 
the pellet resuspended in Hanks buffered salt solution (HBSS, Invitrogen, USA, pH 
7.0) then centrifuged at 2000 × g for 5 min at 4 °C to pellet the nuclear material and 
membrane aggregates.  The membranes retained in the supernatant were assayed 
for protein concentration by the Bradford method (BioRad, Hercules, Ca. USA) and 
aliquoted for storage at −80 °C in HBSS until time of use.   
 
Sample Preparation 
 
When necessary, samples were dialyzed against diH2O before further 
processing, using SpectrPor®500-M.W. cutoff dialysis membrane (Spectrum 
Laboratories Inc., Rancho Domingo, Ca.). Control experiments showed 100% 
recovery from the dialysis procedure. Plasma and kidney extracts were applied to a 
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VYDAC 218TP1010 C-18 reverse phase column [The Separations Group Inc. 
(Grace Vydac), Hesperia, CA], and eluted with a 2–55% linear gradient of 
acetonitrile (.01%TFA) over 30 min at 1 ml/min. Each biological sample (dialyzed, 
HPLC fractionated or not) was then reduced to dryness (Savant SpeedVac, Thermo 
Electron Corporation, Waltham MA) and re-dissolved in 100µl assay buffer (1 nM 
125I-Y-Ugn in HBSS minus NaHCO3, 20 mM Sodium Citrate, 0.75% bovine serum 
albumin [Sigma, St. Louis, Mo, USA]). I then assessed and adjusted the pH of each 
sample using a miniaturized glass microelectrode (Microelectrodes Inc., Bedford, 
N.H.) and NaOH or HCl accordingly. Most samples were assayed at a standard pH 
of 4.5, but in some experiments the pH was systematically adjusted over a range to 
define the binding optimum.   
 
Binding Reaction 
 
 Prepared samples were then incubated in replicate in polypropylene tubes 
with 20µl of T84 cell membranes (15–25µg protein).  After 1 h of incubation at 25 °C, 
samples were diluted in 1ml of ice cold rinse buffer, pipetted up and down, rapidly 
filtered through Whatman GF/C glass microfiber filters presoaked in distilled water 
and then quickly rinsed twice with 5 ml of ice cold rinse buffer consisting of 50mM 
Tris-HCl at pH 7.0.  Bound radioligand (retained by the filter) was quantified with a 
gamma counter (Packard Cobra, PerkinElmer Life and Analytical Sciences Inc., 
Waltham, Ma, USA). Ugn concentrations in sample solutions were calculated by 
interpolation on a standard curve computed from a dilution series of synthetic rat 
Ugn standard incubated in parallel with the unknowns. Non-specific binding was 
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determined by incubating T84 cell membranes with 125I-Y-Ugn and 10-5 M unlabeled 
Y-Ugn in place of Ugn standards or unknowns. 
 
Statistical Analysis 
 
Values are expressed as a mean ±SEM. GraphPad Prism 5.0 (LaJolla, Ca.) 
was used for analysis of binding kinetics data. All formulas used in the software are 
derived from the Cheng-Prusoff equation (137, 143).  
 
Experimental Animals 
 
Rat experiments were performed on Sprague Dawley rats obtained from a 
commercial supplier (Harlan laboratories, Dublin VA).  
Mouse experiments were performed on BL6 wild-type mice and congenic Ugn 
knockout mice that were backcrossed >10 generations into the BL6 line. These 
animals were obtained from Dr. Mitchell Cohen at Cincinnati Children's Hospital 
Medical Center. 
All animals were maintained on a 12 hour light/dark cycle in an AALAC-
approved facility with continuously available veterinary care and uninterrupted 
access to water and standard rat chow.   All experimental procedures were 
approved by the Institutional Animal Care and Use Committee at the University of 
North Carolina at Chapel Hill, and were carried out in accordance with the NIH 
Guide for the Care and Use of Laboratory Animals.  
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C. Results 
 
Computation of 125I Iodinated Y-Ugn concentration 
 
The HPLC purified probe produced had ~130,000 CPMs/µl. The specific 
activity of 125I is 2.19 x 106 Ci/mole or 4.5 x 10-7 moles/Ci. One Ci is equal to 2.2 x 
1012 DPM, and the Packard Cobra gamma counter used for assessment of 
radioactivity present in samples is estimated to have a counting efficiency of 40%. 
Therefore, 1 CPM is equal to 2.5 DPM. Based on this I estimate I produced a stock 
solution of 3.25 x 10-7 M. Using this estimate, and published data for the optimal 
concentrations for the high affinity binding vs low affinity binding, I determined that I 
should use the radioligand in experiments at 750 CPM/µl, or a concentration of ~1 x 
10-9 M 125I -Y-Ugn. To confirm this, I performed a saturation binding experiment to 
determine the KD of the binding relationship using my ligand and the T84 cell 
membrane preparation as prepared in our laboratory. 
 
Determination of KD and Optimal Assay Conditions 
 
 Increasing concentrations of radioligand were incubated with a static amount 
membranes/receptors in the presence and absence of cold ligand (10-5M Y-Ugn). 
Specific binding was computed as the difference between total binding and non-
specific binding in the presence of a saturating amount of unlabeled Y-Ugn. The 
results are illustrated in Figure 3.2 by a logarithmic line of best fit with an R2 = .96.  
Statistical analysis with GraphPad Prism determined the KD to be 1.5 x 10-9 ± 4.0 x 
10-10 and maximal binding to be 275 CPMs/µg membrane protein. The cooperativity 
seen by other groups with regards to binding of STa to GC-C seems to not be 
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present in this data. This could be due to differences in the ligand or as previous 
publications hypothesized this dual affinity could be due to enzymatic activity which 
might not be preserved in my membrane vesicle preparations 
The next receptor-ligand relationship parameter relevant for optimizing the 
assay was the time it takes for the binding reaction to come to equilibrium. This was 
done by determining specific binding at a variety of different time points. The results 
in Figure 3.3 show that the reaction comes to equilibrium at 120 minutes, with 87% 
of max specific binding at 60 minutes and  97% of max specific binding by 90 
minutes. Non-specific binding only increased from 59 CPM at 10 minutes incubation 
to 150 CPM at 240 minutes. The curve was fit to the data using GraphPad Prism 
and had an R2 value of .998. Based on this study, I optimized my protocol by 
incubating samples for 70 minutes, which allows for near-maximal binding. Under 
these conditions, small differences in incubation times of samples will have 
negligible effects on the results. 
To show that the ligand receptor binding relationship is reversible I attempted 
to determine an off-rate. In this experiment I incubated membranes with a fixed 
concentration of radioligand in the presence and absence of a blocking 
concentration of cold peptide for 90 minutes and then diluted the reaction 90-fold. 
For practical limitations, I could not dilute the binding reaction any more than this, 
nor did I have a way to immobilize the receptor to rinse the free ligand away. The 
graph in Figure 3.4 shows that when the ligand concentration is reduced, the specific 
binding drops to a new equilibrium level over the course of 70 minutes. The new 
level is approximately 50% of initial level. This illustrates that the ligand binding is 
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reversible, a key concern when determining if this binding relationship is useful for a 
competitive binding assay. 
Next I performed an experiment to determine the pH optimum for the binding 
assay. I wanted to perform the reaction at an acidic pH if possible, because previous 
studies using whole cell T-84 assays had shown that the affinity of GC-C for Ugn 
increases at acidic pH (<6) while the affinity for Gn increases at basic pH (>7). Thus, 
the assay would be most specific for Ugn at acidic pH, and the specificity would 
decrease as the pH increased. Note that the ability to vary the pH dramatically in the 
whole cell assay was limited by the lysis of the cells at pH less than 5.0. The results 
in Figure 3.5 show that, contrary to the cell lysis and destruction in the whole cell 
assay that prohibits enzymatic production of cGMP at lower pH conditions, this low 
pH increases the affinity of the ligand for the receptor in a simple binding situation. 
These results show the optimal pH for the assay was in the range of 3.8 - 4.8. I 
decided to use a standard pH of 4.5. To achieve this, a sample buffer of 4.5 was 
combined with the standard 7.0 pH membrane vesicle preparations, and all buffers 
had the NaHCO3 (pKa = 10.3) omitted to shift the pH of combined buffers to a more 
acidic range. Figure 3.5 shows that there is a relatively stable plateau with little 
variation in binding between pH 4.0 and 4.8.   
As another consideration, I noticed in my early assays that the Ugn peptide 
tends to adhere hydrophobically to plastic tubes. For example, a simple experiment 
with radiolabel showed that transfer from one tube to the next resulted in >10% loss 
due to nonspecific binding to the tube. I also noticed that excess amounts of 
unlabeled Y-Ugn (added to some tubes for non-specific binding determinations) 
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would partially prevent this loss, presumably by occupying the hydrophobic binding 
sites on the plastic. I then tested to see if bovine serum albumin (BSA) added to the 
sample buffer could inhibit non-specific binding in the same fashion, and found that 
concentrations above 0.7% BSA fully inhibited this binding. Additionally I had to 
determine if BSA would affect the binding of Y-Ugn to GC-C. The results showed 
that BSA in the buffer has little effect on total binding, but acts to strongly inhibit non-
specific binding (presumably to the tubes, and also possibly to the membranes), and 
therefore gives a better signal due to reduced background. Based on these results, I 
add .75% BSA to my assay buffer before any cold or radiolabeled peptides are 
added so that they will remain in solution and not bind to the tube. 
 
Concentration Dependent Radioligand Displacement by Ugn  
 
In order to quantify Ugn in bio-samples, Ugn must displace the radioligand 
from the receptor in a concentration dependent manner that can be accurately 
modeled with an equation that allows interpolation of unknown values on a standard 
curve.  Furthermore it must be statistically shown that the formula used for 
interpolation of values is appropriate for the binding relationship. The major 
considerations are 1) is it a single receptor system, 2) is there cooperatively in 
binding and 3) do the Y-Ugn radioligand and endogenous Ugn have the same 
affinity for the receptor? I used synthetic rat Ugn-15 for my standard, in anticipation 
that the affinities of Ugn-15 and Y-Ugn-15 for the receptor might be the same. The 
results shown in Figure 3.6 the amount of radioactivity bound when competing with 
different concentrations of synthetic rat Ugn-15. The statistical model that best fit the 
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data was a system with a homologous receptor, no cooperatively for binding and a 
slightly different affinity of the receptor for the two ligands.  The curve of best fit had 
an R2 = .9985 and this computed to a Ki = 1.042 x 10-9 ± .328 x 10-9 (95% C.I.). 
 
Assessment of Uroguanylin Family Peptides  
 
The T-84 whole cell based assay detects Guanylin family peptides with 
varying degrees of sensitivity, commonly thought to reflect differential affinities of the 
ligands for the receptor. This could also, however, be due to differential ability to 
stimulate enzymatic production of cGMP after binding to the GC-C receptor. A 
competitive binding assay would be able to measure the ligand-receptor binding 
affinities directly for the different peptides. Ugn is synthesized as a propeptide 
(proUgn) that has a very low affinity for GC-C (82, 113, 165), but after processing in 
relevant tissue compartments in the rat to the 15 amino acid (16 in human) the 
mature form is able to bind GC-C with high specificity (40, 113). Figure 3.7 illustrates 
that Ugn has a 1000 fold greater affinity for GC-C than does proUgn.  
Additionally, previous studies have shown that the Ugn peptide shifts back 
and forth between two distinct conformations, termed Ugn-A and Ugn-B (87). For the 
rat isoforms of Ugn, this reaction occurs at a rate of 1–2 cycles per sec at 37° C at 
neutral pH (57), and therefore any sample of rat Ugn is a racemic mix of the two 
forms.  In the human isoform (h-Ugn-16), the extra leucine residue on the C-
terminus inhibits the conformational change, and extends the half-life of the separate 
conformers to 48 hours (29, 101). Additionally, the two conformations have different 
properties on a reverse phase HPLC column, and therefore can be isolated from 
each other.  In the whole T-48 cell assay employed previously it had been observed 
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that these two different topoisomers have differential ability to elicit cGMP production 
(29). They also have different physiological effects when infused into animals (135). 
When I assayed the human Ugn-A and Ugn-B using the competitive binding assay, I 
observed (Figure 3.8) that Ugn-A had a three-fold greater affinity for the receptor 
than the racemic mix of synthetic rat Ugns, but Ugn-B had a ten fold lower affinity 
than the racemic rat mix. These results are consistent with previous studies of mine 
using whole cells. 
The Ugn related peptide Guanylin is also produced in the small intestine and 
has been found in the plasma as a propeptide but is not found in the urine of most 
mammalian species (99). This is due to its susceptibility to proteolytic cleavage (33, 
51). A single experiment found a Gn-like peptide in the urine of opossum when 8 
liters of starting material was enriched. The concentration was estimated to be 10-
10M Gn (83).   It is therefore important to know if Gn in levels that might be present in 
urine samples could contribute to the displacement of radioligand when attempting 
to quantify Ugn. Figure 3.9 shows that at pH 4.5 Gn has a Ki =  1.7 x 10-7,  and must 
be present at levels higher than 10-8 M to elicit a response. This is much higher than 
the 10-10 M that past investigations have detected (83). Additionally, differences in 
affinity between the two molecules is such that when samples are diluted to put Ugn 
in an appropriate range for the assay, Gn at known levels would be well below the 
threshold for detection. 
The molecule that has the greatest potency for stimulating cGMP production 
by GC-C in T-84 cells is the heat stable toxin from enteric E. coli (STa). STa is ~10 
fold more potent than Ugn-15 at pH 5.0. When I assayed STa for radioligand 
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displacement from GC-C/membranes, it had approximately the same Ki and 
therefore the same affinity for the receptor as the synthetic rat Ugn-15 standard 
(Figure 3.10). Previous studies have suggested that initiation of catalytic activity by 
GC-C has a cooperative effect on further STa binding to the receptor, and therefore 
the lack of catalytic activity in the membrane preparations (in the absence of GTP, 
which is required as the substrate for cGMP synthesis) could render the affinity the 
same as Ugn-15. 
 
Optimization of Conditions for Biological Samples 
 
The method utilized for analysis of biological samples is to dry them to 
complete dryness and resuspend them in an equal volume or less of sample buffer, 
in order to increase sensitivity of Ugn detection while minimizing the loss due to 
purification or enrichment steps. With the receptor binding competition assay being 
dependent on pH, each individual sample must be assessed for proper pH. Trials of 
different buffer compositions determined that a buffering salt with a pKa near the 
range of the desired pH was optimal. The buffer that I use is made with Hank’s 
Balanced Salt Solution and sodium citrate added. Citrate has a pKa of 4.8, so this is 
ideal. However, HBSS can optionally contain NaHCO3, which has a pKa of 10.3. 
Empirically I observed that physiologic samples in buffer without NaHCO3 were 
easier to pH properly with minimal addition of acid and base, reducing changes in 
volume and thus Ugn concentration. A test was done on the buffer with and without 
NaHCO3 to determine if it had an effect on binding. The absence of NaHCO3 had no 
statistically significant effect on the specific binding of Y-Ugn to the membrane 
preparations. 
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Assessment of Urinary Ugn with Binding Assay  
 
The ability of the proposed assay to accurately quantify Ugn in biological 
samples requires that these biological samples not alter the ligand-receptor binding 
relationship in any way.  To investigate this, I used the assay to quantify a serial 
dilution of a urine sample. The results reported in Figure 3.11 show the radioligand 
displacement signal from full strength urine plotted on the line of best fit for the Ugn-
15 standard displacement curve (orange circle). This sample was estimated to be 
~10-8 M Ugn. When I plotted the radioligand binding for each urine dilution, dividing 
this interpolated [Ugn] by the dilution factor the values fell precisely on the curve of 
best fit for the Ugn-15 standard. This demonstrates that the “unknown” that is being 
detected by the assay has exactly the same affinity for the receptor as does the 
authentic rat Ugn standard. 
To further ensure that some component of the urine was not altering the Y-
Ugn-GC-C binding relationship, I prepared a dilution series of Ugn-15 standards in 
normal-strength urine by resuspending dried urine in one half of its original volume 
of sample buffer and combining aliquots with equal volumes of the Ugn-15 standards 
at twice their desired concentrations. Therefore the signal observed for each sample 
should reflect the sum of the [Ugn-15 standard] and the [Urinary Ugn]. Any deviation 
would imply enhancement or diminishing of the radioligand binding by urine 
constituents in a manner that was independent of the Ugn present in the sample. 
The results in Figure 3.11 show that when the concentration of neat urine is 
determined and then added to the concentration of Ugn-15 in the urine spiked 
samples, the curve (blue symbols) values fall right on the curve of best fit for [Ugn]. 
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Assessment of Urinary Ugn From a Ugn-/- Mouse  
 
An additional effort was made to determine that no constituents of urine other 
than Ugn are responsible for radioligand displacement by utilizing urine from 
knockout mice that have the gene coding for Ugn disabled. Rats and mice have the 
same sequence for mature Ugn-15, and both being from the same subfamily, 
Murinae, it would be expected that their urine composition would be very similar. 
Urine was collected from wild type and knockout animals, dried to dryness and a 
serial dilution of each was assessed in the binding assay. As can be seen in Figure 
3.12, wild type mouse urine is able to displace radioligand binding in a concentration 
dependent manner, exactly the same as I previously observed with rat urine. 
However the urine from the Ugn-/- mouse had no effect on binding. 
 
Protocol Modifications to Compensate for Experimental Urine Properties 
 
The receptor binding competition assay depends on a fixed affinity of the 
receptor for radioligand Ugn in the sample. Any alterations in this relationship can 
give a false signal, negative or positive (if the radioligand affinity is increased of 
decreased, respectively). Additionally, sample characteristics, or treatment of 
samples during processing or sample collection, might cause precipitation of the 
radioligand that would confound the assay by changing the concentration of free 
ligand available for binding. 
In this regard, the urine samples generated during physiological studies 
(including those from animals undergoing peptide infusions, Gut Tie-off experiments 
and diet studies) could potentially contain exogenous molecules and properties not 
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normal to basal urine. During Gut Tie-off experiments, for example, animals are 
infused with a 10% mannitol solution in order to maintain GFR. During many studies, 
animals are also infused with FITC-conjugated inulin for clearance determinations.  
I tested the effects of mannitol on the ligand-receptor relationship by adding 
concentrations of mannitol that would be expected in the urine after infusion into the 
circulation of anesthetized animals. I found that mannitol does in fact affect the 
relationship, inhibiting radioligand binding. Therefore, I tested the ability to dialyze 
away the mannitol by spiking a rat urine sample with a known amount of synthetic 
Ugn and ±mannitol, then dialyzing, drying and comparing.  I observed that accurate 
quantification of Ugn in the urine was restored after 2 hours of dialysis with 500MW-
cutoff membrane against diH2O with no loss of Ugn in the sample, as its size is 
~1.7kDa.  
 
Assessment of Ugn in Plasma and Kidney Extract  
 
The receptor binding competition assay was used to assess the amount of 
Ugn in plasma and tissue extracts to ascertain if the increased sensitivity would 
allow for detection in tissues where Ugn had previously not been found. Neat 
samples of plasma and kidney extract were analyzed and did inhibit binding but not 
in a concentration dependent manner as was seen with urine. Sample were purified 
across a C-18 reverse phase column and single 1ml/minute fractions were collected. 
Samples from fractions in the range where Ugn is known to elute were dried, 
suspended in assay buffer and pH adjusted. Enigmatically some fractions adjacent 
to where Ugn was expected to elute from the column displayed enhanced binding of 
radioligand, more CPMs bound than with no competitor present. No inhibition to 
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binding was detected where Ugn elutes from the column. Additional kidney extracts 
were analyzed that had been spiked with synthetic rat Ugn before HPLC processing 
and sample preparation, at amounts equal to an extract concentration of 10-9M Ugn. 
These fractions gave comparable binding to equal molarity Ugn standard therefore 
Ugn in urine and plasma is likely below the detection threshold of this assay, ~2 x 
10-10 M Ugn. 
 
 
D. Discussion 
 
These studies detail the development of a novel assay technique for 
quantifying Ugn in biological samples. The results of these studies confirm that this 
assay can be used to address specific questions regarding the role of Ugn in post-
prandial natriuresis that were previously unanswerable. Results indicate that this 
Ugn assay can be used to determine peptide levels in smaller sample sizes and with 
greater sensitivity than prior assays. The sensitivity is almost two orders of 
magnitude greater than the previous T84 cell method for quantification of Ugn. 
In addition to being more sensitive, it is more accurate for the different peptide 
family members. The previous assay was dependent on the catalyzed synthesis of 
cGMP via GC-C and it is not known whether the different ligands have the same 
potency in stimulating this synthesis at a comparable level of binding.  
The results presented here indicate that because the observed KD of the two 
of ligands, Ugn and STa, are approximately equal, that the receptor occupancy at a 
given concentration is hypothesized to be the same. This would lead to the 
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conclusion that the ability of STa to elicit greater production of cGMP via GC-C than 
Ugn at a comparable concentration is not due to affinity for the receptor but due to 
increased catalytic activity when bound. This differential catalytic activity could also 
apply to other guanylin family members, and is significant because it means that the 
previously utilized whole cell T-84/cGMP assay may not have been accurate if a 
different peptide family member was being used as the standard for quantification. 
Statistical analysis of the kinetics of the binding of the radiolabeled Y-Ugn to 
the T-84 membrane preparations and in competition with pure synthetic Ugn 
indicates that there is a single class of receptors, GC-C as confirmed by earlier work 
with GC-C knockout animals (96). The results indicate that the tyrosinated Ugn has 
a slightly greater affinity for the receptor than the synthetic Ugn-15 as illustrated by 
its lower KD. 
A number of specific experiments were performed to evaluate whether this 
assay would allow me to accurately determine Ugn levels in urine (and other 
biological samples). The key points are:  
• The radioligand displacement by rat urine and wild type mouse urine 
dilutes the same as it does for synthetic Ugn standard 
• Urine from a Ugn knockout mouse fails to inhibit radioligand binding 
• There is stability in the amount of binding displacement between pH 
4.0 and 4.7 
• Exogenous factors (inulin and mannitol) have no effect on binding or 
can be dialyzed away with no change in signal 
• Plasma and kidney extract Ugn content is below detection threshold 
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By applying a variation of the Cheng-Prusoff equation to the radioligand 
displacement resulting from a concentration response curve of synthetic rat Ugn, an 
accurate measuring tool has been developed to quantify Ugn in biological samples. 
This tool can be used to investigate questions that previously were intractable, and 
has allowed me to address previously undefined aspects of the role of Ugn in Na+ 
and fluid homeostasis, which will be illustrated in Chapter 4. 
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Figures 
 
 
 
 
Figure 3.1 Graphic of T-84 Cell Assay vs Membrane Binding Assay. A) 
Illustrates binding of Ugn (blue oval) to GC-C (red receptor) in whole T-84 cells to 
catalyze cGMP production in a concentration dependent manner. B) Illustrates 
competition between Ugn and 125I-radiolabeled Y-Ugn for binding to GC-C in T-84 
cell membrane homogenates. 
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Figure 3.2 Specific Binding Curve. Graph of specific binding to GC-C at various 
radioligand concentrations. All radioligand concentration were used on an equal 
amount of membranes. KD was determined to be 1.5 x 10-9 +- 4 x 10-10 and maximal 
binding to be 275 CPMs/µg membrane protein. R2 = 0.964, Mean±SEM.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Association Rate Binding Curve. Graph of the amount of specific 
binding (CPMs) when membranes are incubated with 10-9 M 125I -Y-Ugn for various 
lengths of time, R2 = 0.998, Mean±SEM. 
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Figure 3.4 Disassociation Rate Binding Curve. Graph of specific binding (CPMs) 
when maximally bound ligand was diluted 90-fold for various lengths of time. R2= 
0.974, Mean±SEM. 
 
 
 
 
Figure 3.5 Association Curve at Various pHs. Graph of specific binding (percent 
of max CPMs bound) when membranes were incubated with 10-9 M 125I -Y-Ugn at 
various pHs. n=3 values are Mean±SEM. 
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Figure 3.6 Radioligand Displacement by Recombinant Rat Ugn. Graph of 
specific binding (CPMs) when membranes were incubated with various 
concentrations of recombinant rat Ugn-15 for 70 minutes. R2 = 0.9985 n=3 values 
are Mean±SEM. 
 
 
Figure 3.7 Radioligand Displacement by Recombinant Rat proUgn. Graph of 
total binding (CPMs) when membranes were incubated with various concentrations 
of recombinant rat Ugn (black line and diamonds) or recombinant rat proUgn (Purple 
line and circles) for 70 minutes. R2 = 0.9677 n=3 values are Mean±SEM. 
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Figure 3.8 Radioligand Displacement by Recombinant Human Ugn-A and Ugn-
B. Graph of total binding (CPMs) when membranes were incubated with various 
concentrations of recombinant rat Ugn (black line and diamonds) or recombinant 
human Ugn-A (Red line and squares) or human Ugn-B (Yellow line and circles) for 
70 minutes. Ugn-A R2 = 0.9686 Ugn-B R2 = 0.9892, n=3 values are Mean±SEM. 
 
 
Figure 3.9 Radioligand Displacement by Recombinant Rat Gn. Graph of total 
binding (CPMs) when membranes were incubated with various concentrations of 
recombinant rat Ugn (black line and diamonds) or of recombinant rat Guanylin 
(green line and circles) for 70 minutes. Gn has a Ki = 1.7 x 10-7    R2 = 0.9587 n=3 
values are Mean±SEM. 
 111 
 
Figure 3.10 Radioligand Displacement by E. Coli Sta. Graph of total binding 
(CPMs) when membranes were incubated with various concentrations of 
recombinant rat Ugn (black line and diamonds) or E. coli heat stable toxin (red line 
and circles) for 70 minutes. R2 = 0.9834, n=3 values are Mean±SEM. 
 
 
Figure 3.11 Radioligand Displacement by Rat Urine. Graph of total binding 
(CPMs) when membranes were incubated with various concentrations of 
recombinant rat Ugn (black line and diamonds) or a dilution series of rat urine (light 
orange line and squares) for 70 minutes. Orange circle indicates interpolation of 
“Ugn” in the sample that the dilution series of the urine “[Ugn]” was based on. R2 = 
0.9699, n=3 values are Mean±SEM. 
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Figure 3.12 Radioligand Displacement by Rat Urine. Graph of total binding 
(CPMs) when membranes were incubated with various concentrations of 
recombinant rat Ugn (black line and diamonds) or a various concentrations of 
recombinant rat Ugn in rat urine (blue line and circles) for 70 minutes. Red circle 
indicates interpolation of “Ugn” in the urine sample that was added to the 
recombinant Ugn. R2 = 0.9819, n=3 values are Mean±SEM. 
 
 
Figure 3.13 Radioligand Displacement by Ugn-/- Mouse Urine. Graph of total 
binding (CPMs) when membranes were incubated with various concentrations of 
recombinant rat Ugn (black line and diamonds) or a dilution series of mouse Ugn+/+ 
urine (light orange line and squares) or a dilution series of mouse Ugn+/+ urine (light 
orange line and circles) or a dilution series of mouse Ugn-/- urine (red line and 
squares) for 70 minutes. n=3 values are Mean±SEM.
 
 
 
 
 
 
CHAPTER IV 
 
 
 
 
INTESTINAL PROUROGUANYLIN PLAYS A ROLE IN VOLUME 
HOMEOSTASIS, POSSIBLY A DIRECT RESPONES TO ORAL 
SODIUM  
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A. Introduction and Hypothesis 
 
The Roles of proUgn and Ugn in Post-Prandial Natriuresis 
 
The central hypothesis that has guided work in the Ugn field over the past 15 
years is that the polypeptide product of the proUgn gene is 1) generated within the 
intestine, 2) released from the intestine in response to oral Na+ intake, and 3) 
participates in the post-prandial natriuresis (PPN) that occurs in the kidney after oral 
Na+ intake. Evidence presented thus far in this thesis is generally consistent with this 
hypothesis. The Ugn gene encodes a propeptide (proUgn) that is produced and 
stored in the intestine and secreted into the bloodstream. As shown below (Figure 
4.5), essentially all (~90%) of this circulating proUgn is supplied by the intestine. 
Evidence presented in Chapter 2 demonstrates that circulating proUgn is filtered by 
the kidney where it is completely broken down into smaller metabolites (including 
Ugn) that can induce natriuresis by an as-yet undefined mechanism (134, 154). 
However, the situation is complicated by the fact that the kidney also makes proUgn 
(Chapter 2). Although the kidney does not release its proUgn into the circulation 
(Nicholas Moss, unpublished data), the locally produced propeptide could 
nevertheless play a paracrine or exocrine role within the kidney to regulate Na+ 
excretion. Therefore, to rigorously implicate Ugn and proUgn in the hypothesized 
entero-renal endocrine pathway that initiates PPN, changes in circulating proUgn 
and urinary Ugn are predicted to be linked to dietary intake of Na+. Furthermore, it is 
important to show that the changes in peptide levels induced by dietary Na+ are 
adequate to stimulate a natriuretic response commensurate with their postulated 
function. Using the proUgn assay described in Chapter 2 and the Ugn assay 
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described in Chapter 3, it is possible to investigate two key questions that are 
corollaries of the central hypothesis: a) Does intake of dietary Na+ directly affect 
circulating proUgn and urinary Ugn levels? b) Are changes in urinary Ugn levels 
induced by salt diet the direct result of changes in plasma proUgn concentration?   
 
Changes in Ugn and proUgn due to Sodium 
 
In the introductory chapter, Table 1.1 presents the results from studies in 
which Ugn-related peptide levels were measured in tissue, plasma, and urine before 
and after adjustments in dietary Na+ (24, 25, 50, 95, 100, 152). These data do not 
strongly support a entero-renal link that is mediated by Ugn or proUgn.   Expression 
of proUgn mRNA in the intestine and plasma proUgn polypeptide levels do not been 
consistently change in response to increased salt intake, as published results on this 
issue are contradictory and fragmentary. For example, one study demonstrated an 
increase in intestinal mRNA due to changes of Na+ in the water but not in the food 
(23), while another study reported no change in intestinal mRNA in response to 
chronically increased Na+ in the food but a 2-fold increase eight hours after gavage 
of a oral Na+ bolus (25), and a third study noted a 30% increase in enteric Ugn 
mRNA expression by Northern blot in response to a sustained high Na+ diet (50). 
Changes in plasma proUgn and/or Ugn levels in response to dietary Na+ have also 
been noted, but these results, too, are debatable. 
A problematic aspect of these past studies is the lack of a sensitive assay that 
is specific for Ugn. To date, studies analyzing changes in this system due to 
alteration in dietary Na+ have reported their results in terms of “Ugn-related 
peptides”. The radioimmunoassay commonly used to determine these values utilizes 
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an antibody directed towards Ugn.  As described in Chapter 1, Ugn defines the C-
terminus of the propeptide and its sequence is shared among multiple peptide 
species generated from the proUgn gene (Ugn-15, Ugn-18, Ugn-24 and proUgn) 
(81, 101, 108). The solution to this problem is HPLC purification of Ugn from each 
biological sample, but this reduces sensitivity and requires large sample sizes. 
The most comprehensive study, by Fukae et.al.(67), looked at changes in 
gene expression and polypeptide levels in animals on a 5% Na+ diet, relative to 
those in animals maintained on a control diet. Samples were taken at day 7 on each 
diet, so the experimental animals were in a state that would be considered salt-
adapted.  Fukae et al. saw a greater than 3-fold increase in urinary “Ugn-related 
peptides” but no change in plasma “Ugn-related peptides”. Expression of the proUgn 
gene in the kidney and the intestine both apparently increased in relation to a 
housekeeping gene, but no statistical significance was noted for these responses. 
Only two studies have looked at a time period short enough to be considered 
an acute response; one study was performed by Dr. Mitchell Cohens’ group (50) and 
the other by Carrithers et.al. (25). These results are in slight disagreement with each 
other with regards to a short-term intestinal response to high salt. The Carrithers 
study saw a 2-fold increase in intestinal Ugn mRNA when animals that were being 
fed a low Na+ diet were given a gavage of a bolus of NaCl. This is simply mRNA 
message though and not expression or secretion. 
Cohen’s group took a plasma sample from mice 24 hours after a switch from 
normal to high salt diet. Western blot analysis showed a 40% decrease in circulating 
proUgn. This is not the expected response for a signaling molecule that activates 
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salt excretion in response to salt ingestion. Another study by this group with the 
same protocol, Ugn-/- mice showed that these mice had an impaired renal response 
to abrupt increases in dietary Na+ content, transiently excreting less Na+ in the urine 
than wild-type animals during the first two days after switching to high salt chow (50). 
The combination of these experiments—a deficient natriuretic response from 
proUgn-/- animals to a salt load, but no increase in plasma proUgn in wild-type 
animals subjected to the same salt load—leads to an alternate hypothesis: that 
intestinal proUgn is irrelevant, and proUgn produced locally within the kidney (see 
Chapter 2) is responsible for regulating post-prandial salt excretion. 
 
Circadian proUgn Expression and Excretion 
 
Excretion of Ugn in the urine has a circadian rhythm. During a study of 
patients with heart failure, Carrithers et.al. (24) noted that healthy humans excrete 
more Ugn in the urine during the 6 hour daylight period from 8am to 2pm than from 
the other 3 periods. This cycle is more pronounced in males than females (24). 
Another experiment looking at intestinal tissue from mice that were sacrificed 
at six evenly spaced times throughout a 24 hour period showed highest mRNA 
levels in the periods of darkness (when the animals are awake and active) (152) 
Interestingly, expression was elevated first in the ileum, followed by an increase in 
the jejunum with a phase delay of 2 hours. This is contrary to what is expected if 
luminal content of Na+ (ingested during the animals’ waking hours) is the trigger for 
increased expression, as the jejunum is proximal to the ileum. 
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Receptor or Signaling Mechanism of proUgn in the Kidney 
 
proUgn is known to act through GC-C in the intestine via Ugn, but less is 
known about the mechanism that mediates Ugn's actions in the kidney. In addition, 
there is uncertainty about where Ugn acts in the kidney.  Some reports allude to 
effects in the proximal tubule (94), while others emphasize effects in the collecting 
duct (26, 27, 30). 
A number of lines of evidence argue that GC-C is not the primary receptor 
responsible for Ugn’s actions in the kidney. 1) When the gene for GC-C is disabled 
in mice, the intestinal effects of Ugn are severely compromised, but the animals are 
still renally responsive to infusions of Ugn (22, 98). 2) Human Ugn occurs in two 
semi-stable isomeric forms (A and B). The B form increases Na+ excretion when 
infused into rats, even though it is almost completely incapable of activating GC-C 
(135). 3) Functional biochemical measurements and RT-PCR analyses show that 
GC-C expression is negligible in the rat kidney (Qian et al, submitted), even though 
isolated rat kidneys respond well to Ugn infusions (57, 67, 139). 4) In vitro responses 
to Ugn have been observed in renal cell lines that fail to express GC-C (74,170).   
Thus, GC-C appears to be unnecessary for the renal effects of Ugn. 
Therefore, it seems probable that Ugn acts on an alternate, cGMP-independent 
receptor in the kidney. Several groups have suggested that this renal receptor for 
Ugn is a pertussis toxin-sensitive G protein (22, 74, 129). 
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Prior studies with Ugn/proUgn infusions 
 
The effects of Ugn on the kidney have been studied extensively. Ugn has 
been tested in rats and mice both in vivo and in isolated perfused kidneys. Dose 
dependent increases in UK+V, UNa+V and urine volume were seen following bolus 
intravenous injections of Ugn to conscious animals, using a technique known as the 
sealed-mouse renal function assay (23). In an isolated perfused kidney preparation, 
Ugn infusion elicited diuresis, natriuresis and an increase in GFR (56, 108, 187). 
Ugn can both depolarize and hyperpolarize membranes at high and low 
concentrations, respectively, in isolated collecting duct principal cells (172). 
In contrast, investigation into the renal effects of proUgn is limited. The 
natriuretic effects of proUgn have been reported by our research group (112, 136) 
and by Greenberg et al. in abstract from a meeting that has not been published (76). 
In all of these studies proUgn increased Na+ excretion and urine volume without 
affecting GFR and with very small increases (or in some cases decreases) in UK+v 
or FEK. 
The Ugn infusion studies raise a critical question about physiological 
relevance, as the doses of peptide required to elicit natriuretic responses in rats and 
mice exceed reasonable physiological levels (56). One plausible rationale for the 
apparent low potency of Ugn-15 is that an alternate metabolite derived from proUgn 
may be the true mediator of the entero-renal natriuretic pathway. In this case, the 
renal phenotype of the Ugn knockout mouse would reflect the loss of the alternate 
metabolite, rather than the loss of Ugn per se. This hypothesis is strongly supported 
by a previous report from our laboratory showing that human proUgn is more 
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natriuretic than Ugn when the two are infused intravenously at equivalent doses 
(136). Consistent with this concept, my infusion studies with radiolabeled 
recombinant proUgn (reported in Chapter 2, Figure 2.8b) suggest the production of 
at least one alternative proUgn digestion product within the renal tubules. Although 
the structure and biological activity of this novel peptide are not yet known, it is an 
intriguing candidate for future studies. 
 
Responses to Oral Na+ are impaired in proUgn Knockout Animals  
 
The creation of a proUgn/Ugn knockout mouse was a major step forward in 
the investigation of proUgn and/or Ugn as the agent(s) responsible for post-prandial 
natriuresis (118). The knockout animals are hypertensive, suggesting a prominent 
role for one or both of these peptides in volume homeostasis, with a significant 
impact on blood pressure control (118). The animals’ hypertension is considered 
salt-insensitive, as the difference in blood pressure is approximately the same 
between the proUgn-+/+ and proUgn-/- mice on low, normal and high salt chow. In 
addition, when the knockout animals are challenged with an oral salt load, they are 
not able to excrete to excrete it as fast as wild type animals (50). This defect (shown 
graphically in Figure 1.4 of the Introduction to this thesis)  is the strongest evidence 
to date that proUgn plays a role in PPN.. 
The aim of the studies presented in this chapter is to provide direct evidence 
that the proUgn/Ugn signaling pathway is responsive to changes in oral Na+ intake. I 
tested the hypothesis that a change in salt intake would produce a change in 
circulating proUgn levels, which in turn would lead to a change in urinary Ugn 
excretion. I predicted that these responses would be bi-directional (i.e. that 
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increases or decreases in salt intake would lead to corresponding increases or 
decreases in peptide levels). I focused on proUgn in plasma, because my initial 
studies (Chapter 2) revealed that it is orders of magnitude more abundant in plasma 
than Ugn (which is below the limit of detection of my most sensitive assay). Previous 
studies from our lab have shown that circulating proUgn is derived primarily (and 
perhaps exclusively) from the intestine, consistent with the PPN hypothesis (105). I 
focused on Ugn in the urine, because my initial pulse-chase tracer studies showed 
that infused proUgn is converted to Ugn and other metabolites within the kidney, and 
excreted exclusively in processed form (Chapter 2). Furthermore, a number of 
laboratories have shown that Ugn is abundant in the urine produced by a healthy 
kidney, whereas proUgn is detectable only in urine produced by failing kidneys (68, 
124). As a further investigation of the hypothesis that urinary Ugn is derived from 
circulating proUgn, I used the quantitative assays described in Chapters 2 and 3 to 
measure the stoichiometric relationship between proUgn infused into the plasma and 
Ugn recovered in the urine.  
 
B. Methods and Materials 
 
Animals Used 
 
All experiments were performed on Sprague Dawley rats (Harlan laboratories, 
Dublin VA). Animals were maintained on a 12 hour light/dark cycle (on/off at 
8am/pm) in an AALAC-approved facility with continuously available veterinary care 
and uninterrupted access to water and standard rat chow. All experimental 
procedures were approved by the Institutional Animal Care and Use Committee at 
 122 
the University of North Carolina at Chapel Hill, and were carried out in accordance 
with the NIH Guide for the Care and Use of Laboratory Animals. 
 
Sodium Diet Studies 
 
In all diet studies, animals were housed individually in metabolic cages 
(Techniplast, Milan, Italy) with access to deionized water and food ad libitum. The 
rats were acclimated to the cages at least 2 days before study. The diet consisted of 
either low salt chow (LS) (0.02% Na+ Cat #TD.90228), normal salt chow (NS) 
(0.26% Na+ Cat #TD.90229) or high salt chow (HS) (3.1% Na+ Cat #TD.92012) 
(Harlan Teklad, Madison, WI) for various times (see Figure 4.1). Food and water 
intake and feces excreted were measured gravimetrically every 6 hours. Urine was 
collected under mineral oil to limit evaporation. Urine was collected every 6 hours 
and the volume was determined gravimetrically. Urine samples were frozen at the 
time of collection and stored at -80°C for future analysis. Arterial plasma was 
sampled via an indwelling carotid artery cannula from a subset of animals. Na+ and 
K+ concentrations in plasma and urine were measured by flame emission 
photometry (Model 943, Instrumentation Laboratory Co., Lexington MA). Animals 
were sacrificed at various time points during the study (days marked with black dots 
in Figure 1) to obtain plasma and tissue samples for analysis. The time of sacrifice 
for each group was 4am. The method of sacrifice was urethane anesthesia (Sigma-
Aldrich, St. Louis Mo. USA) followed by midline incision of the peritoneal cavity. 
Each animal was exsanguinated, and blood was collected into heparinized tubes. 
Kidney and duodenum were flushed with ice cold saline, minced and stored in 
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RNAlater (Ambien Inc., Carlsbad Ca. USA) for 24 hours at room temperature, then 
stored short term at 4°c prior to PCR analysis. 
 
Installation of Indwelling Carotid Artery Cannula 
 
Rats were anesthetized with sodium pentobarbital (60 mg/kg, ip) and 
prepared for aseptic surgery with 80% EtOH and 10% topical povidone-Iodine 
(Novaplus, Irving Tx, USA). A sterile subcutaneous port (PMINA-CBAS-C30 
Soloport; Instech Solomon, Plymouth Meeting, Pennsylvania, USA) was implanted in 
the neck. The attached polyurethane heparin coated catheter was tunneled over the 
right shoulder into the neck region and cannulated into the exposed carotid artery. 
After surgery, the animals received intramuscular injections of buprenorphine HCl 
(Carpuject, 0.3 mg/ml; Hospira Inc., Lake Forest Il. USA) every 12 hours for 60 
hours. The catheters were flushed daily with 200µL of Heparin Lock Flush (100 USP 
Units/ml)(Hospira Inc., Lake Forest Il. USA). The area of the port was disinfected 
with 90% ethanol before puncture. Blood samples were collected into heparinized 
tubes, centrifuged and plasma was separated from the red blood cells, aliquoted and 
frozen at -80°C for later analysis.  
 
RT-PCR amplifications 
 
Random hexamer-primed cDNA was prepared from isolated RNA, using the 
SuperScript® III First-Strand Synthesis System (Invitrogen, Carlsbad CA), according 
to the supplier's protocol. Subsequent RT-PCR analysis employed primer pairs and 
probes (Table 1) synthesized by the Animal Clinical Chemistry and Gene Expression 
Core of the UNC Department of Laboratory Medicine and Pathology (directed by Dr. 
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H. Kim). Each sample included a fluorescent probe with a reporter dye (fluorescein) 
at the 5’ end and a quencher dye (tetramethylrhodamine) at the 3’ end, as indicated 
in Table 1. Amplifications were performed in duplicate in a 96-well plate in the ABI 
Prism 7700 sequence detector (PE Biosystems) for 40 thermal cycles (15 sec at 
94°C and 1 min at 60°C), as described by Kim et al. (94). Fluorescence was 
continuously measured in each well, and the fractional cycle at which each sample 
crossed a fluorescence threshold, CT, was determined using software provided by 
the manufacturer. CT values were not corrected for differences in amplification 
efficiency, because efficiencies were consistently close to 1.9 (note: a 100% efficient 
reaction that doubles with each cycle has an efficiency of 2.0). 
 
Measurement of proUgn in plasma and urine 
 
ProUgn concentrations in plasma and urine were measured with the 
quantitative Western blot assay described in Chapter 2. Though proUgn is 
undetectable in the urine, results from Chapter 2 show that proUgn is filtered at the 
glomerulus and ends up in the urine.  In the absence of direct measurements (the 
gold standard), a reliable estimate of GFR is required for calculations of peptide 
conversion ratios, and to correlate estimated tubule concentrations with physiologic 
responses. Technical limitations of my study prohibited direct determination of GFR. 
Prior studies with conscious rats have reported GFR in the range of ~0.85 
ml/min/100g bw (124) or 2.5 ml/min for a 260g rat (5). GFR has a circadian 
component in mammals. For example, humans show a 33% reduction in GFR while 
sleeping (105, 185). Results from studies in rats cite a 0.9 ml/min reduction in GFR 
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while animals are sleeping, consistent with the 33% reductions in humans. This 
would give an estimated sleeping GFR of 1.75ml/min for a 300g rat. (151) 
 
Measurement of Ugn in urine 
 
This assay of Ugn in urine is a modification of a previously described radio-
receptor binding assay (78). Our assay is based on competitive binding between 
Ugn and 125I -labeled Y-Ugn at GC-C receptors in an isolated T-84 cell membrane 
preparation. Concentrations of Ugn in urine samples are calculated from a standard 
curve generated with rat. The assay is highly specific for guanylin family peptides, 
which are limited to Ugn in urine (51). The details of this assay are presented in 
Chapter 3. 
 
Analysis of Data from Metabolic Balance  
 
Ugn excretion rates are expressed as fmol/min. Urine Ugn concentrations are 
expressed as pmol/ml, which approximates the concentration of Ugn within terminal 
nephron segments and may be correlated with biological activity. Net excreted 
amount of Ugn for each rat was calculated by subtracting Ugn excretion in the 
control collection period from excreted amounts during the infusion and post infusion 
collection periods, and is expressed as pmol/kg BW. 
Graphing and statistical testing were performed with the Prism 5.3 graphing 
and analysis program (Graphpad Software, San Diego, CA) and Excel (Microsoft, 
Remond Wa.). Paired t-tests were used for comparison of urinary Ugn excretion, 
water consumption, and food consumption. Group comparisons for circadian 
changes in plasma proUgn were made with one-way analysis of variance (ANOVA) 
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using diet interventions as column variables and times of day for plasma or urine 
collection as row variables. Comparisons were also made with two-way ANOVA to 
determine which variable was responsible for any variation seen in the data.  
In the absence of direct measurements, a reliable estimate of GFR is required 
to calculate peptide conversion ratios, and to correlate estimated tubule 
concentrations with physiologic responses. Technical limitations of my study 
prohibited direct determination of GFR. Prior studies with conscious rats have 
reported GFR in the range of ~0.85 ml/min/100g bw (124, 177) or 2.5 ml/min for a 
260g rat (5). GFR has a circadian component in mammals. For example, humans 
show a 33% reduction in GFR while sleeping (105, 185). Results from studies in rats 
cite a .9 ml/min reduction in GFR while animals are sleeping, consistent with the 
33% reductions in humans. This would give an estimated sleeping GFR of 
1.75ml/min for a 300g rat. (151)   
 
Peptides Used 
 
Rat Ugn for use in intravenous infusion experiments and as a standard in Ugn 
binding assays was purchased from commercial suppliers (Anaspec Inc, San Jose 
CA and Peptides International Inc, Louisville KY). The radioligand for binding studies 
was prepared from N-tyrosyl rat Ugn (Y-Ugn, Bachem Inc. Torrance CA). Y-Ugn was 
labeled with 125I using precoated iodination tubes according to the manufacturer’s 
instructions (Thermo Scientific, Rockford, IL ) then purified by reverse phase HPLC 
before use. Recombinant rat proUgn (provided by Ironwoods Pharmaceutical Inc.) 
was produced as a His-tagged trxA fusion protein from plasmid pTM203 in an 
Origami (DE3) bacterial expression system. The fusion protein was purified by 
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immobilized metal ion affinity chromatography, and proUgn was released by 
cleavage with PreScission protease.  
 
Peptide Infusion Protocols 
 
  Rats were anesthetized with sodium pentobarbital (60 mg/kg, ip) and 
prepared for clearance experiments with a PE240 cannula in the trachea, one PE50 
and two PE 10 cannulae in a jugular vein, a PE50 cannula in the left femoral artery 
and a PE10 cannula in each ureter. Rats received an initial volume expansion 
(infusion of isotonic saline amounting to 6% of body weight over 60 min) followed by 
an intravenous maintenance infusion of isotonic saline at 10 µl/min/100g BW for the 
remainder of the experiment. 10 µl/min of the maintenance infusion was provided 
through a PE10 cannula to deliver peptide infusions; the balance was administered 
via the PE50 cannula. Supplemental anesthetic was provided as required through 
the second PE10 intravenous cannula. Blood samples were obtained from the 
femoral artery cannula, which was otherwise connected to a pressure transducer 
system for measurement of arterial pressure (Model 50110, Stoelting Instruments 
Wood Dale, IL). Arterial pressure was digitized with an A/D converter (Keithley 
instruments, Cleveland, OH Model KUSB 3100) for display and storage on a 
personal computer running open layers data acquisition software (Dtx_Ez, Data 
Translation Inc).  20 min urine collections were started 1 hr after the volume 
expansion period. Renal excretory responses to intravenous infusions were 
determined for proUgn and Ugn at a dose of 10 nmol/kg This dose is based on our 
previous studies, which showed human Ugn-A to be natriuretic at a doses between 
20 and 50 nmol/kg BW (135) and human proUgn to be natriuretic at a dose of 10 
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nmol/kg BW (36). Urine Ugn concentrations were measured in all urine collections, 
while proUgn concentrations were measured in urine only from rats receiving 
proUgn infusions. Plasma proUgn was measured before the start of proUgn 
infusions and at the completion of the 60 min infusion period.  
 
Analysis of Data from Peptide Infusion Studies 
 
Basal Ugn excretion rates are expressed in fmol/min. Net excreted amount of 
Ugn for each rat was calculated by subtracting Ugn excretion in the control collection 
period from excreted amounts during the infusion and post infusion collection 
periods and expressed as pmol/kg BW. 
Results from both kidneys in each collection period were averaged before 
calculating group means ± standard error of the mean (SEM). All graphing and 
statistical testing were performed with the Prism 5.3 graphing and analysis program 
(Graphpad Software, San Diego, CA). Group comparisons were made with one-way 
ANOVA using peptide doses as column variables and individual measurements from 
each clearance period for each rat as row variables. Columns were subdivided into 
pre-infusion, infusion, and post infusion groups and tested against corresponding 
values from vehicle-infused rats with Bonferroni’s method for multiple comparisons. 
 
Intestinal Circulation Ligation Studies 
 
Rats are prepared as prior for peptide infusion studies with the addition of an 
infusion of 10% mannitol 0.9% saline at 100µl/min. Following connection of cannula 
and stabilization of animals, the peritoneal cavity is opened and the bowels are 
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exteriorized and wrapped in saline soaked gauze. Ligatures are placed around the 
superior mesenteric artery, the celiac artery and the portal vein. The ligatures are 
tightened in that order allowing time for pressure in the subsequent vasculature bed 
to drop before tightening the next ligature. Urine samples are collected every 20 
minutes and arterial plasma samples every 40 minutes. Samples are analyzed as 
described above. 
 
C. Results 
The General Effects of the Na+ Diet 
 
The Na+ content of the chow fed to the rats had little effect on their overall 
food consumption. Table 4.2 and Figure 4.2a present the daily consumption for the 
cohort of rats on the different diets, showing that they ate the same amount of NS or 
LS chow, but that there was a slight decrease during the HS phase. Significant 
changes are noted on the graph (asterisks in Figure 4.2a). With food consumption 
stable, changes in Na+ content of the food had a significant effect on the animals 
Na+ intake and excretion (Figures 4.2b and 4.2c).  
Though the change from NS chow to LS Na+ chow seemed to have little 
effect on food consumption, there was a significant reduction in water consumed 
(Figure 4.3a) initially after switching from NS to LS, however water consumption 
recovered to previous level. The switch from LS to HS chow elicited a three-fold 
increase in water consumption during the first collection period (3pm to 9pm) and a 
two-fold increase for the first 24-hour period (Figure 4.3a). This rise in water 
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consumption continued to increase through the duration of the animals eating HS 
chow, and correlated with the increase in Na+ intake (Figure 4.2b). 
There were some significant changes in food and water consumption and 
urine flow rate that would be expected for a circadian sleep cycle and large changes 
in Na+ consumption. Significance is noted on the graphs.  
Animals in the diet study had an average starting weight of 311±11g and 
during the course of the study had an average weight gain of 3.9±0.5 g/day. There 
was an unaccounted “metabolic” disappearance of weight in the study as, on 
average, animals had a 30.6g/day difference between the addition of the water they 
drank with the food they ate minus the weight of excretion of urine and feces. This 
loss does seem to be circadian and coincides with when they are active and 
urinating most.  
As a further discrepancy, Na+ is only recovered at an average rate of 78%. 
This could be partially accounted for by the fecal contents, which were not 
monitored. Interestingly, the percent recovered is dependent on the percent Na+ 
content of the food. When the animal is on NS, the amount recovered in the urine is 
~60%, on LS chow ~50%, and on HS chow ~90%. This implies that a portion of lost 
Na+ is in the fecal contents and it is a fixed amount, which comprises a smaller 
percent of the expected excretion when the intake is higher. Evaporative loss of fluid 
on cage parts and resulting precipitation of ions on surfaces could also explain some 
or all of the imbalances.  
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Circadian Changes in Urinary Ugn and plasma proUgn 
 
Utilizing the sensitive radioligand binding displacement assay, urine samples 
could be assayed with no purification step. This allowed me to collect samples over 
shorter times (less than 24 hr) in order to assess of circadian changes in urinary Ugn 
excretion. The day/ night cycle had a profound effect on this parameter. Excretion 
was significantly higher during the 9pm to 3am and 3am to 9am periods when the 
animals were awake, active and consuming food. This is illustrated in Figure 4.4 
(black circles).  
Plasma sampling was performed on a subset of animals, using an indwelling 
carotid cannula to take repeated samples from conscious animals every six hours 
over a 24-hour period. The plasma proUgn levels were also found to be circadian 
with the same peak level at 3am as Ugn shown in Figure 4.4 (white circles). 
Interestingly, the urinary Ugn changes in phase with the changes in plasma proUgn 
levels, consistent with the hypothesis that the plasma propeptide is the source of the 
Ugn that appears in the urine. ANOVA for both plasma proUgn concentration and 
urinary Ugn excretion showed that both change significantly with time of day (Tables 
4.3 and 4.4 respectively).  
Is the amount of proUgn in the plasma sufficient to account for the Ugn that 
appears in the urine? To make this calculation, it is necessary to know the filtered 
load of proUgn, which requires a measurement of the animals’ GFR. I used 
published estimates of GFR, taking into account the animals’ weights and the time of 
day. Using the average of 311 g for the rats from the study, I estimate GFR to be 
2.65 ml/min while awake and with a 30% reduction for circadian variation, 
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1.85ml/min while asleep and 2.35 ml/min for the period in the morning when the 
lights are on but the room sees high traffic of DLAM staff and researchers. My 
calculations (table 4.5) estimate that 0.30±0.045% of the proUgn filtered load gets 
converted into Ugn excreted in the urine.   
This estimate of the percent of filtered proUgn converted to Ugn is 
surprisingly low, and shows that the filtered load of propeptide is enormously larger 
than would be required to produce the Ugn in urine (and would be so even if my 
estimates of GFR are wrong). It also implies that a small change in proUgn 
processing within the kidney could significantly affect urinary Ugn: a fractional 
increase in the percent of proUgn being processed could result in a many-fold 
change in the level of Ugn excreted. 
It must be emphasized that there could also be a renal source for the urinary 
Ugn, in which case an even smaller percent of the filtered load of proUgn would be 
converted. As prior studies have not detected proUgn in the urine of normal animals, 
one might conclude that over 99% of the filtered proUgn is converted into another 
metabolite or completely degraded. 
 
Plasma ProUgn is Derived Primarily (and Perhaps Exclusively) from Intestinal 
Secretion 
 
According to the central hypothesis in the Ugn field, proUgn is released from 
the intestine into the plasma, and delivered to the kidney to regulate salt excretion. 
To investigate the extent to which plasma proUgn has an enteric source, we ligated 
the vascular input to and outflow from the intestine and measured plasma levels of 
proUgn as a function of time after the ligation. As shown in figure 4.5, the plasma 
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concentration of proUgn fell rapidly after ligation, reaching very low levels (< 15%) 
within 140 min. Previous studies have shown that renal clearance of radiolabeled 
recombinant proUgn is rapid (see chapter 2), and the rate of disappearance of 
exogenous radiolabeled proUgn in these pulse-chase studies is comparable to the 
rate of loss of endogenous non-radioactive proUgn observed here. Thus, the data 
suggest that most (and perhaps all) of the circulating pool of plasma proUgn is 
supplied by the intestine, and are consistent with a high rate of enteric release 
coupled with a rapid rate of renal clearance.  
 
Urinary Ugn Changes in Response to Dietary Na+ 
 
Analysis of urinary Ugn in samples showed significant changes in response to 
dietary Na+ content (Figure 4.6a).  The change from NS (0.26%) to LS (0.02%) 
resulted in a 15% decrease in the daily rate of excretion (NS 130.2±0.2 vs. LS 
111.5 ± 9.1). There was little change in the “basal” excretion rate of Ugn when the 
animals were quiescent (during the 9 am to 9 pm time period), but when active and 
eating (during the 3am to 9am time period), there was a significant difference 
between NS chow (day 4) Ugn excretion (31.9±5.8 fmol/min) and the LS chow (day 
5) excretion (20.1±3.8 fmol/min, p< 0.02, paired t-test) (Figure 4.6a). This trend of 
significantly less urinary Ugn excretion from 3am to 9am continued through the third 
day, but a normal-appearing circadian increase had returned by the fourth day. 
Thus, Ugn excretion was lower than normal while the animals were adapting to the 
abrupt change in their Na+ intake (i.e. when intake and excretion were not yet in 
balance – see Days 4-9 Table 4.2), but returned to normal once the animals had 
regained a state of metabolic equilibrium.  
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When the animals were switched from LS to HS diet, the 3am collection 
Urinary Ugn was significantly higher (HS {day 10} 43.6±7.5 fmol/min vs LS {day 9}  
23.3±2.6 fmol/min p<0.05, paired t-test). The circadian peaks on HS chow were 
significantly different from the NS chow peaks for every day (Figure 4.6a, day 11, 
p<.0.003; day 12,p<0.04; day 13,p<0.04; day 14,p<0.02). Comparing the quiescent 
(3pm-9pm) period for the HS animals to the NS animals shows that for the first three 
days  (day1 vs. day 10, 11 and 12) that the “trough” of the circadian peak (i.e. 
“basal” secretion during the quiescent period) was not significantly different but day 
13 and day 14 (p<0.01 and p<0.04 respectively) the trough was significantly higher. 
Figure 4.6b shows that the daily excretion of Ugn increased significantly for the 
duration of the HS diet treatment and appears to have achieved a new steady-state 
rate by day 3. Figure 4.7a shows that the troughs and the peaks of urinary Ugn 
correlate closely with the circadian cycle of Na+ excretion the first two days on HS 
diet. 
 
Plasma ProUgn Does Not Change in Response to Dietary Na+ 
 
The plasma proUgn data presented in Figure 4.4 were obtained by collecting 
plasma from an indwelling carotid artery cannula.  Unfortunately, the implanted ports 
did not stay patent for more than 6-7 days, which limited a more extensive analysis 
during full diet regime, as originally planned. Nevertheless, the ports were used to 
gather limited data about the effects of dietary Na+ changes on plasma proUgn at 
specific time points in different sets of animals. Table 4.3 lists these values, showing 
circadian changes in plasma proUgn that were basically unaffected by diet 
conditions. The table also shows the results of ANOVA evaluation of different dietary 
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Na+ treatments compared with NS. None of the Na+ changes achieves overall 
statistical significance.  However, two-way ANOAVA reaffirms proUgn variation as a 
function of time of day regardless of dietary Na+. 
Additional plasma samples were collected from a separate set of animals 
treated in parallel to those in metabolic cages. These separate animals were 
sacrificed by guillotine at 4am on specific points during the study. This time was 
chosen because it is when the circadian changes in plasma proUgn and urinary Ugn 
levels were both at their highest (Figure 4.4). Plasma from these animals was 
analyzed by quantitative proUgn western blot assay at four critical time points: 
adapted to NS, adapted to LS, adapted to HS, and 12 hours after the switch from LS 
to HS.  The results indicate there was no significant change in the plasma proUgn 
concentration (Figure 4.8a).  The value observed for the animals that had become 
adapted to HS chow was 15-20% higher than other groups, but this tendency did not 
achieve statistical significance even with the relatively large sample size of ~ 10 
animals per treatment group.  
In Figure 4.8b, the colored circles illustrate the relationship between urinary 
Ugn and plasma proUgn levels at these four different dietary Na+ conditions at 3am. 
The grey dashed line is the average plasma proUgn value for all diet conditions. 
During no diet conditions is there a significant difference from this. The red dashed 
line plots the theoretical values of plasma proUgn that would be required to generate 
each value of urinary Ugn at a fixed 0.3% conversion rate. It is evident that the 
actual proUgn values do not fall on the theoretical line, and, indeed, appear to be 
completely independent of dietary status.  There are the three additional time 
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periods plotted for NS diet (green circles without error bars) that illustrates again the 
circadian change of Ugn excretion its association with plasma proUgn. 
 
Changes in proUgn mRNA Expression in Response to Dietary Na+ 
Because Ugn levels in the urine changed in response to salt diet, q-rtPCR 
was used to determine whether either the intestine or the kidney increased their 
levels of the proUgn-encoding mRNA transcript. A salt-dependent change in 
expression levels would serve as an indirect assessment of whether either tissue 
might be generating proUgn at a higher rate under any of the dietary conditions.  
Figure 4.9a represents the difference in cycle threshold (ΔCt) values 
determined by real time RT-PCR amplification between proUgn and ß-Actin (chosen 
as a control housekeeping gene) in these two tissues. For the intestine, the ß-Actin 
Ct was consistent across all diets (not shown), and the proUgn Ct decreased slightly 
for the different diet conditions (0.8 cycle Ct difference between NS and HS 
adapted). For kidney samples the proUgn gene expression reached threshold more 
than 2 cycles sooner for HS adapted than for NS, and there was also a slight 
concurrent increase in Ct for ß-Actin Ct (not shown). Using the Δ-Δ-Ct method 
(Figure 4.9b) to compute expression changes, there was 70% increase in Ugn 
expression in the kidney between NS and HS day 1, and a 100% (two–fold) increase 
by day 5 on HS diet. This Δ-Δ-Ct approximation of expression also showed that 
intestinal proUgn mRNA levels did not change immediately after the switch to HS, 
and increased non-significantly by 40% by 5 days after the switch. Thus, the qRT-
PCR data suggest that higher mRNA levels may be required to support an 
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accelerated rate of proUgn synthesis in the kidney under high salt conditions. This 
would be consistent with a higher rate of renal proUgn secretion, requiring, in turn, a 
higher rate of de novo synthesis to maintain the tissue pool of propeptide at a normal 
level. In contrast, intestinal mRNA expression is independent of salt diet. This 
correlates well with the observation (Figure 4.8) that plasma proUgn (secreted by the 
intestine – Figure 4.5) also does not change as a function of salt intake. Thus, two 
lines of evidence (plasma propeptide levels and enteric mRNA levels) argue against 
the hypothesis that the intestine is the tissue source of a Ugn/proUgn signal that 
regulates PPN. The mRNA expression data also demonstrate that there is ~50 times 
more proUgn transcript in the intestine than the kidney (data not shown), in good 
agreement with past findings.   
 
Excretion of Ugn in Urine After proUgn and Ugn Infusions 
 
Chapter 2 investigated the metabolic fate of radiolabeled proUgn (infused into 
the plasma). However, these studies were non-quantitative. In order to evaluate the 
stoichiometric relationship between plasma proUgn and excreted Ugn, we infused 
known amounts of recombinant proUgn and measured both the resulting plasma 
levels of propeptide and the excreted amounts of Ugn. 
After 60 minutes of intravenous infusion with rat proUgn at 10 nmol/kg BW, 
plasma proUgn concentration increased from 2.2±0.3 (n=6) to 37±9.6 pmol/ml over 
the same time period (p<0.0001 n=3, unpaired t test). This is significantly higher 
than would be seen in normal rats, but is within the range that can be achieved in 
patho-physiological conditions, as such a level is commonly achieved in rats with 
renal failure produced by a 5/6 reduction in renal mass (N. Moss, unpublished 
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observation). In Figure 4.10a Ugn excretion is shown as fmol of Ugn excreted in the 
urine per minute before, during, and after the proUgn infusion. The total recovered 
amount of Ugn in urine (summed over the infusion and post-infusion periods) was 
206±39 pmol/kg, which amounts to 2% of the infused dose of proUgn (Figure 4.10c). 
This contrasts with plasma proUgn levels, which increased by ~1700% during the 
infusion rates. The extremely low recoveries of Ugn derived from proUgn suggest 
either that Ugn production within the tubules is relatively inefficient, or that Ugn may 
be produced but is largely degraded and/or reabsorbed before it is excreted in the 
final urine. 
To examine this latter possibility, and for comparison with the results of 
propeptide infusions (Figure 4.10a), urinary Ugn excretion in response to 
intravenous infusions of rat Ugn itself is shown in Figure 4.10b. The excretion of Ugn 
in urine increased from 0.125±0.03 pmol/min to a peak of 13.7±1.11 pmol/min during 
the 10 nmol/kg infusion (Figure 4.10b). This is more than 10 times higher than the 
excretion achieved with intravenous infusions of the same molar amount of proUgn 
(Figure 4.10a). The amount of Ugn recovered in urine was ~5000 pmol after the 
infusion, or about 50% of the total infused amount (Figure 4.10c). The fate of 
unrecovered Ugn is unknown, but is not due to delayed excretion, as the urine Ugn 
concentrations returned close to baseline levels in the second hour following the 
intravenous infusion (Figure 4.10b). It is more likely that several processes reduced 
the recovery, including degradation within the proximal tubules and removal from the 
circulation by non-renal clearance mechanisms. However, the relatively robust 
recovery of infused Ugn (~50%), compared to the relatively poor recovery of Ugn 
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derived from infused proUgn (~2%, see above), argues that Ugn is not produced 
stoichiometrically from proUgn within the tubule. In summary, proUgn infusions 
produce very small increases in urinary Ugn excretion relative to those observed 
when Ugn itself is infused. 
The Ugn concentration in urine provides an index of the intratubular “dose” of 
the peptide. As shown in Figure 10d, the “dose” of Ugn generated from the 10 
nmol/kg proUgn infusion is very low compared to the “dose” generated by the 10 
nmol/kg Ugn infusion. Surprisingly, however, in companion studies performed by 
Nick Moss, the proUgn infusion actually had a greater natriuretic effect than the Ugn 
infusion (Figure 4.11a vs 4.11b). Since none of the infused proUgn appeared in the 
urine (i.e. all of it was metabolized and/or reabsorbed before excretion) this 
observation argues very strongly that proUgn is being processed to something that 
is distinct from (and more potent than) Ugn. Furthermore, since any such material 
did not generate a significant signal in my binding assay, it would likely not be 
derived from the N-terminus of the propeptide. 
 
D. Discussion 
 
Urinary Excretion of Ugn Varies in Proportion to Dietary Na+ intake, but 
Plasma Levels of ProUgn Do Not 
 
Analysis of plasma and urine obtained from rats housed in metabolic cages 
shows that both Ugn and proUgn vary during the normal circadian day/night cycle. 
The changes in proUgn were limited to the plasma (proUgn was undetectable in 
urine under all conditions in my study) and had a high correlation to time of day 
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(Table 3). This circadian rhythm of plasma proUgn is shown in Figure 2; the two 
highest values occurred when the lights were out and the animals were active and 
eating (Figure 4.2). The intestinal expression of proUgn mRNA has previously been 
shown to change in a circadian cycle, with ileum and duodenum levels highest 
during active hours (25). Data in Figure 4.5 show that the intestine is the primary 
(and perhaps exclusive) source for circulating proUgn, suggesting that enteric 
secretion of proUgn also displays a diurnal rhythm.  
The urinary Ugn changes are also constrained to a circadian rhythm (Table 
4.4). This has previously been observed in humans, and again this cycle is 
associated with the wakeful phase (24). Figure 4.4 shows that urinary Ugn changes 
in phase with plasma proUgn supporting the hypothesis that intestinal plasma 
proUgn is a source for excreted Ugn, and that changes in circulating proUgn would 
result in changes in Ugn. Note that some circadian protein expression cycles are 
driven by inherent cyclical changes in gene expression (based on an internal “clock” 
that is stimulus-independent) while others are due to the cyclic nature of some 
external stimulus that drives expression (such as photoperiod, or food intake) (66, 
71, 146). Based on these concepts, it could be hypothesized that changes in urinary 
Ugn are derived from an intestinal source that cycles in response to Na+ intake. 
In addition to circadian changes, there is a significant correlation between the 
amounts of Ugn excreted in the urine and the Na+ content of the chow being 
consumed. One-way ANOVA shows that high salt intake significantly affects urinary 
Ugn excretion. This strongly supports the hypothesis that Ugn is involved in Na+ 
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homeostasis.  Following is a list of changes observed (or not observed) in plasma 
proUgn and urinary Ugn in relation to dietary Na+: 
• A decrease in food Na+ content causes a significant transient (18-24 
hour) drop in urinary Ugn excretion 
• On a low Na+ diet urinary Ugn excretion is nearly normal after the 
animal has adapted to a new lower Na+ intake level (48 hours)  
• An increase in Na+ diet causes both transient and significant sustained 
increases in urinary Ugn 
• No significant changes in levels of plasma proUgn in response to 
dietary Na+ but proUgn levels do change significantly in a circadian 
rhythm.  
• No significant change in proUgn transcript levels in the intestine but 
significant changes were seen in the kidney 
 
These data are in good agreement with (but much more far-reaching than) 
the limited observations of absolute amounts of protein and fold change in response 
to dietary stimuli that have been previously reported. They support the concept that 
a change in dietary Na+ results in a change in the levels of renal metabolites of 
proUgn, specifically Ugn, that appear in the urine. 
In addition to the strong association that I observe between urinary Ugn 
excretion and Na+ intake, there is also a strong association between Na+ excretion 
and Ugn gene status. Figure 4.7b illustrates results reported by Dr. Mitchell Cohen’s 
group when studying a whole animal Ugn knockout model that they developed (50). 
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The phenotype of these mice is associated with impaired Na+ excretion over the first 
36 hours after a switch to HS food, as indicated by the pink shaded region. When 
compared to the graph of my data in figure 6a, which is appropriately lined up, it is 
evident that the phase of impaired excretion (days 1 and 2) is associated with a 
transient period of maximal Ugn excretion. The transient peak is then replaced by a 
prolonged plateau phase of constant excretion at a lower level.  
On day 15 of the study, the first day of NS food after being on HS food the 
animals greatly increased their food intake. Specifically, the first period after the 
change they ate more chow on average than any other period during the study. 
Despite this increased food intake, the NS animals only consumed 32.7±2.1 
milligrams of Na+ compared to 187.3 ±23.9mg for the same period the prior day on 
HS chow.  During these same periods, the excretion of Ugn was significantly greater 
on the HS chow that was consumed in less quantity but with a greater Na+ content 
(46.7±11.6 vs, 29.4±6.9 fmol/min, t-test p< 0.03). From this I conclude that the mass 
of food in the stomach is unlikely to be responsible for changes in urinary Ugn; 
rather, it is the Na+ content of that food.  
 
The Source of Urinary Ugn  
 
The implication of my results, taken as a whole, is that changes in urinary 
Ugn excretion do accompany shifts in oral Na+ consumption, but these are not 
driven by changes in plasma proUgn levels that are generated by the intestine. 
Rather, my data favor the hypothesis that the “diet-responsive” component of urinary 
Ugn is coming from the kidney. Evidence that supports this idea includes: (1) the 
proUgn transcript is expressed in the kidney (Figure 4.9); (2) the proUgn polypeptide 
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is present as well (Chapter 2, Table 2.2); (3) renal expression of the proUgn 
transcript is regulated by oral Na+ intake (at least for the shift to high salt), whereas 
enteric expression is not (Figure 4.9b); (4) plasma proUgn is secreted primarily (and 
perhaps exclusively) by the intestine (Figure 4.5); (5) but plasma proUgn levels are 
not affected by dietary Na+ (Figure 4.8a). 
proUgn is present in the plasma at very high levels relative to most circulating 
hormones (134), and Figure 2.5 in Chapter 2 and Figure 4.10 in this Chapter 
demonstrate that at least some of this circulating propeptide does get converted to 
Ugn and is excreted in the urine in that form. Quantitative analysis (Table 4.5) 
reveals that sufficient Ugn can be generated from normal basal levels of plasma 
proUgn to account for the basal levels of urinary Ugn. At a 0.3% conversion rate this 
filtered load is adequate to supply the urinary Ugn excreted and exogenous infusions 
of proUgn convert to Ugn at a rate of 2%, well above that threshold (Figure 4.10). 
However, the plasma proUgn level does not change in response to dietary Na+ 
increases but urinary Ugn does, so there is a disconnect from this 0.3% conversion 
rate. This implies that the kidney is supplying the increased Ugn and this is 
reasonable given the renal content of proUgn is 15 times greater than the highest 6-
hour excretion period on a molar basis. For renal production to supply the whole Ugn 
excretion, the conversion rate would have to be greater than 6% to utilize the entire 
stored kidney pool in one period. An alternative is that both sources contribute to this 
excreted urinary Ugn. Thus, there may be two components to the Ugn that is 
excreted in urine: a constant, baseline diurnal rhythm that is generated by cyclical 
secretion of proUgn into the plasma from the intestine, and a variable “diet-
 144 
responsive” transient component that occurs after a switch in intake and is 
generated by the kidney. 
At least one alternative to a renal source of proUgn should be considered. It is 
possible that proUgn levels in plasma are not in themselves salt-sensitive, but that 
the processing of plasma proUgn into Ugn is salt sensitive. My data indicate that if 
plasma proUgn is, in fact, the sole source for urinary Ugn, then <1 percent of the 
filtered load of proUgn is sufficient to account for all of the urinary Ugn. Thus, if 
activity of an intrarenal enzyme, such as a brush border endopeptidase, were 
controlled by Na+, then a constant filtered load of proUgn would be able to produce 
these varying amounts of urinary Ugn. This could be complementary to the central 
idea of the entero-renal axis, as the intestine would be exerting control over 
natriuresis through subtle changes in plasma proUgn that are magnified by an 
increased percentage processed into Ugn.  
 
Final Thoughts 
 
The present studies do not support the hypothesis that proUgn plays a central  
role of an entero-renal signal that responds to an enteric Na+ load. The absence of 
any significant changes in intestinal proUgn expression or plasma proUgn levels 
after changes in dietary Na+ argue that the mechanism is either extra-intestinal, or is 
more subtle than a major change in secretion levels. Thus, the role of Ugn or proUgn 
in salt homeostasis is not as simple as predicted by the PPN model. My 
observations support the idea that there may be two different tissue sources for 
urinary Ugn—a renal source that responds to a dietary Na+ stimulus, and a 
constitutive intestinal source with a circadian rhythm. 
 145 
Estimations of percent conversion of proUgn to Ugn indicate that if the 
primary role of enteric proUgn is to produce urinary Ugn, then it does so in a very 
inefficient manner.  With an estimated 0.3% conversion of endogenous proUgn to 
Ugn at physiological plasma concentrations (2.5 to 4.5 pmol/ml), and a conversion 
rate of ~2% at 37pmol/ml plasma after 10 nmol/kg exogenous infusion, it might well 
be that Ugn is not the primary intended product within the kidney, but rather is a 
byproduct during the production of the true metabolite. In this regard, data presented 
in figure 11 show that after infusion of equivalent doses of Ugn and proUgn, the 
response to proUgn is significantly greater than the response to Ugn. This can be 
contrasted with substantially lower intratubular Ugn concentrations when equal 
moles of proUgn or Ugn were infused systemically (figure 8d). Thus, a substantially 
lower filtrate Ugn concentration is inducing a greater natriuretic response when 
plasma proUgn is the source. The implication is that an alternate metabolite is 
physiologically active. This is one of the most interesting and crucial areas for future 
research in the Ugn field. 
In addition, my data also raise the intriguing question of whether circulating 
proUgn might play a role in some homeostatic mechanism that is not predicted by 
the prevailing PPN model. Such a mechanism could act outside the kidney, though 
this would require an as-yet unidentified processing mechanism to generate 
appropriate biologically active metabolites. Plausible target tissues for such extra-
renal actions include the adrenal gland, the pancreas, the liver, and the reproductive 
organs, all of which have been shown to express GC-C either constitutively or in 
response to developmental or pathophysiological events (22, 74, 129, 145, 182). 
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Tables 
 
Table 1: primers used for RT-PCR 
primer set forward primer reverse primer probe 
A (proUgn) ca/ccagggtgtctacatcaag tctcc/ttccaactcattcagc ftggcttccaagtccagctg/agaatcq 
B (β-actin) tgcctgacggtcaggtca caggaaggaaggctggaag fcactatcggcaatg
agcggttccgq 
 
Table 4.1 Primers and Probes for rtPCR Is a diagram of the primers and probes 
used for q-rtPCR to determine relative amounts of mRNA present for genes of 
interest in tissues of interest. 
 
 
Table 4.2 Sodium Diet Study Data The effects of diet changes on the daily 
amounts of food, water, and Na+ consumed, Na+ excreted and urine flow rate for all 
animals included in the diet study. 
 
 Day 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
 0.26% Na+ Chow 0.02% Na+ Chow 3.1% Na+ Chow 0.26% Na 
Food 
Intake 
(g) 
25.79 
±1.16 
25.40 
±0.83 
27.68 
±1.24 
26.33 
±1.12 
26.99 
±1.21 
27.53 
±1.55 
27.05 
±1.61 
25.57 
±1.70 
24.61 
±0.92 
20.96 
±2.18 
22.65 
±1.8 
23.89 
±1.70 
24.01 
±2.01 
23.60 
±1.24 
28.42 
±0.66 
30.13 
±1.29 
Water 
intake 
(ml) 
31.46 
±1.49 
35.02 
±1.50 
31.94 
±8.11 
29.99 
±3.70 
23.64 
±3.03 
26.63 
±3.29 
28.58 
±3.70 
29.42 
±4.14 
30.09 
±4.05 
67.25 
±9.31 
74.82 
±10.3 
84.09 
±10.8 
88.63 
±12.4 
69.21 
±14.9 
37.93 
±2.96 
35.16 
±3.72 
Na+ 
Intake 
(mEq) 
2.58 
±0.13 
2.87 
±0.09 
2.98 
±0.14 
3.45 
±0.23 
0.23 
±0.01 
0.24 
±0.01 
0.24 
±0.01 
0.23 
±0.01 
0.22 
±0.01 
28.91 
±2.37 
31.39 
±1.87 
32.95 
±1.86 
33.04 
±2.16 
31.81 
±1.68 
3.21 
±0.07 
3.41 
±0.15 
UNa+ 
Excretion 
(mEq) 
1.50 
±0.08 
1.76 
±0.04 
1.84 
±0.23 
1.99 
±0.23 
0.54 
±0.07 
0.13 
±0.01 
0.11 
±0.01 
0.11 
±0.01 
0.11 
±0.01 
16.88 
±0.87 
26.94 
±2.31 
30.57 
±1.44 
31.51 
±2.62 
27.89 
±1.44 
3.67 
±0.83 
1.46 
±0.53 
Urine 
Volume 
(ml) 
11.60 
±0.60 
12.48 
±0.44 
15.69 
±2.84 
14.04 
±1.58 
12.25 
±1.33 
13.69 
±1.49 
14.30 
±0.98 
15.09 
±1.69 
15.45 
±1.83 
42.96 
±4.74 
61.59 
±7.05 
69.84 
±7.40 
71.44 
±9.99 
65.02 
±7.24 
19.70 
±2.00 
16.01 
±0.16 
Feces 
(g) 
 
14.15 
±0.85 
16.54 
±1.89 
15.03 
±2.17 
12.03 
±1.04 
11.06 
±0.96 
9.41 
±1.51 
10.63 
±1.63 
10.96 
±2.08 
10.58 
±1.63 
8.48 
±1.18 
8.36 
±0.97 
8.23 
±1.32 
9.32 
±1.06 
9.62 
±1.95 
11.70 
±1.16 
13.24 
±1.49 
Sodium 
Imbalance 
(Percent 
recovered) 
58.2 61.5 61.8 57.8 230.6 56.0 45.9 49.7 49.2 58.4 85.8 92.8 95.4 87.7 114.4 42.8 
Water 
Imbalance 
(Percent 
recovered) 
36.9 35.6 49.1 46.8 51.8 51.4 50.0 51.3 51.4 63.9 82.3 83.1 80.6 93.9 51.9 45.5 
Solid 
Imbalance 
(Percent 
recovered) 
62.08 65.10 54.30 45.69 40.97 34.18 39.32 42.88 42.97 40.45 36.91 34.46 38.80 40.75 41.15 43.94 
Number of 
Animals 3 3 7 10 10 10 10 10 10 10 10 10 10 10 7 3 
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proUgn in 24 hour Plasma Collections During Diet Study Intervals (pmol/ml) 
Collection 
period 
Normal 
salt 
Normal to 
Low 
Low Salt 
Adapted 
Low to 
High 
High Salt 
Adapted 
High to 
Normal  
9PM 3.16 3.25 3.41 2.57 4.14 3.58 
3AM 4.50 3.74 4.56 4.19 4.65 3.43 
9AM 2.95 2.96 2.98 2.71 3.11 2.84 
3PM 2.93 2.57 2.48 2.21 2.65 2.80 
Values are 
in pmol of 
proUgn per 
ml Plasma 
 1 way ANOVA compared to Normal Salt 
Mean 
Difference 
 
-0.2523 
 
-0.02362 
 
-0.463 
 
0.2593 
 
-0.2197 
p < 0.05 n/s n/s n/s n/s n/s 
 
2 way ANOVA of all Values 
Source of Variation % of total variation P value  
Diet 11.03  0.1148  
 
Time 73.6  < 0.0001  
 
 
 
Table 4.3 Analysis of Diet and Circadian Effects on Plasma proUgn Analysis of 
plasma samples obtained from animals during Na+ diet study. Samples were drawn 
every six hours over a 24-hour time period. 1-way ANOVA was performed for each 
dietary intervention versus animals fed normal (0.26% Na+) chow. 2-way ANOVA 
was performed on the entire data set.  
 
Urinary Ugn Excretion During Diet Study Intervals (fmol/min) 
Collection 
period 
Normal 
salt 
Normal 
to Low 
Low Salt 
Adapted 
Low to 
High 
High Salt 
Adapted 
High to 
Normal  
9PM 19.26 21.41 19.45 27.43 46.70 29.37 
3AM 30.61 20.15 23.31 43.58 47.36 24.11 
9AM 26.39 22.07 18.51 42.45 46.39 22.31 
3PM 16.94 16.47 16.66 21.85 34.28 16.22 
Values are 
fmol of Ugn 
Excreted 
per Minute 
into Urine 
 1 way ANOVA compared to Normal Salt 
Mean 
Difference -3.275 -3.817 10.53 20.38 -0.2975 
p < 0.05 n/s n/s n/s Yes n/s 
 
2 way ANOVA of all Values 
Source of Variation % of total variation P value  
Diet 71.78  < 0.0001  
 
Time 16.65  0.0032  
 
 
 
Table 4.4 Analysis of Diet and Circadian Effects on Urinary Ugn Analysis of 
Urinary Ugn in samples obtained from animals during Na+ diet study. Samples were 
collected every six hours over a 16-day period. 1-way ANOVA was performed for 
each dietary intervention versus animals fed normal (0.26% Na+) chow. 2-way 
ANOVA was performed on the entire data set. These analyses were carried out 
using values that represent the mean of 4 animals. 
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Estimation of percent of Filtered proUgn converted into Ugn 
 Time GFR 
(ml/min) 
Plasma 
proUgn 
(pmol/ml) 
Filtered 
Load 
proUgn 
(pmol) 
Urinary 
Ugn  
(pmol/ 
period) 
Percent of 
proUgn 
converted 
to Ugn 
Mean 9pm 1.75 3.73 2346.9 5.90 0.25 
SEM 3am 2.65 4.55 4335.9 10.28 0.25 
 9am 2.65 3.15 3004.0 9.01 0.30 
 3pm 2.3530 2.92 1837.3 7.54 0.41 
     Mean  0.30 
     SEM 0.045 
       
 
3am NS (day4) 2.65 4.55 4336.2 10.28 0.25 
3am LS (day 9) 2.65 4.59 4380.4 8.39 0.19 
3am LS->HS (day 10) 2.65 4.22 4028.4 15.69 0.39 
3am HS (day 14) 2.65 5.35 5107.0 17.05 0.33 
       
 
Table 4.5 Estimation of proUgn to Ugn Conversion with Effects of Diet and 
Circadian Variation Analysis of the percent of the filtered load of plasma proUgn 
that is converted to Urinary Ugn.  
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Figures 
 
 
Figure 4.1 Sodium Diet Study Feeding Protocol Schematic illustration of the Na+ 
content of the chow and the days and times when biological samples and metabolic 
data were obtained. 
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 Figure 4.2 Na+ Handling and Food Consumption During Sodium Diet Study  
A) Food consumption in grams (g) for each 6 hour time period over the entire time 
course of the diet study. B) Na+ consumption in mEq per minute for each 6 hour time 
period C) Na+ excretion in mEq per minute for each 6-hour time period. An all 
graphs, vertical lines indicate 9pm and black/white boxes indicate night/day status. 
The yellow bar indicates 0.02% Na+ LS chow and the red bar indicates 3.1% Na+ HS 
chow. Values are mean ±SEM, n=8-11. Asterisks indicate p<0.001 (**) and 
p<0.0005 (***) for paired t-test of values from same animals. 
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Figure 4.3 Water Handling During Sodium Diet Study A) Water consumption (ml) 
for each 6 hour time period over the entire time course of the diet study. B) Urine 
excretion (ml per minute). In both graphs, vertical lines indicate 9pm and black/white 
boxes indicate night/day status. The yellow bar indicates 0.02% Na+ LS chow and 
the red bar indicates 3.1% Na+ HS chow. Values are mean ±SEM, n=8-11. Asterisks 
indicate p<0.001 (**) and p<0.0005 (***) for paired t-test of values from same 
animals. 
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Figure 4.4 Circadian changes in Circulating proUgn and Urinary Ugn Excretion 
White symbols indicate urinary Ugn excreted in picomoles during the 6-hour time 
period that the data point is centered on. The black symbols denote plasma proUgn 
(picomoles/ml) at that time point. Values are mean ±SEM, n=8 for proUgn, n=13 for 
Ugn. Statistics calculated using a paired t-test comparing each animal’s urinary Ugn 
to its own sample from adjacent time period. * = p<0.025 ** = p<0.005 *** =p<0.002.  
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Figure 4.5 Plasma proUgn Levels Change Following Entero-Hepatic 
Circulation Ligation.  The red symbols indicate the amount of proUgn in the 
plasma at time points following the ligation of intestinal arteries and portal vein 
(Black arrow). * = p<0.05 ** = p<0.01, n=3. 
 
 154 
 
 
Figure 4.6 Urinary Ugn Excretion During Sodium Diet Study A) Urinary Ugn 
excretion for each 6 hour time period over the entire time course of the diet study. 
The vertical lines indicate 9pm and the black/white boxes indicate night/day status. 
B) Black symbols indicate summed 24-hour urinary Ugn excretion (pmol/day). In 
both graphs the yellow bar indicates 0.02% Na+ LS chow and the red bar indicates 
3.1% Na+ HS chow. Values are mean ±SEM, n=4. Asterisks indicate p<0.05 (*), 
p<0.001 (**) and p<0.005 (***) for paired t-test of values from same animals. 
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Figure 4.7 Urinary Ugn Excretion Correlated to Na+ Excretion in Diet Study 
Animals and Compared to Knockout Mouse Phenotype Data A) The black 
symbols indicate Ugn excretion in fmol/min. The red symbols indicate Na+ excretion 
in mEq/min. Vertical lines correspond to 9pm and black/white boxes indicate 
night/day status. B) Data taken from studies performed by Elitsur et.al. 2006 (50). 
White symbols indicate Na+ excretion from proUgn knockout mice. Black symbols 
indicate Na+ excretion from wild-type mice. The shaded pink area between the 
curves highlights the time when Na+ excretion differs between strains in the study. 
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Figure 4.8 Circulating Plasma proUgn During Sodium Diet Study and 
processing into Urinary Ugn A) Black circles represent the plasma proUgn 
concentration in pmol/ml at 3am during that diet intervention. Urinary Ugn is gray in 
the background, for comparison of relative changes. Black/white boxes indicate 
night/day status. The yellow bar indicates 0.02% Na+ LS chow and the red bar 
indicates 3.1% Na+ HS chow. B) Circles represent the plasma proUgn concentration 
in pmol/ml at 3am during that diet intervention. Green = NS, Yellow = LS, Orange = 
HS day 1 and Red = HS day 5. The grey dashed line indicates the average plasma 
value observed at 3am regardless of dietary Na+. The red dotted line indicates 
expected urinary Ugn excretion at 0.3% conversion of hypothetical filtered load at 
each given plasma proUgn value. Values are mean ±SEM, proUgn n=9-11, Ugn 
n=4. 
 
 157 
 
 
Figure 4.9 Ugn mRNA Expression Changes in Response to Diet A) Difference in 
cycle times (∆Ct) between ß-Actin and proUgn, determined by quantitative-RT-PCR 
amplification. Values are plotted against the diet conditions under which tissue 
samples were collected. The pink bar is intestine, and the burgundy bar is kidney 
(values are mean ±SEM, n=8-11). B) Graph showing the ∆∆Ct analysis of the Cycle 
threshold values from qRT-PCR of kidney and intestinal proUgn mRNA. HS-adjusted 
is significantly higher that NS for kidney Ugn expression. Urinary Ugn is in the 
background (grey diamonds and line) for comparison to relative changes. The red 
dashed line indicates basal expression level of proUgn mRNA, **P<.03. 
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Figure 4.10 Urine Ugn Excretion in Response to Intravenous Infusions of Rat 
proUgn and Ugn. A) Urine Ugn excretion in fmol/min before, during and after 
intravenous infusion of 10ng/kg b.w. proUgn. The horizontal bar indicates the 60 min 
infusion period.. B) Urine Ugn excretion in pmol/min before, during and after 
intravenous infusions of 10ng/kg b.w. Ugn The horizontal bar indicates the 60 min 
infusion period.  C) The amounts of Ugn recovered in urine during the infusion and 
post infusion periods associated with the proUgn and Ugn infusions shown in panels 
a and b is expressed as a percentage of peptide infused, D) Urinary Ugn 
concentrations (pmol/ml) during the infusion periods illustrated in panels a and b. All 
values are Mean ± SEM, n=3. As a reference, Urinary Ugn in a conscious animal on 
a NS diet is excreted at ~25 fmol/min, and the corresponding plasma proUgn 
concentration is 2 pmol/ml. 
 
 
 
 
 159 
 
 
 
 
 
 
 
 
 
 
Figure 4.11 Sodium excretion (UNaV, nEq/min/gKW) in response to intravenous 
peptide infusions. A) Response to rat Ugn infusions (filled squares) of 10nmol/kg 
b.w..  UNaV from a vehicle control group is shown by open triangles. The infusion 
period is indicated by the shaded section of the bar along the x-axis. B) Response to 
rat proUgn infusions (filled circles) in the amounts indicated.  The protocol was the 
same as for Ugn infusions. **=p<0.01 by 1 way ANOVA with Bonferroni’s multiple 
range testing. 
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A. A Role for Prouroguanylin 
 
High blood pressure affects more than 70 million Americans, putting them at a 
much greater risk for heart disease or a stroke (125). Sodium (Na+) is a major 
determinant of blood osmolarity and volume, and therefore its net balance plays a 
critical role in blood pressure (70).  Managing high blood pressure clinically usually 
involves reducing dietary Na+. For some individuals these changes in salt intake 
have no effect, while in others they do. High blood pressure that can be lowered by a 
reduction in salt intake is referred to as salt-sensitive hypertension. The reason for 
this difference in individuals is not clearly understood and therefore it is important to 
understand all the mechanisms involved in Na+ and volume homeostasis (91).   
One mechanism hypothesized to play a role in Na+ homeostasis is the post-
prandial natriuretic response. This is best described as the faster urinary excretion of 
Na+ after an oral NaCl load than after an equimolar intravenous NaCl load (24, 100, 
152). The current teleological model for post-prandial natriuresis (PPN) is that salt 
ingestion causes the intestine to secrete a natriuretic endocrine agent, signaling to 
the kidney to excrete salt in anticipation of the Na+ that will imminently be absorbed. 
Thus, PPN is thought to be mediated by an entero-renal endocrine axis. The 
concept of endocrine signaling between the GI tract and other organs has 
considerable precedent, as the GI tract is considered the largest endocrine organ in 
humans (12). There are many different types of endocrine cells throughout the 
enteric epithelium including the enterochromaffin cells in the small intestine that 
secrete prouroguanylin (proUgn)(179). 
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proUgn is a plausible candidate for mediating the entero-renal axis 
responsible for PPN. It is highly expressed in the proximal intestine where such a 
signal could originate (11, 113), its well-established digestion product Ugn has the 
ability to regulate epithelial electrolyte transport (22, 23, 50, 102), and Ugn is present 
in the urine (83, 99, 141), indicating that it has access to the lumen of the nephron, a 
relevant target tissue for homeostatic regulation of Na+ excretion. Evidence from 
mice where the gene for proUgn has been disabled clearly shows that the 
polypeptide product(s) encoded by the Ugn gene can affect blood pressure and Na+ 
excretion (50, 118)  
 
B. Prouroguanylin, an Unconventional Endocrine Agent 
 
Typical and Atypical Endocrine Axes 
 
Endocrine axes are crucial for homeostasis, and underlying physiological 
processes as diverse as growth, reproduction, and nutrient management. Typical 
endocrine axes allow organs to communicate with each other. Some endocrine axes 
are simple, in that an input to one organ stimulates the release of a bioactive 
peptide, amine, or other type of signaling molecule into the biological system. This 
signal travels through the circulation to the target organ and is received as a 
message that triggers a physiological change. Gastrin is an example of a simple 
endocrine model. Luminal stimuli in the stomach and intestine induce a specific 
population of cells, G-cells, to secrete mature, bioactive gastrin into the blood where 
it travels to the gastric glands and stimulates the production of acid by parietal cells 
(184).  
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Some endocrine axes employ intermediate endocrine organs to relay the 
message, such as the hypothalamic-pituitary-adrenal axis response to stress (30). 
The hypothalamus secretes vasopressin and corticotropin-releasing hormone, active 
hormones that regulate the pituitary gland (115, p.1056-1057). This stimulates the 
secretion of adrenocorticotropic hormone (ACTH) from the pituitary. ACTH is an 
active hormone that stimulates the adrenal gland to release cortisol, which travels 
via the circulation to multiple target tissues, eliciting the desired outcomes.  
The Renin-Angiotensin-Aldosterone system is an example of endocrine 
complexity, where multiple steps in the signaling cascade allow for various inputs to 
generate or modify the signal, which in turn acts on multiple targets (11). 
Angiotensinogen (the inactive prohormone) is released into the circulation from the 
liver. Angiotensinogen circulates in unprocessed form until an appropriate stimulus 
causes the kidney to secrete a protease known as renin. Renin acts within the 
circulation to process angiotensinogen into angiotensin I, which is subsequently 
processed by Angiotensin Converting Enzyme (another ectoprotease) into 
angiotensin II (ang II). AngII then travels to the kidney to relay the message. This is 
different from most endocrine mechanisms, in that the initial circulating form of the 
hormone is the biologically inactive precursor, and conversion to active form occurs 
only after the prohormone has been delivered to the vasculature (88).  
Carrier proteins provide another layer of endocrine complexity. Carrier 
proteins can prolong the half-life of a circulating hormone, and can also control how 
much free hormone is available to bind a receptor (16, 130). This means that the 
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effective concentration of the hormone in the plasma is based on both the amount 
being secreted and the amount of carrier protein in the plasma.  
  
Ugn or proUgn as the Messenger for PPN? 
 
Early work in the field suggested that proUgn might be the endocrine agent of 
an unconventional endocrine axis. The intestine produces the majority of the proUgn 
in the body, but the site where this enteric pool of proUgn is converted to Ugn had 
not been identified. The circulating pool was assumed to be predominantly Ugn, but 
some larger molecular weight immunoreactive species (proUgn) had also been 
detected (24, 95). Because of the lack of specificity of the assay used, it was not 
possible to accurately identify which peptide species were present, or in what 
amounts (24, 95). 
My studies show that very little processing of proUgn takes place within 
intestinal tissues. The intestinal ratio of proUgn to Ugn is ~20:1. So where is proUgn 
processed? Does this occur within the circulatory system, or within the renal 
tubules? My analyses demonstrate that intact proUgn circulates at relatively high 
levels in plasma, whereas the level of circulating Ugn is below the detection limit of 
my most sensitive assay. I also analyzed the fate of radiolabeled recombinant 
proUgn in pulse-chase infusion studies, and found that the propeptide circulates 
intact, and appears to be only converted to Ugn within the renal tubules after 
filtration at the glomerulus (chapter 2b). In this study, no mature Ugn was detected in 
the circulation; all of the radioactivity seen in arterial plasma was full-length proUgn 
or free amino acids. This is distinct from the typical endocrine axes described above, 
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where the prohormone is processed to the mature peptide intracellularly at the site 
of synthesis, and is secreted and delivered to the target in active form.  
My data suggest that proUgn acts in an unconventional endocrine axis where 
the endocrine message is delivered in unprocessed form and the target organ is 
responsible for some modulation of the signal. This is unusual but not without 
precedent. T-kininogen is an example as it is secreted as a propeptide and is 
cleaved into active form at the site where its effect is required (160).  
 
Additional Complexity in the Ugn/proUgn Signaling Axis 
 
There is also the likelihood that the kidney processes proUgn into multiple 
bioactive metabolites, as revealed by my pulse-chase studies Chapter 2. One of 
these species eluted from a reverse phase HPLC column with a retention time 
corresponding to that of an authentic Ugn standard. However the predominant 
species eluted with a retention time where no known metabolite has previously been 
identified. In the past, bioactive peptides derived from proUgn have always been 
identified by T-84 cell bioassay analysis, which means that only GC-C binding 
ligands have been considered. As it turns out, this is a severe limitation: experiments 
using GC-C knockout mice (22, 99), peptide infusion studies (135) and cell culture 
models (76, 101) have all shown that proUgn and Ugn have effects in the kidney that 
are mediated by some alternate receptor that is distinct from GC-C.  
A detailed analysis of the physiologic responses to infused rat Ugn and rat 
proUgn shows that the two peptides do not act the same (see chapter 4 and 136). 
When equal molar infusions were compared, proUgn caused greater a natriuresis at 
one-fifth the concentration of Ugn, while Ugn showed a slightly greater anti-kaliuretic 
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effect than did proUgn (136). These studies were performed at doses slightly above 
the physiological range but still within values seen in animals with kidney 
pathologies. The implication is that proUgn has biological actions that cannot be 
accounted for by Ugn. It could be that each proUgn molecule is cleaved into multiple 
bioactive fragments and they have additive or complementary effects.  
The kidney itself has also previously been shown to express proUgn, but 
before my studies it was not known whether any portion of this intrarenal pool of 
proUgn was processed and stored as Ugn. My early studies (chapter 2) found that 
the renally stored form was exclusively proUgn and no Ugn could be detected by T-
84cell/cGMP analysis. In follow-up studies I also found that Ugn levels in the kidney 
were below the detection threshold of the improved binding assay detection method 
for Ugn. This indicates that any secretion of proUgn by the kidney is most likely in 
the form of the intact propeptide. Processing must occur after (or coincident with) 
secretion. 
Proposed future studies: Two compelling questions are; 1) what are the 
renal metabolites (excreted in urine) that proUgn is being broken down into (in 
addition to Ugn), and 2) is urinary Ugn derived from proUgn produced by the kidney 
or circulating in the plasma and derived from the intestine). To answer both of these 
questions I propose to use an isolated perfused kidney prep (IPK).  
The first phase of this study would be to identify the renal metabolites by 
infusing large amounts of proUgn peptide into the IPK to see if the isolated organ 
could be made into a “metabolite factory”. A recirculating perfusate with a very high 
dose of proUgn might increase the yield of peptide fragments. Our infusion studies 
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of non-pharmacological doses of proUgn achieved a yield of 2%, much higher than 
the upper limit of 0.3% seen in whole animals. It is possible this could be improved 
at much higher doses. This flow through would then be subjected to LC-MS analysis 
to identify all fragments produced. The parent sequence of any possible fragments is 
known with precision, which will make the chance of successful identification much 
greater.  
In attempting to answer the question of whether urinary metabolites are 
derived from the renal pool of proUgn vs. renal processing of the plasma pool of 
proUgn, the IPK could also be a good solution. If the kidney is the source of altered 
urinary Ugn levels in response to oral Na+, I hypothesize the signal that activates the 
kidney to secrete proUgn and/or its metabolites into the tubular lumen could be 
either the sympathetic nerves or subtle changes renal pressure or salt delivery. 
These would all have to be accounted for in any investigation. An in situ preparation 
might be possible where renal artery and vein would be cannulated with care to 
minimize perturbations to the renal nerves. Failing this, it might be best to stimulate 
the renal nerves with an electrode to simulate normal nerve activity and 
microvascular tone. The perfusate would be a saline solution with no proUgn but 
some basal amount of BSA for oncotic pressure. Subtle alterations could be made 
could be made to salinity and pressure of the perfusate to see what might optimize 
peptide production. The newly developed binding assay would be a key tool for 
these analyses, as it would allow high throughput analysis of samples form many 
different conditions, and provide high sensitivity for detection of small amounts of 
Ugn excretion. The results I expect to see would be measurable levels of Ugn 
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(and/or other metabolites) in the urine. This may be altered by renal nerve activity or 
by conditions of slightly increased pressure or salinity 
 
C. Prouroguanylin as a Control Mechanism of Basal Sodium 
Excretion 
 
Intestinal Prouroguanylin as a Circadian Control Mechanism of Renal Sodium 
Excretion 
 
Biological circadian rhythms are a phenomenon common among all species 
on earth (45).  There are genes, such as Clock, that encode proteins and 
transcription factors that act as master regulators of many other genes that are 
expressed in this circadian cycle (71). Many of these are highly conserved from 
humans down to Drosophila (66, 71). Some circadian cycling phenomena are not 
directly controlled by genes that cycle autonomously, but are instead dictated by 
environmental cues that are encountered in each 24-hour cycle, such as food intake 
(146).  
Chapter 4 reports my finding that levels of urinary Ugn and plasma proUgn 
have a circadian rhythm. The data also show that intestinally sourced plasma 
proUgn could potentially be the main precursor for urinary Ugn, as the measured 
concentration of gut-derived proUgn in the plasma coupled with the observed rate of 
conversion in the kidney (urinary Ugn ≈ 0.3% of proUgn filtered load) is adequate to 
provide the basal levels of Ugn in the urine (see Table 4.5). This 0.3% estimated 
rate of conversion would be constant throughout the 24-hour cycle, as the diurnal 
changes in these two proteins occur concomitantly. 
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The basal secretion of proUgn by the intestine into the plasma with circadian 
periodicity should be sufficient to drive a basal natriuresis in the kidney. Results 
presented from chapters 2 and 4 show that infusions of proUgn into the plasma 
induce a significant increase in Na+ excretion (figure 2.7,136).  
My hypothesis is that intratubular Ugn (or some other metabolite) generated 
from circulating proUgn causes natriuresis at a basal level, and that this is a 
component of normal urine generation 24 hours a day. Thus, the diurnal cycle of 
plasma proUgn levels provides a mechanism for enhancement of Na+ excretion 
during active hours. This would have the consequence of accelerating Na+ excretion 
in the nighttime hours when Na+ is being ingested. The circadian increase in proUgn 
secretion from the intestine could actually be triggered by the ingestion of food, or it 
could be the consequence of spontaneous, free-running cyclic changes in gene 
expression driven by an internal circadian clock. Either of these ideas would be 
consistent with the observation by Dr. Mitchell Cohen’s group that the hypertension 
in proUgn -/- mice is salt insensitive (50). Specifically, I suggest that the basal level 
of intratubular Ugn (generated from basal plasma proUgn) is responsible for a 
portion of renal Na+ excretion that is independent of Na+ intake. When this 
component is missing (due, for example, to knocking out the Ugn gene), then Na+ is 
retained, and blood pressure rises until pressure natriuresis is sufficient to eliminate 
the retained Na+ (shaded portion of Figure 4.7 B).  
Proposed future studies: In order to test this, I would propose experiments 
that use conditional knockout mice in which the gene for Ugn has been disabled 
exclusively in the intestine. One way to do this would be to place the recombinase 
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gene under control of the serotonin promoter, which it is highly active in 
enterochromaffin cells where intestinal proUgn is produced. This should not affect 
renal expression of proUgn, as the only other tissue where serotonin is known to be 
expressed is the central nervous system (9). Note that proUgn has not been seen to 
be expressed in the nervous system (150). This model would be useful to determine 
whether the changes seen in Ugn excretion in response to high Na+ are from a renal 
or enteric source. My hypotheses are that 1) the conditional knockout animals would 
have high blood pressure and little Ugn in the urine on normal Na+ chow (due to 
confirmation of the prior hypothesis that proUgn is the mediator of a basal level of 
Na+ excretion through its constitutive release from the intestine), 2) the Ugn present 
in their urine would represent basal renal excretion and when the Na+ content of the 
chow is altered, this level will change concomitantly, and 3) these animals would 
behave like wildtype animals with respect to Na+ excretion when challenged with a 
large oral NaCl bolus. If a conditional knockout is not attainable to test these 
hypotheses, an alternative might be to transplant the kidneys of wildtype animals 
into constitutive, whole body Ugn-/- animals (37, 38).  
Another way to investigate the nature of the circadian release of proUgn from 
the intestine would be through controlled feeding-time diet studies. Animals would be 
housed in metabolic cages and access to chow would be restricted to short periods 
where the lights were on and the animals would otherwise be quiescent. The same 
parameters as used in the previous study would be monitored to determine if 
circadian plasma proUgn and urinary Ugn levels are altered. If the circadian control 
mechanism is genetic, I would expect to see a biphasic excretion in Ugn with the 
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normal active phase increase reduced but a modest increase during the quiescent 
phase. If the intake of Na+ during the active phase of the circadian cycle is the sole 
or primary mechanism causing the increased urinary Ugn (environmental cue) then I 
would expect to see the circadian increase in Ugn excretion associated with the 
experimentally-adjusted time period when the animals are being fed.  
 
D. Prouroguanylin as a Control Mechanism of Renal Sodium 
Excretion in Response to High Na+ Intake 
 
Renal Prouroguanylin as a Control Mechanism for Increased Sodium 
Excretion During High Na+ Diet Consumption 
 
Data presented in chapter 2 show that the kidney is the only tissue in the 
body that produces a significant amount of proUgn aside from the intestine. The 
renal pool of proUgn is significantly smaller than the intestinal pool (table 2.2). 
However, renal proUgn mRNA increased two-fold on the high Na+ chow conditions. 
Secretion from the kidney could be a much more efficient way to produce urinary 
Ugn than the estimated 0.3% conversion of filtered plasma proUgn. Renal Ugn 
mRNA not only goes up in response to high salt diet but it also goes down in 
response to low salt intake (see day one of LS period). If plasma proUgn levels (with 
circadian variation) are not affected by dietary salt intake (as shown by my Chapter 4 
studies), and if the rate of conversion of plasma proUgn to Ugn within the kidney is 
also not affected by salt intake (a reasonable assumption), then changes in urinary 
Ugn excretion have to be controlled by changes in renal release of Ugn or proUgn. 
This hypothesis implies that if the kidney makes a basal contribution to urinary Ugn, 
then the 0.3% conversion rate of endogenous plasma proUgn could be an 
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overestimate. An intrarenal cellular processing and secretion mechanism that 
efficiently produced Ugn (100% conversion) would only require mobilizing 6% of the 
steady-state stored pool of renal proUgn to provide the increased excretion of Ugn 
noted during high Na+ intake during the diet study. Note that I detected a small 
amount of free Ugn in the intestine (where proUgn levels are considerably higher 
than in the kidney), and the intestinal level of free Ugn was ~5% of the proUgn level 
(pretty close to the 6% processing rate required in the kidney – which would have 
generated a level of free Ugn that is below the detection limit of my assay). 
Therefore I hypothesize renal production and excretion of Ugn is the source of the 
increased excretion of Ugn during high Na+ intake periods. This is a phase of the 
diet study that the previous hypothesis failed to address. This is utilization of the 
same model for different contexts, much the same way my previous diet study 
showed   
Figure 5.1 illustrates how these two proUgn sources might contribute together 
to the urinary excretion of Ugn during the diet study. The plasma contribution is an 
estimated excretion based on filtered load of proUgn from observed values (pink 
shaded region). The renal contribution (burgundy shaded region) is hypothetical, and 
based on the concept that there is a basal excretion rate that will go down when the 
dietary Na+ is restricted and up when dietary Na+ is boosted. This response of the 
kidney to dietary Na+ could be controlled by mechanisms such as the sympathetic 
nervous system or even renal Na+ or stretch sensors (8, 147).  
Future studies to investigate these hypotheses could include the use of 
genetic models such as the intestine specific conditional knockout mouse mentioned 
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in section C. The “inverse” genetic model would be useful to further evaluate this 
hypothesis. Animals with a kidney specific Ugn knockout or transplant of Ugn-/- 
kidneys into wildtype animals would be expected to be normotensive. This blood 
pressure phenotype would be wholly dependent on the basal excretion of Ugn from 
the renal source. I would expect these animals to have normal levels of plasma 
proUgn and lower urinary Ugn, but they would still display circadian changes in 
urinary Ugn that would match parallel circadian changes in plasma proUgn. 
Additionally I predict that post-prandial Na+ excretion will be blunted in these animals 
(i.e. they would have delayed Na+ excretion after a dietary Na+ increase, similar to a 
constitutive Ugn-/- knockout). 
The significance of these experiments, if the hypothesis is proven, is that 
proUgn would be shown to participate in two different mechanistic post-prandial 
responses; a) a circadian response that increases Na+ excretion constitutively 
during active hours by increasing enteric secretion of proUgn and, b) an oral salt 
induced response that increases Na+ excretion in response to renal Ugn supplied by 
the kidney itself. 
 
E. Final Thoughts 
The intestine is a sensing organ that monitors the timing, the volume and the 
composition of ingested food and modulates the organism in response. I propose 
that the changes I describe in Chapter 4 (particularly the circadian nature of enteric 
proUgn signaling) is appropriate for modulating Na+ excretion to match general 
circadian changes in Na+ consumption, but is not appropriate to regulate excretion in 
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response to the intake of specific loads of Na+. The circadian changes in plasma 
proUgn may be triggered by circadian cycles in Na+ intake, but not in a measured 
dose relationship as proposed by the original PPN hypothesis. I also speculate that 
the kidney responds specifically to bolus intakes of Na+ by secretion of proUgn (or 
Ugn) into the lumen of the nephron, where it regulates the component of Na+ 
excretion that is driven directly by Na+ ingestion (controlled by an as-yet undescribed 
mechanism). Thus, the idea that proUgn participates in an entero-renal endocrine 
axis which mediates post-prandial natriuresis is not supported by my data. The more 
likely explanation is that proUgn participates in an entero-renal endocrine axis that 
modulates Na+ excretion in a circadian cycle to match activity and general Na+ 
intake. Additionally, renal proUgn could be a key component of the mechanism that 
drives post-prandial natriuresis (a response to specific enteric Na+ loads), but its 
activation is reliant on a renal sensing mechanism or CNS input. 
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Figures 
 
Figure 5.1 Model of hypothetical sources for Urinary Ugn. The black and 
white boxes indicate night an day. The yellow (0.02%Na+) and red (3.1%Na+) bars 
indicate Na+ content in the chow. Combined shaded region represents the urinary 
Ugn excreted and is approximately accurate for my results. The pink shaded region 
represents a hypothetical amount of Ugn contributed by the filtered plasma proUgn 
being filtered and processed at less than 0.3%. For these pink areas under the curve 
each day is approximately integrated to represent a steady state contribution, with 
no change due to salt status but a circadian variation. The burgundy-shaded region 
represents the hypothetical contribution from the kidney to affect the changes seen 
in urinary Ugn that unchanging plasma fails to answer. For the kidney to be playing 
the role of “salt-responding” organ it would not only have to increase in response to 
high salt but also have to have a substantial contribution to basal excretion in order 
to drop in the level observed during these period. 
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